array(5) { [0]=> array(49) { ["IBLOCK_SECTION_ID"]=> string(3) "149" ["~IBLOCK_SECTION_ID"]=> string(3) "149" ["ID"]=> string(4) "1854" ["~ID"]=> string(4) "1854" ["IBLOCK_ID"]=> string(1) "2" ["~IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["~NAME"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["ACTIVE_FROM"]=> NULL ["~ACTIVE_FROM"]=> NULL ["TIMESTAMP_X"]=> string(19) "03.08.2020 11:18:57" ["~TIMESTAMP_X"]=> string(19) "03.08.2020 11:18:57" ["DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det/" ["~DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det/" ["LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["~LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["DETAIL_TEXT"]=> string(25621) "

Introduction

Survival rates of children and adolescents with oncological diseases significantly improved due to development of novel chemotherapy (ChT) protocols. In large part, this could be explained by more aggressive treatment, thus requiring a more careful selection of supportive and symptomatic therapy. Pain is among the most common symptoms which trouble both sick children themselves, and their parents [1].

Hematopoietic stem cell transplantation (HSCT) is a high-risk treatment aimed for therapy of both oncological, non-malignant hematological and some orphan diseases. Early post-transplant period is accompanied by such common conditions, e.g., weakness, pains and insomnia. These complaints are presented in 8 to 55% of autologous HSCTs [2], and 60 до 80% of allogeneic HSCT recipients [3]. Oral and gastrointestinal mucositis is among common painful complications occurring in 20 to 40% of chemotherapy (ChT) courses, and in up to 80% cases of conditioning treatment preceding HSCT, dependent on the drug combination applied [4].

Cytotoxic drugs used for conditioning therapy before allo-HSCT could damage endothelium of liver with subsequent development of veno-occlusive disease which could manifest with hepatomegaly accompanied by right upper quadrant pain due to extensive distension of Glisson capsule. This complication may encounter in 13.7% cases of HCST, as well as after ChT course [5]. In our experience, pain syndromes may be also connected with development of acute hemorrhagic cystitis, infections, fast engraftment, bone marrow necrosis, bone pain associated with corticosteroid withdrawal etc.

Thrombocytopenia, agranulocytosis, and, sometimes, renal dysfunction comprise special features in the patients after HSCT and some ChT regimens, thus limiting the opportunities for usage of nonsteroid anti-inflammatory drugs (NSAID), as first step of WHO analgetic ladder. Administration of these medicines as analgetics, could also hide fever of infectious origin. One should also note limited routes for administration of painkillers, i.e., per oral uptake could be difficult due to evolving mucositis. Rectal administration is not recommended, because of high-risk translocation of gut microflora in neutropenic conditions, whereas intramuscular injections are contraindicated, due to thrombocytopenia and painful manipulation [6, 7]. In this view, management of weak and moderate pain with NSAID may be difficult, and one should change the therapy for second-line treatment at early stages. Previously, WHO has excluded the second stage of pain relief ladder using weak opioids, e.g., codeine [7]. From 2009 to 2012, several cases of breath depression were registered in children under 5 years old after codeine postoperative analgesia after tonsillectomy. Most likely, this side effect was associated with individual genetic feature of cytochrome enzymes e.g., ultra-fast codeine activation by CYP2D6 with excessive production of morphine which, under normal excretion rates, could be accumulated at toxic concentrations.

In particular, tramadol is mostly inactivated by two enzymes, CYP2D6 and CYP3A4, whereas unchanged М1 metabolite, is, in turn, is excreted with urine. The analgetic effects of the drug are explained by, at least, two mechanisms, i.e., interaction between tramadol/M1 metabolite and μ-opiate receptors (OPRM1), as well as inhibition of serotonin and norepinephrine reuptake by tramadol, thus suppressing pain impulse transmission at the level of spinal cord [8, 9]. Undoubtedly, the patients with ultra-fast tramadol metabolism are in high-risk group, especially, in cases of high-dose treatment and appropriate comorbidities of respiratory system, sleep apnea in tonsillar hyperplasia, or obesity conditions [10]. Therefore, some authors recommend to admit the patients to inpatient unit as early as 24 hours before treatment, in cases of acute nociceptive pain in patients administered tramadol and uncertain CYP2D6 activity levels [11]. Concerning the analgetic capacity, tramadol takes an intermediate position between NSAID and potent opioids, but at the same time, some publications report on less common frequency of sedation, respiratory depression, constipation and other side effects typical to strong opioids [12]. At the present time, tramadol is widely used for treatment of nociceptive pain in traumas and after surgical interventions in children [13, 14, 15, 16, 17, 18]. For moderate pain, the WHO analgesia ladder presumes low doses of strong opioids (oxycodone or morphine) to be the main alternative for weak opioids.

High individual variability of efficient dose is a specific feature of morphine administration. This characteristic could be explained by differences in its bioavailability, metabolism and excretion. The main morphine metabolites are as follows: morphine-6-glucuronide, which exhibits higher analgetic ability, but can elicit nausea, vomiting, excessive sedation, as well as morphime-3-glucuronide with probable antianalgetic and neurotoxic effects [19]. Several studies report about efficiency and safety of low-dose-morphine when managing moderate pain, e.g., in pediatric practice [20, 21, 22, 23]. In turn, the adverse effects of morphine derivatives are not shown at the present time (19).

Worth of note, however, both morphine and tramadol, may also display some side effects, including nausea, vomiting, respiratory depression, urinary retention, constipation, skin itching etc., thus causing discomfort to the patient [24, 25]. Therefore, the aim of our study was to evaluate efficiency and safety of tramadol and low-dose morphine in the treatment of moderate pain in children.

Patients and methods

The study was conducted in the Anesthesiology Department of R. M. Gorbacheva Memorial Institute for Pediatric Hematology, Oncology and Transplantation. The study included 159 primary admittances of the patients 1 to 17 years old (a median of 8 years) with complaints of moderate pain. Their age distribution is shown in Fig. 1.

The diagnoses were as follows: solid malignancies, 55.4% (n=88); hemoblastoses, 35.2% (n=56); non-malignant hematological disorders, 5% (n=8) and orphan diseases 4.4% (n=7).

Of them, 13.8% (n=22) were subjected to ChT, 68.8% (n=109) underwent allo- or auto-HSCT with myeloablative treatment regimen; 17.6% (n=28) received HSCT with non-myeloablative conditioning. The main reasons for pain syndrome were: mucositis, 85.5% (n=136), bone pain associated with hematopoiesis recovery, 5% (n=8); progression of primary disease, 5% (n=8); intestinal graft-versus-host disease (GvHD) 1.3%, (n=2), mucositis combined with acute cystitis 2.5% (n=4); paraproctitis, 0.7% (n=1), as seen in Fig. 2.

The intensity if pain was evaluated 3 times a day throughout the observation period to age-matched scale adapted to abilities of the patient (FLACC, verbal scale, Wong-Baker Faces Pain Rating Scale, or visual analogue scale). The total time of observation, including, changing lines of analgesic therapy, if necessary, ranged from 1 to 20 days (median 6 days). The response to therapy was assessed integrally by such parameters as: pain intensity (permanent and activity-evoked), quality of night sleep, ability of food and drink intake without an pain related failure, the possibility of non-pharmacological treatment and patient satisfaction. All the patients were classified into 2 groups in a ratio 3:1. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients in the 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). The initially prescribed analgetic was the first line of therapy, if there was a change of therapy, then the new analgetic was considered the second line of therapy. Drug infusion was performed permanently, via central venous catheter under hospital conditions. Pain intensity and drug acceptability were evaluated 2-3 times a day. In cases of insufficient analgesia, i.e., non-reduced or enhanced pain, lack of food and fluid intake because of pain etc., the drug was changed, or morphine dosage was increased. The analgetics were also changed in case of bad tolerance of current therapy. The choice of drug was made individually, depending on clinical situation.

Statistical evaluation was performed by means of SPSS software, using Chi-square test. When checking statistical hypotheses, the difference was presumed significant by p<0.05.

Results

The results of our study have revealed that the therapy was effective in 40.7% (n=48) and 58.5% (n=24) for tramadol and low-dose morphine treatment respectively, whereas in 0.8% of the cases, tramadol administration was prolonged to the end of staying in the unit/transfer to hospice, with good therapy acceptability. Enhanced analgetic treatment was required in 53.4% (n=63) for the 1^st group versus 39.0% (n=16) for the patients in the 2^nd group (Table 1).

Table 1. First line therapy results

Adverse effects in the first (tramadol-treated) group were observed in 5.1% (n=6). In particular, we observed one case of somnolescence with subsequent excitation in a girl of 4 years old; one case of dizziness with tremor in a girl of 11 years old. Two cases of involuntary contractions of striated muscles were detected: a 6 years old girl had twitching of right hand by 2 days after tramadol injections, and a 10 years old boy developed involuntary contractions of mimic muscles after 3 days of treatment, probably, due to serotoninergic effect of the drug. We have also seen one case of vomiting and nausea in the 17 years old female, as well as a case of nausea and anxiety in the 16 years old female. At the next treatment courses, this pain management was based on strong opioids. Their injection was accompanied by similar side effects. However, the mentioned side effects were no health-threatening. Subsequently 6 years old girl required the change of therapy to fentanyl. In other cases after cancellation of tramadol infusion, weak pain persisted, but further analgesia was not necessary. In the second group, only one female patient (2.4% of total) treated with low-dose morphine developed intestinal paralysis that was resolved after the therapy change.

Upon statistical analysis with Chi-square method, no significant differences were found between the tramadol group and low-dose morphine-treated groups in effectiveness and frequency of side effects (p=0.237).

In case of inefficiency of tramadol or low doses of morphine the second line of therapy included morphine in a low dose (after tramadol administration) was used in 29.1% (n=23), morphine in a standard dose (from 0.02 mg/kg/hr) in 17.7% (n=14) or fentanyl at a dose of 0.05 mcg/kg/hr in 53.2% (n=42) (Table 2).

Table 2. Distribution of the 2^nd line therapy medicines

We also evaluated the safety of low and standard doses of morphine in the second line of pain management therapy (Table 3). As result, we observed that side effects appeared in two cases: one because of nausea and vomiting and one due to complaints of blurred focus of vision, which was possibly associated with myosis. In group of standard doses of morphine one case of postrenal urinary retention. All three cases required a revision of treatment.

Table 3. Results of second line therapy with morphine in low and standard doses

Upon statistical analysis with Chi-square method, no significant differences were found between the standard and low-dose morphine-treated patients in effectiveness and frequency of side effects (p=0.271).

Discussion

Currently, some authors state that the respiratory depression is rarely encountered when tramadol dosage is carefully maintained [26, 27]. Frequency of nausea and vomiting are compatible (10-40%) when administering tramadol or opioids [28]. In our experience, a case of intestinal paralysis should be noted in a female patient from 2^nd group with mucositis. She had also side effects in the course of immune suppressors (nephro- and neurotoxicity), as well as pancytopenia and hemorrhagic syndrome that could be risk factors of this condition. Concerning adverse effects associated with tramadol prescription, the literature presents only single cases of generalized cramps due to excessive dosage and drug administration to a child under 1 year old [29]. One may also suggest an evolving serotonin syndrome connected to high dosage of serotoninergic drugs (selective serotonin reuptake inhibitors, some monoamine oxidase inhibitors), which includes excitation, ataxia, increased sweating, diarrhea, fever, hyperreflexia, and tremor. In our study, similar symptoms were seen in 4 patients, however, at less significant. This is, probably, connected with non-opioid effects of the drug (inhibition of serotonin and norepinephrin reuptake) [30, 31]. However, one cannot exclude ultra-fast CYP2D6 activity. That is the key aspects influencing tramadol efficiency and, potentially, genetic studies could serve as a predictor of efficacy and safety of the drug. Meanwhile, the CYP2D6 gene polymorphism is quite variable and requires time-consuming molecular genetic studies, thus reducing value of this technique in case of acute pain. One should also understand that the genotype will correspond to phenotype, with regard to variable clearance and body weight [8]. Therefore, we observe the children at the hospital within first 24 hours after starting tramadol infusion. For the patients requiring longer analgesia period, than in our study, tramadol shows lesser potential risk of dependence compared to classical opioids [32]. It’s also important to note that administration of tramadol has a less strict legal regulation [33, 34]. Due to social prejustice, its administration causes lesser anxiety on the part of parents and adolescent patients with respect to adverse effects, ex., addiction. Similarly, in cases with inefficiency of this therapy, the parents take easier administration of strong opioids [35, 36]. In future, tapentadol and local morphine applications could be promising therapeutic options [37]. However, there are only modest data on the studies of these medications in children and adolescents.

Conclusions

Based on the study data, we may suggest that tramadol exerts analgetic effects which are comparable to low-dose morphine. However, administration of these drugs needs dynamic observation of pediatric patients in the hospital at initial steps of therapy, due to some features of individual response and probable side effects. These issues also require further studies in larger groups of patients.

Authors are grateful to Elena V. Verbitskaya, assistant professor of the department of clinical pharmacology and evidence-based medicine, for her help in statistical data processing.

Conflict of interests

The authors declare no conflicts of interest.

References

1. Tutelman PR, Chambers CT, Stinson JN, Parker JE, Fernandez CV, Witteman HO, Nathan PC, Barwick M, Campbell F, Jibb LA, Irwin K. Pain in children with cancer: prevalence, characteristics, and parent management. Clin J Pain. 2018 ;34(3):198-206.
2. Anderson KO, Giralt SA, Mendoza TR, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39(12):759-66.
3. Bevans MF, Mitchell SA, Marden S. The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer. 2008;16(11):1243-1254.
4. Bowena JM, Wardill HR. Advances in the understanding and management of mucositis during stem cell transplantation. Curr Opin Support Palliat Care. 2017; 11(4), 341-346.
5. Richardson PG, Grupp SA, Pagliuca A, Krishnan AJ, Ho VT, Corbacioglu S. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2017; 6(3):75-93.
6. Ma JD, El-Jawahri AR, LeBlanc TW, Roeland EJ. Pain syndromes and management in adult hematopoietic stem cell transplantation. Hematol Oncol Clin North Am. 2018; 32 (3), 551-567.
7. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: World Health Organization; 2012.
8. Allegaert K, Holford N, Anderson BJ, Holford S, Stuber F, Rochette A, Trocóniz IF, Beier H, de Hoon JN, Pedersen RS, Stamer U. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. Clin Pharmacokinet. 2015; 54(2):167-178.
9. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg. 2017;124(1):44-51.
10. Anderson BJ, Thomas J, Ottaway K, Chalkiadis GA. Tramadol: keep calm and carry on. Pediatr Anesth. 2017;27:785‐788.
11. Rodieux F, Vutskits L, Posfay-Barbe KM, Habre W, Piguet V, Desmeules JA, Samer CF. When the safe alternative is not that safe: tramadol prescribing in children. Front. Pharmacol. 9:148. DOI: 10.3389/fphar.2018.00148.
12. Marzuillo P, Calligaris L, Barbi E. Tramadol can selectively manage moderate pain in children following European advice limiting codeine use. Found Acta Pædiat. 2014; 103:1110-1116.
13. Ali S, Sofi K, Dar AQ. Comparison of intravenous infusion of tramadol alone with combination of tramadol and paracetamol for ostoperative pain after major abdominal surgery in children. Anesth Essays Res. 2017; 11:472–476. DOI: 10.4103/aer.AER_23_17.
14. Friedrichsdorf SJ, Postier AC, Foster LP, Lander TA, Tibesar RJ, Lu Y, Sidman JD. Tramadol versus codeine/acetaminophen after pediatric tonsillectomy: a prospective, double-blinded, randomized controlled trial. J Opioid Manag. 2015; 11: 283-294. DOI: 10.5055/jom.2015.027.
15. Liaqat N, Dar SH. Comparison of single-dose nalbuphine versus tramadol for postoperative pain management in children: a randomized, controlled trial. Korean J Anesthesiol. 2017; 70: 184-187. DOI: 10.4097/kjae.2017.70. 2.184.
16. Schnabel A, Reichl SU, Meyer-Friessem C, Zahn PK, Pogatzki-Zahn E. Tramadol for postoperative pain treatment in children. Cochrane Database Syst Rev. 2015; 3:CD009574. DO: 10.1002/14651858.CD009574.pub2.
17. Yenigun A, Et T, Aytac S, Olcay B. Comparison of different administration of ketamine and intravenous tramadol hydrochloride for postoperative pain relief and sedation after pediatric tonsillectomy. J Craniofac Surg. 2015; 26: e21-e24. DOI: 10.1097/scs.0000000000001250.
18. Neri E, Maestro A, Minen F, Montico M, Ronfani L, Zanon D, Favret A, Messi G, Barbi E. Sublingual ketorolac versus sublingual tramadol for moderate to severe posttraumatic bone pain in children: a double-blind, randomised, controlled trial. Arch Dis Child. 2013; 98: 721-724. DOI: 10.1136/archdischild-2012-303527.
19. Lee YJ, Suh S-Y, Song J, Lee S, Seo A-R, Ahn HY, Lee MA, Kim C-M, Klepstad P. Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study. BMC Palliat Care. 2015; 14: 53. DOI:10.1186/s12904-015-0052-9.
20. Bandieri E, Romero M, Ripamonti C, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34(5):436-442. DOI: 10.1200/JCO.2015.61.0733.
21. Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G. Use of strong opioids in advanced cancer pain: A randomized trial. J Pain Symptom Managem. 2004; 27:409-416.
22. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, Speranza R, Tassinari D, Magnani P, Saccani D, Montanari L, Roudnas B, Amadori D. A validation study of the WHO analgesic ladder: A two-step vs three-step strategy. Support Care Cancer.2005; 13: 888-894.
23. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Ficorella C, Verna L, Tirelli W, Villari P, Arcuri E. Low morphine doses in opioid naive cancer patients with pain. J Pain Symptom Managem. 2006; 31:242-247.
24. Duedahl TH, Hansen EH. A qualitative systematic review of morphine treatment in children with postoperative pain. Paediatr Anaesth. 2007; 17: 756-774.
25. Verghese ST, Hannallah RS. Acute pain management in children. J Pain Res. 2010; 3:105-123.
26. Hannam JA, Anderson BJ, Potts A. Acetaminophen, ibuprofen, and tramadol analgesic interactions after adenotonsillectomy. Pediatr Anesth. 2018; 28(10): 841-851. DOI: 10.1111/pan.13464.
27. Hassanian-Moghaddam H, Farnaghi F, Rahimi M. Tramadol overdose and apnea in hospitalized children, a review of 20 cases. Res Pharm Sci. 2015; 10(6):544-552.
28. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Pediatr Anesth. 2011; 21:266-273.
29. Li X, Zuo Y, Dai Y. Children's seizures caused by continuous intravenous infusion of tramadol analgesia: Two rare case reports. Pediatr Anesth.2012; 22 (3):308-309.
30. Savage R. Medical assessor serious reactions with tramadol: Seizures and serotonin syndrome. Prescriber Update. 2007; 28(1): 11-13.
31. Sansone RA, Sansone LA. Tramadol: Seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont). 2009; 6 (4): 17-21.
32. Kirienko P.A. Usage if tramadol hydrochloride in routine clinical practice (review of literature). Rossiisky Medizinskyi Zhurnal. 2004; 8:512 (In Russian).
33. Order of the Ministry of Health of Russian Federation of January 14/2019 №4N "On Approving the Procedure for Prescribing Medicines, Forms of Prescription Forms for Medicines Procedure for Formulating the Forms. Recording and Storage", enactment date: 28.05.2020. http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=344178&fld=134&dst=1000000001,0&rnd=0.7542220165183926#0878938710536209 (In Russian).
34. Appendix No.2 to the Disposal of Russian Government of 12.10.2019 № 2406-r. http://static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf (In Russian).
35. Sichetti D, Bandieri E, Romero M, Di Biagio K, Luppi M, Belfiglio M, Tognoni G, Ripamonti CI. ECAD Working Group: Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. Ann Oncol. 2010; 21(10):2088-2093.
36. Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, Apolone G. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014; 32(36):4149-4154.
37. Kolesnikov YA. Prospective usage of a combination of locally injected nonsteroid anti-inflammatory drugs and opioids when treating pains of peripheral genesis. Vestnik Anestesiologii I Reanimatologii. 2019; 16(3):41-47 (In Russian).

" ["~DETAIL_TEXT"]=> string(25621) "

Introduction

Survival rates of children and adolescents with oncological diseases significantly improved due to development of novel chemotherapy (ChT) protocols. In large part, this could be explained by more aggressive treatment, thus requiring a more careful selection of supportive and symptomatic therapy. Pain is among the most common symptoms which trouble both sick children themselves, and their parents [1].

Hematopoietic stem cell transplantation (HSCT) is a high-risk treatment aimed for therapy of both oncological, non-malignant hematological and some orphan diseases. Early post-transplant period is accompanied by such common conditions, e.g., weakness, pains and insomnia. These complaints are presented in 8 to 55% of autologous HSCTs [2], and 60 до 80% of allogeneic HSCT recipients [3]. Oral and gastrointestinal mucositis is among common painful complications occurring in 20 to 40% of chemotherapy (ChT) courses, and in up to 80% cases of conditioning treatment preceding HSCT, dependent on the drug combination applied [4].

Cytotoxic drugs used for conditioning therapy before allo-HSCT could damage endothelium of liver with subsequent development of veno-occlusive disease which could manifest with hepatomegaly accompanied by right upper quadrant pain due to extensive distension of Glisson capsule. This complication may encounter in 13.7% cases of HCST, as well as after ChT course [5]. In our experience, pain syndromes may be also connected with development of acute hemorrhagic cystitis, infections, fast engraftment, bone marrow necrosis, bone pain associated with corticosteroid withdrawal etc.

Thrombocytopenia, agranulocytosis, and, sometimes, renal dysfunction comprise special features in the patients after HSCT and some ChT regimens, thus limiting the opportunities for usage of nonsteroid anti-inflammatory drugs (NSAID), as first step of WHO analgetic ladder. Administration of these medicines as analgetics, could also hide fever of infectious origin. One should also note limited routes for administration of painkillers, i.e., per oral uptake could be difficult due to evolving mucositis. Rectal administration is not recommended, because of high-risk translocation of gut microflora in neutropenic conditions, whereas intramuscular injections are contraindicated, due to thrombocytopenia and painful manipulation [6, 7]. In this view, management of weak and moderate pain with NSAID may be difficult, and one should change the therapy for second-line treatment at early stages. Previously, WHO has excluded the second stage of pain relief ladder using weak opioids, e.g., codeine [7]. From 2009 to 2012, several cases of breath depression were registered in children under 5 years old after codeine postoperative analgesia after tonsillectomy. Most likely, this side effect was associated with individual genetic feature of cytochrome enzymes e.g., ultra-fast codeine activation by CYP2D6 with excessive production of morphine which, under normal excretion rates, could be accumulated at toxic concentrations.

In particular, tramadol is mostly inactivated by two enzymes, CYP2D6 and CYP3A4, whereas unchanged М1 metabolite, is, in turn, is excreted with urine. The analgetic effects of the drug are explained by, at least, two mechanisms, i.e., interaction between tramadol/M1 metabolite and μ-opiate receptors (OPRM1), as well as inhibition of serotonin and norepinephrine reuptake by tramadol, thus suppressing pain impulse transmission at the level of spinal cord [8, 9]. Undoubtedly, the patients with ultra-fast tramadol metabolism are in high-risk group, especially, in cases of high-dose treatment and appropriate comorbidities of respiratory system, sleep apnea in tonsillar hyperplasia, or obesity conditions [10]. Therefore, some authors recommend to admit the patients to inpatient unit as early as 24 hours before treatment, in cases of acute nociceptive pain in patients administered tramadol and uncertain CYP2D6 activity levels [11]. Concerning the analgetic capacity, tramadol takes an intermediate position between NSAID and potent opioids, but at the same time, some publications report on less common frequency of sedation, respiratory depression, constipation and other side effects typical to strong opioids [12]. At the present time, tramadol is widely used for treatment of nociceptive pain in traumas and after surgical interventions in children [13, 14, 15, 16, 17, 18]. For moderate pain, the WHO analgesia ladder presumes low doses of strong opioids (oxycodone or morphine) to be the main alternative for weak opioids.

High individual variability of efficient dose is a specific feature of morphine administration. This characteristic could be explained by differences in its bioavailability, metabolism and excretion. The main morphine metabolites are as follows: morphine-6-glucuronide, which exhibits higher analgetic ability, but can elicit nausea, vomiting, excessive sedation, as well as morphime-3-glucuronide with probable antianalgetic and neurotoxic effects [19]. Several studies report about efficiency and safety of low-dose-morphine when managing moderate pain, e.g., in pediatric practice [20, 21, 22, 23]. In turn, the adverse effects of morphine derivatives are not shown at the present time (19).

Worth of note, however, both morphine and tramadol, may also display some side effects, including nausea, vomiting, respiratory depression, urinary retention, constipation, skin itching etc., thus causing discomfort to the patient [24, 25]. Therefore, the aim of our study was to evaluate efficiency and safety of tramadol and low-dose morphine in the treatment of moderate pain in children.

Patients and methods

The study was conducted in the Anesthesiology Department of R. M. Gorbacheva Memorial Institute for Pediatric Hematology, Oncology and Transplantation. The study included 159 primary admittances of the patients 1 to 17 years old (a median of 8 years) with complaints of moderate pain. Their age distribution is shown in Fig. 1.

The diagnoses were as follows: solid malignancies, 55.4% (n=88); hemoblastoses, 35.2% (n=56); non-malignant hematological disorders, 5% (n=8) and orphan diseases 4.4% (n=7).

Of them, 13.8% (n=22) were subjected to ChT, 68.8% (n=109) underwent allo- or auto-HSCT with myeloablative treatment regimen; 17.6% (n=28) received HSCT with non-myeloablative conditioning. The main reasons for pain syndrome were: mucositis, 85.5% (n=136), bone pain associated with hematopoiesis recovery, 5% (n=8); progression of primary disease, 5% (n=8); intestinal graft-versus-host disease (GvHD) 1.3%, (n=2), mucositis combined with acute cystitis 2.5% (n=4); paraproctitis, 0.7% (n=1), as seen in Fig. 2.

The intensity if pain was evaluated 3 times a day throughout the observation period to age-matched scale adapted to abilities of the patient (FLACC, verbal scale, Wong-Baker Faces Pain Rating Scale, or visual analogue scale). The total time of observation, including, changing lines of analgesic therapy, if necessary, ranged from 1 to 20 days (median 6 days). The response to therapy was assessed integrally by such parameters as: pain intensity (permanent and activity-evoked), quality of night sleep, ability of food and drink intake without an pain related failure, the possibility of non-pharmacological treatment and patient satisfaction. All the patients were classified into 2 groups in a ratio 3:1. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients in the 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). The initially prescribed analgetic was the first line of therapy, if there was a change of therapy, then the new analgetic was considered the second line of therapy. Drug infusion was performed permanently, via central venous catheter under hospital conditions. Pain intensity and drug acceptability were evaluated 2-3 times a day. In cases of insufficient analgesia, i.e., non-reduced or enhanced pain, lack of food and fluid intake because of pain etc., the drug was changed, or morphine dosage was increased. The analgetics were also changed in case of bad tolerance of current therapy. The choice of drug was made individually, depending on clinical situation.

Statistical evaluation was performed by means of SPSS software, using Chi-square test. When checking statistical hypotheses, the difference was presumed significant by p<0.05.

Results

The results of our study have revealed that the therapy was effective in 40.7% (n=48) and 58.5% (n=24) for tramadol and low-dose morphine treatment respectively, whereas in 0.8% of the cases, tramadol administration was prolonged to the end of staying in the unit/transfer to hospice, with good therapy acceptability. Enhanced analgetic treatment was required in 53.4% (n=63) for the 1^st group versus 39.0% (n=16) for the patients in the 2^nd group (Table 1).

Table 1. First line therapy results

Adverse effects in the first (tramadol-treated) group were observed in 5.1% (n=6). In particular, we observed one case of somnolescence with subsequent excitation in a girl of 4 years old; one case of dizziness with tremor in a girl of 11 years old. Two cases of involuntary contractions of striated muscles were detected: a 6 years old girl had twitching of right hand by 2 days after tramadol injections, and a 10 years old boy developed involuntary contractions of mimic muscles after 3 days of treatment, probably, due to serotoninergic effect of the drug. We have also seen one case of vomiting and nausea in the 17 years old female, as well as a case of nausea and anxiety in the 16 years old female. At the next treatment courses, this pain management was based on strong opioids. Their injection was accompanied by similar side effects. However, the mentioned side effects were no health-threatening. Subsequently 6 years old girl required the change of therapy to fentanyl. In other cases after cancellation of tramadol infusion, weak pain persisted, but further analgesia was not necessary. In the second group, only one female patient (2.4% of total) treated with low-dose morphine developed intestinal paralysis that was resolved after the therapy change.

Upon statistical analysis with Chi-square method, no significant differences were found between the tramadol group and low-dose morphine-treated groups in effectiveness and frequency of side effects (p=0.237).

In case of inefficiency of tramadol or low doses of morphine the second line of therapy included morphine in a low dose (after tramadol administration) was used in 29.1% (n=23), morphine in a standard dose (from 0.02 mg/kg/hr) in 17.7% (n=14) or fentanyl at a dose of 0.05 mcg/kg/hr in 53.2% (n=42) (Table 2).

Table 2. Distribution of the 2^nd line therapy medicines

We also evaluated the safety of low and standard doses of morphine in the second line of pain management therapy (Table 3). As result, we observed that side effects appeared in two cases: one because of nausea and vomiting and one due to complaints of blurred focus of vision, which was possibly associated with myosis. In group of standard doses of morphine one case of postrenal urinary retention. All three cases required a revision of treatment.

Table 3. Results of second line therapy with morphine in low and standard doses

Upon statistical analysis with Chi-square method, no significant differences were found between the standard and low-dose morphine-treated patients in effectiveness and frequency of side effects (p=0.271).

Discussion

Currently, some authors state that the respiratory depression is rarely encountered when tramadol dosage is carefully maintained [26, 27]. Frequency of nausea and vomiting are compatible (10-40%) when administering tramadol or opioids [28]. In our experience, a case of intestinal paralysis should be noted in a female patient from 2^nd group with mucositis. She had also side effects in the course of immune suppressors (nephro- and neurotoxicity), as well as pancytopenia and hemorrhagic syndrome that could be risk factors of this condition. Concerning adverse effects associated with tramadol prescription, the literature presents only single cases of generalized cramps due to excessive dosage and drug administration to a child under 1 year old [29]. One may also suggest an evolving serotonin syndrome connected to high dosage of serotoninergic drugs (selective serotonin reuptake inhibitors, some monoamine oxidase inhibitors), which includes excitation, ataxia, increased sweating, diarrhea, fever, hyperreflexia, and tremor. In our study, similar symptoms were seen in 4 patients, however, at less significant. This is, probably, connected with non-opioid effects of the drug (inhibition of serotonin and norepinephrin reuptake) [30, 31]. However, one cannot exclude ultra-fast CYP2D6 activity. That is the key aspects influencing tramadol efficiency and, potentially, genetic studies could serve as a predictor of efficacy and safety of the drug. Meanwhile, the CYP2D6 gene polymorphism is quite variable and requires time-consuming molecular genetic studies, thus reducing value of this technique in case of acute pain. One should also understand that the genotype will correspond to phenotype, with regard to variable clearance and body weight [8]. Therefore, we observe the children at the hospital within first 24 hours after starting tramadol infusion. For the patients requiring longer analgesia period, than in our study, tramadol shows lesser potential risk of dependence compared to classical opioids [32]. It’s also important to note that administration of tramadol has a less strict legal regulation [33, 34]. Due to social prejustice, its administration causes lesser anxiety on the part of parents and adolescent patients with respect to adverse effects, ex., addiction. Similarly, in cases with inefficiency of this therapy, the parents take easier administration of strong opioids [35, 36]. In future, tapentadol and local morphine applications could be promising therapeutic options [37]. However, there are only modest data on the studies of these medications in children and adolescents.

Conclusions

Based on the study data, we may suggest that tramadol exerts analgetic effects which are comparable to low-dose morphine. However, administration of these drugs needs dynamic observation of pediatric patients in the hospital at initial steps of therapy, due to some features of individual response and probable side effects. These issues also require further studies in larger groups of patients.

Authors are grateful to Elena V. Verbitskaya, assistant professor of the department of clinical pharmacology and evidence-based medicine, for her help in statistical data processing.

Conflict of interests

The authors declare no conflicts of interest.

References

1. Tutelman PR, Chambers CT, Stinson JN, Parker JE, Fernandez CV, Witteman HO, Nathan PC, Barwick M, Campbell F, Jibb LA, Irwin K. Pain in children with cancer: prevalence, characteristics, and parent management. Clin J Pain. 2018 ;34(3):198-206.
2. Anderson KO, Giralt SA, Mendoza TR, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39(12):759-66.
3. Bevans MF, Mitchell SA, Marden S. The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer. 2008;16(11):1243-1254.
4. Bowena JM, Wardill HR. Advances in the understanding and management of mucositis during stem cell transplantation. Curr Opin Support Palliat Care. 2017; 11(4), 341-346.
5. Richardson PG, Grupp SA, Pagliuca A, Krishnan AJ, Ho VT, Corbacioglu S. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2017; 6(3):75-93.
6. Ma JD, El-Jawahri AR, LeBlanc TW, Roeland EJ. Pain syndromes and management in adult hematopoietic stem cell transplantation. Hematol Oncol Clin North Am. 2018; 32 (3), 551-567.
7. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: World Health Organization; 2012.
8. Allegaert K, Holford N, Anderson BJ, Holford S, Stuber F, Rochette A, Trocóniz IF, Beier H, de Hoon JN, Pedersen RS, Stamer U. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. Clin Pharmacokinet. 2015; 54(2):167-178.
9. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg. 2017;124(1):44-51.
10. Anderson BJ, Thomas J, Ottaway K, Chalkiadis GA. Tramadol: keep calm and carry on. Pediatr Anesth. 2017;27:785‐788.
11. Rodieux F, Vutskits L, Posfay-Barbe KM, Habre W, Piguet V, Desmeules JA, Samer CF. When the safe alternative is not that safe: tramadol prescribing in children. Front. Pharmacol. 9:148. DOI: 10.3389/fphar.2018.00148.
12. Marzuillo P, Calligaris L, Barbi E. Tramadol can selectively manage moderate pain in children following European advice limiting codeine use. Found Acta Pædiat. 2014; 103:1110-1116.
13. Ali S, Sofi K, Dar AQ. Comparison of intravenous infusion of tramadol alone with combination of tramadol and paracetamol for ostoperative pain after major abdominal surgery in children. Anesth Essays Res. 2017; 11:472–476. DOI: 10.4103/aer.AER_23_17.
14. Friedrichsdorf SJ, Postier AC, Foster LP, Lander TA, Tibesar RJ, Lu Y, Sidman JD. Tramadol versus codeine/acetaminophen after pediatric tonsillectomy: a prospective, double-blinded, randomized controlled trial. J Opioid Manag. 2015; 11: 283-294. DOI: 10.5055/jom.2015.027.
15. Liaqat N, Dar SH. Comparison of single-dose nalbuphine versus tramadol for postoperative pain management in children: a randomized, controlled trial. Korean J Anesthesiol. 2017; 70: 184-187. DOI: 10.4097/kjae.2017.70. 2.184.
16. Schnabel A, Reichl SU, Meyer-Friessem C, Zahn PK, Pogatzki-Zahn E. Tramadol for postoperative pain treatment in children. Cochrane Database Syst Rev. 2015; 3:CD009574. DO: 10.1002/14651858.CD009574.pub2.
17. Yenigun A, Et T, Aytac S, Olcay B. Comparison of different administration of ketamine and intravenous tramadol hydrochloride for postoperative pain relief and sedation after pediatric tonsillectomy. J Craniofac Surg. 2015; 26: e21-e24. DOI: 10.1097/scs.0000000000001250.
18. Neri E, Maestro A, Minen F, Montico M, Ronfani L, Zanon D, Favret A, Messi G, Barbi E. Sublingual ketorolac versus sublingual tramadol for moderate to severe posttraumatic bone pain in children: a double-blind, randomised, controlled trial. Arch Dis Child. 2013; 98: 721-724. DOI: 10.1136/archdischild-2012-303527.
19. Lee YJ, Suh S-Y, Song J, Lee S, Seo A-R, Ahn HY, Lee MA, Kim C-M, Klepstad P. Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study. BMC Palliat Care. 2015; 14: 53. DOI:10.1186/s12904-015-0052-9.
20. Bandieri E, Romero M, Ripamonti C, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34(5):436-442. DOI: 10.1200/JCO.2015.61.0733.
21. Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G. Use of strong opioids in advanced cancer pain: A randomized trial. J Pain Symptom Managem. 2004; 27:409-416.
22. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, Speranza R, Tassinari D, Magnani P, Saccani D, Montanari L, Roudnas B, Amadori D. A validation study of the WHO analgesic ladder: A two-step vs three-step strategy. Support Care Cancer.2005; 13: 888-894.
23. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Ficorella C, Verna L, Tirelli W, Villari P, Arcuri E. Low morphine doses in opioid naive cancer patients with pain. J Pain Symptom Managem. 2006; 31:242-247.
24. Duedahl TH, Hansen EH. A qualitative systematic review of morphine treatment in children with postoperative pain. Paediatr Anaesth. 2007; 17: 756-774.
25. Verghese ST, Hannallah RS. Acute pain management in children. J Pain Res. 2010; 3:105-123.
26. Hannam JA, Anderson BJ, Potts A. Acetaminophen, ibuprofen, and tramadol analgesic interactions after adenotonsillectomy. Pediatr Anesth. 2018; 28(10): 841-851. DOI: 10.1111/pan.13464.
27. Hassanian-Moghaddam H, Farnaghi F, Rahimi M. Tramadol overdose and apnea in hospitalized children, a review of 20 cases. Res Pharm Sci. 2015; 10(6):544-552.
28. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Pediatr Anesth. 2011; 21:266-273.
29. Li X, Zuo Y, Dai Y. Children's seizures caused by continuous intravenous infusion of tramadol analgesia: Two rare case reports. Pediatr Anesth.2012; 22 (3):308-309.
30. Savage R. Medical assessor serious reactions with tramadol: Seizures and serotonin syndrome. Prescriber Update. 2007; 28(1): 11-13.
31. Sansone RA, Sansone LA. Tramadol: Seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont). 2009; 6 (4): 17-21.
32. Kirienko P.A. Usage if tramadol hydrochloride in routine clinical practice (review of literature). Rossiisky Medizinskyi Zhurnal. 2004; 8:512 (In Russian).
33. Order of the Ministry of Health of Russian Federation of January 14/2019 №4N "On Approving the Procedure for Prescribing Medicines, Forms of Prescription Forms for Medicines Procedure for Formulating the Forms. Recording and Storage", enactment date: 28.05.2020. http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=344178&fld=134&dst=1000000001,0&rnd=0.7542220165183926#0878938710536209 (In Russian).
34. Appendix No.2 to the Disposal of Russian Government of 12.10.2019 № 2406-r. http://static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf (In Russian).
35. Sichetti D, Bandieri E, Romero M, Di Biagio K, Luppi M, Belfiglio M, Tognoni G, Ripamonti CI. ECAD Working Group: Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. Ann Oncol. 2010; 21(10):2088-2093.
36. Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, Apolone G. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014; 32(36):4149-4154.
37. Kolesnikov YA. Prospective usage of a combination of locally injected nonsteroid anti-inflammatory drugs and opioids when treating pains of peripheral genesis. Vestnik Anestesiologii I Reanimatologii. 2019; 16(3):41-47 (In Russian).

" ["DETAIL_TEXT_TYPE"]=> string(4) "html" ["~DETAIL_TEXT_TYPE"]=> string(4) "html" ["PREVIEW_TEXT"]=> string(0) "" ["~PREVIEW_TEXT"]=> string(0) "" ["PREVIEW_TEXT_TYPE"]=> string(4) "text" ["~PREVIEW_TEXT_TYPE"]=> string(4) "text" ["PREVIEW_PICTURE"]=> NULL ["~PREVIEW_PICTURE"]=> NULL ["LANG_DIR"]=> string(4) "/ru/" ["~LANG_DIR"]=> string(4) "/ru/" ["SORT"]=> string(3) "500" ["~SORT"]=> string(3) "500" ["CODE"]=> string(100) "otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det" ["~CODE"]=> string(100) "otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det" ["EXTERNAL_ID"]=> string(4) "1854" ["~EXTERNAL_ID"]=> string(4) "1854" ["IBLOCK_TYPE_ID"]=> string(7) "journal" ["~IBLOCK_TYPE_ID"]=> string(7) "journal" ["IBLOCK_CODE"]=> string(7) "volumes" ["~IBLOCK_CODE"]=> string(7) "volumes" ["IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["~IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["LID"]=> string(2) "s2" ["~LID"]=> string(2) "s2" ["EDIT_LINK"]=> NULL ["DELETE_LINK"]=> NULL ["DISPLAY_ACTIVE_FROM"]=> string(0) "" ["IPROPERTY_VALUES"]=> array(18) { ["ELEMENT_META_TITLE"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["ELEMENT_META_KEYWORDS"]=> string(0) "" ["ELEMENT_META_DESCRIPTION"]=> string(504) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клетокClinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation" ["ELEMENT_PREVIEW_PICTURE_FILE_ALT"]=> string(5749) "<p style="text-align: justify;">Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель – оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.</p> <h3>Материалы и методы</h3> <p style="text-align: justify;">В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.</p> <h3>Результаты</h3> <p style="text-align: justify;">Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24). </p> <p style="text-align: justify;">Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.</p> <h3>Выводы</h3> <p style="text-align: justify;">Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность. </p>" ["ELEMENT_PREVIEW_PICTURE_FILE_TITLE"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["ELEMENT_DETAIL_PICTURE_FILE_ALT"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["ELEMENT_DETAIL_PICTURE_FILE_TITLE"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_META_TITLE"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_META_KEYWORDS"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_META_DESCRIPTION"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_PICTURE_FILE_ALT"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_PICTURE_FILE_TITLE"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_PICTURE_FILE_NAME"]=> string(100) "otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det" ["SECTION_DETAIL_PICTURE_FILE_ALT"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_DETAIL_PICTURE_FILE_TITLE"]=> string(336) "Оценка эффективности и безопасности трамадола и морфина в низких дозах при купировании боли у детей после проведения химиотерапии и трансплантации гемопоэтических стволовых клеток" ["SECTION_DETAIL_PICTURE_FILE_NAME"]=> string(100) "otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det" ["ELEMENT_PREVIEW_PICTURE_FILE_NAME"]=> string(100) "otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det" ["ELEMENT_DETAIL_PICTURE_FILE_NAME"]=> string(100) "otsenka-effektivnosti-i-bezopasnosti-tramadola-i-morfina-v-nizkikh-dozakh-pri-kupirovanii-boli-u-det" } ["FIELDS"]=> array(1) { ["IBLOCK_SECTION_ID"]=> string(3) "149" } ["PROPERTIES"]=> array(18) { ["KEYWORDS"]=> array(36) { ["ID"]=> string(2) "19" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:46:01" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(27) "Ключевые слова" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "KEYWORDS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "19" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "4" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "Y" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "Y" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(27) "Ключевые слова" ["~DEFAULT_VALUE"]=> string(0) "" } ["SUBMITTED"]=> array(36) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26456" ["VALUE"]=> string(10) "07.05.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "07.05.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL } ["ACCEPTED"]=> array(36) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26457" ["VALUE"]=> string(10) "05.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "05.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL } ["PUBLISHED"]=> array(36) { ["ID"]=> string(2) "22" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Дата публикации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "PUBLISHED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "22" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Дата публикации" ["~DEFAULT_VALUE"]=> NULL } ["CONTACT"]=> array(36) { ["ID"]=> string(2) "23" ["TIMESTAMP_X"]=> string(19) "2015-09-03 14:43:05" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(14) "Контакт" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "CONTACT" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "23" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(14) "Контакт" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHORS"]=> array(36) { ["ID"]=> string(2) "24" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:45:07" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "AUTHORS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "24" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_RU"]=> array(36) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26458" ["VALUE"]=> array(2) { ["TEXT"]=> string(716) "<p>Екатерина В. Гончарова^1,2, Инга Е. Заводова¹, Никита П. Волков¹, Ольга А. Иванова¹, Максим А. Кучер¹, <br>Алексей Ю. Соколов^2,3, Максим П. Богомольный¹, Глеб Э. Ульрих⁴, Людмила С. Зубаровская¹, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Борис В. Афанасьев¹</span></p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(556) "

Екатерина В. Гончарова^1,2, Инга Е. Заводова¹, Никита П. Волков¹, Ольга А. Иванова¹, Максим А. Кучер¹,
Алексей Ю. Соколов^2,3, Максим П. Богомольный¹, Глеб Э. Ульрих⁴, Людмила С. Зубаровская¹, Борис В. Афанасьев¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_RU"]=> array(36) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26462" ["VALUE"]=> array(2) { ["TEXT"]=> string(1198) "<p>¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ² Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ³ Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия<br> ⁴ Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(1120) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия
³ Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия
⁴ Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_RU"]=> array(36) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26463" ["VALUE"]=> array(2) { ["TEXT"]=> string(5749) "<p style="text-align: justify;">Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель – оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.</p> <h3>Материалы и методы</h3> <p style="text-align: justify;">В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.</p> <h3>Результаты</h3> <p style="text-align: justify;">Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24). </p> <p style="text-align: justify;">Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.</p> <h3>Выводы</h3> <p style="text-align: justify;">Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(5569) "

Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель – оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.

Материалы и методы

В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.

Результаты

Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24).

Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.

Выводы

Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.

Ключевые слова

Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["DOI"]=> array(36) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26459" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-20-27" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-20-27" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_EN"]=> array(36) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26464" ["VALUE"]=> array(2) { ["TEXT"]=> string(556) "<p>Ekaterina V. Goncharova^1,2, Inga E. Zavodova¹, Nikita P. Volkov¹, Olga A. Ivanova¹, Maxim A. Kucher¹, Alexey Y. Sokolov^2,3, Maxim P. Bogomolny¹, Gleb E. Ulrikh⁴, Ludmila S. Zubarovskaya¹, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Boris V. Afanasyev¹ </span></p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(402) "

Ekaterina V. Goncharova^1,2, Inga E. Zavodova¹, Nikita P. Volkov¹, Olga A. Ivanova¹, Maxim A. Kucher¹, Alexey Y. Sokolov^2,3, Maxim P. Bogomolny¹, Gleb E. Ulrikh⁴, Ludmila S. Zubarovskaya¹, Boris V. Afanasyev¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_EN"]=> array(36) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26465" ["VALUE"]=> array(2) { ["TEXT"]=> string(960) "<p>¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br> ² Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia<br> ³ Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia<br> ⁴ Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia</p> <br> <p><b>Correspondence</b><br> Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia<br> Phone: +7 (911) 087 8976<br> E-mail: ek.v.goncharova@gmail.com</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(834) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia
³ Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia
⁴ Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Correspondence
Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: +7 (911) 087 8976
E-mail: ek.v.goncharova@gmail.com

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_EN"]=> array(36) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26466" ["VALUE"]=> array(2) { ["TEXT"]=> string(3241) "<p style="text-align: justify;">A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.</p> <h3>Patients and methods</h3> <p style="text-align: justify;">The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.</p> <h3>Results</h3> <p style="text-align: justify;">When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups. </p> <h3>Conclusion</h3> <p style="text-align: justify;">Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients. </p> <h2>Keywords</h2> <p style="text-align: justify;">Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(3059) "

A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.

Patients and methods

The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.

Results

When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups.

Conclusion

Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients.

Keywords

Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["NAME_EN"]=> array(36) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26460" ["VALUE"]=> string(168) "Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(168) "Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" } ["FULL_TEXT_RU"]=> &array(36) { ["ID"]=> string(2) "42" ["TIMESTAMP_X"]=> string(19) "2015-09-07 20:29:18" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(23) "Полный текст" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(12) "FULL_TEXT_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "42" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(23) "Полный текст" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["PDF_RU"]=> array(36) { ["ID"]=> string(2) "43" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF RUS" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_RU" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "43" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26461" ["VALUE"]=> string(4) "2012" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2012" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF RUS" ["~DEFAULT_VALUE"]=> string(0) "" } ["PDF_EN"]=> array(36) { ["ID"]=> string(2) "44" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF ENG" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "44" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26467" ["VALUE"]=> string(4) "2013" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2013" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF ENG" ["~DEFAULT_VALUE"]=> string(0) "" } ["NAME_LONG"]=> array(36) { ["ID"]=> string(2) "45" ["TIMESTAMP_X"]=> string(19) "2023-04-13 00:55:00" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(72) "Название (для очень длинных заголовков)" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "NAME_LONG" ["DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "45" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(80) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(72) "Название (для очень длинных заголовков)" ["~DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } } } ["DISPLAY_PROPERTIES"]=> array(10) { ["AUTHOR_EN"]=> array(37) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26464" ["VALUE"]=> array(2) { ["TEXT"]=> string(556) "<p>Ekaterina V. Goncharova^1,2, Inga E. Zavodova¹, Nikita P. Volkov¹, Olga A. Ivanova¹, Maxim A. Kucher¹, Alexey Y. Sokolov^2,3, Maxim P. Bogomolny¹, Gleb E. Ulrikh⁴, Ludmila S. Zubarovskaya¹, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Boris V. Afanasyev¹ </span></p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(402) "

Ekaterina V. Goncharova^1,2, Inga E. Zavodova¹, Nikita P. Volkov¹, Olga A. Ivanova¹, Maxim A. Kucher¹, Alexey Y. Sokolov^2,3, Maxim P. Bogomolny¹, Gleb E. Ulrikh⁴, Ludmila S. Zubarovskaya¹, Boris V. Afanasyev¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(402) "

Ekaterina V. Goncharova^1,2, Inga E. Zavodova¹, Nikita P. Volkov¹, Olga A. Ivanova¹, Maxim A. Kucher¹, Alexey Y. Sokolov^2,3, Maxim P. Bogomolny¹, Gleb E. Ulrikh⁴, Ludmila S. Zubarovskaya¹, Boris V. Afanasyev¹

" } ["SUMMARY_EN"]=> array(37) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26466" ["VALUE"]=> array(2) { ["TEXT"]=> string(3241) "<p style="text-align: justify;">A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.</p> <h3>Patients and methods</h3> <p style="text-align: justify;">The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.</p> <h3>Results</h3> <p style="text-align: justify;">When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups. </p> <h3>Conclusion</h3> <p style="text-align: justify;">Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients. </p> <h2>Keywords</h2> <p style="text-align: justify;">Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(3059) "

A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.

Patients and methods

The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.

Results

When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups.

Conclusion

Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients.

Keywords

Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(3059) "

A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.

Patients and methods

The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1^st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2^nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.

Results

When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups.

Conclusion

Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients.

Keywords

Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.

" } ["DOI"]=> array(37) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26459" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-20-27" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-20-27" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-20-27" } ["NAME_EN"]=> array(37) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26460" ["VALUE"]=> string(168) "Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(168) "Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(168) "Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation" } ["ORGANIZATION_EN"]=> array(37) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26465" ["VALUE"]=> array(2) { ["TEXT"]=> string(960) "<p>¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br> ² Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia<br> ³ Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia<br> ⁴ Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia</p> <br> <p><b>Correspondence</b><br> Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia<br> Phone: +7 (911) 087 8976<br> E-mail: ek.v.goncharova@gmail.com</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(834) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia
³ Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia
⁴ Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Correspondence
Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: +7 (911) 087 8976
E-mail: ek.v.goncharova@gmail.com

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(834) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia
³ Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia
⁴ Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Correspondence
Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: +7 (911) 087 8976
E-mail: ek.v.goncharova@gmail.com

" } ["AUTHOR_RU"]=> array(37) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26458" ["VALUE"]=> array(2) { ["TEXT"]=> string(716) "<p>Екатерина В. Гончарова^1,2, Инга Е. Заводова¹, Никита П. Волков¹, Ольга А. Иванова¹, Максим А. Кучер¹, <br>Алексей Ю. Соколов^2,3, Максим П. Богомольный¹, Глеб Э. Ульрих⁴, Людмила С. Зубаровская¹, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Борис В. Афанасьев¹</span></p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(556) "

Екатерина В. Гончарова^1,2, Инга Е. Заводова¹, Никита П. Волков¹, Ольга А. Иванова¹, Максим А. Кучер¹,
Алексей Ю. Соколов^2,3, Максим П. Богомольный¹, Глеб Э. Ульрих⁴, Людмила С. Зубаровская¹, Борис В. Афанасьев¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(556) "

Екатерина В. Гончарова^1,2, Инга Е. Заводова¹, Никита П. Волков¹, Ольга А. Иванова¹, Максим А. Кучер¹,
Алексей Ю. Соколов^2,3, Максим П. Богомольный¹, Глеб Э. Ульрих⁴, Людмила С. Зубаровская¹, Борис В. Афанасьев¹

" } ["SUBMITTED"]=> array(37) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26456" ["VALUE"]=> string(10) "07.05.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "07.05.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "07.05.2020" } ["ACCEPTED"]=> array(37) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26457" ["VALUE"]=> string(10) "05.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "05.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "05.06.2020" } ["SUMMARY_RU"]=> array(37) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26463" ["VALUE"]=> array(2) { ["TEXT"]=> string(5749) "<p style="text-align: justify;">Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель – оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.</p> <h3>Материалы и методы</h3> <p style="text-align: justify;">В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.</p> <h3>Результаты</h3> <p style="text-align: justify;">Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24). </p> <p style="text-align: justify;">Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.</p> <h3>Выводы</h3> <p style="text-align: justify;">Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(5569) "

Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель – оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.

Материалы и методы

В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.

Результаты

Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24).

Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.

Выводы

Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.

Ключевые слова

Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(5569) "

Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель – оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.

Материалы и методы

В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.

Результаты

Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24).

Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.

Выводы

Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.

Ключевые слова

Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность.

" } ["ORGANIZATION_RU"]=> array(37) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26462" ["VALUE"]=> array(2) { ["TEXT"]=> string(1198) "<p>¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ² Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ³ Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия<br> ⁴ Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(1120) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия
³ Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия
⁴ Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(1120) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия
³ Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия
⁴ Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия

" } } } [1]=> array(49) { ["IBLOCK_SECTION_ID"]=> string(3) "149" ["~IBLOCK_SECTION_ID"]=> string(3) "149" ["ID"]=> string(4) "1855" ["~ID"]=> string(4) "1855" ["IBLOCK_ID"]=> string(1) "2" ["~IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["~NAME"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["ACTIVE_FROM"]=> NULL ["~ACTIVE_FROM"]=> NULL ["TIMESTAMP_X"]=> string(19) "03.08.2020 13:33:40" ["~TIMESTAMP_X"]=> string(19) "03.08.2020 13:33:40" ["DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu/" ["~DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu/" ["LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["~LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["DETAIL_TEXT"]=> string(44099) "

Introduction

Over the past decade, international hematological community has been actively engaged in clinical research to standardize medical treatment of patients with chronic Ph-negative myeloproliferative neoplasms (MPNs) and improve the quality of care for this category of patients [1–5].

To identify the problems and areas of concern in management of the Ph(-) MPN patients, a large-scale Landmark Survey of patients and physicians was initiated in USA in 2014 [6, 7]. A total of 813 Ph(-) MPN patients and 457 physicians who treated this cohort participated in this survey. The results of this study were reported for each of the most common Ph(-) MPNs, i.e., myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) in the following sections: understanding of the disease diagnosis by patients and physicians; symptoms experienced by patients and their impact on daily activities, as reported by patients and physicians; disease burden with relation to the patient's quality of life and work productivity reported by patients and physicians; patient’s and physician’s attitudes to the treatment goals; and perception of bilateral physician-patient relationships [8]. The independent responses submitted by patients and physicians were used to find distinct similarities or differences between MF, PV, and ET. In 2016, the project became international, and the electronic survey forms were completed by Ph(-) MPN patients and hematologists who treated these diseases in Australia, Japan, Canada, Germany, Italy, and the UK [9]. The data collected in this survey enabled the researchers to evaluate perception of the physical, psychological, social and other problems that Ph(-) MPN patients face in their daily life, and to improve the awareness of hematologists about these problems.

The next stage of this project took place in 2018, as a research program, to conduct an online survey of 560 Ph(-) MPN patients and 260 hematologists in the emerging market countries: China, Turkey, Russia, Taiwan, South Korea, and Saudi Arabia [10, 11] The results of this survey, along with previous studies conducted in 2014-2016, are of importance for improving Ph(-) MPN medical care and developing standardized approaches to diagnosis and treatment of these chronic disorders. The project could potentially promote the multidisciplinary efforts, working together with patients and their relatives, in order to maximize effects of the Ph(-) MPN therapy.

The aim of this paper is to analyze and systematize the data from the Russian patient and physician survey arranged as part of the Landmark Survey in the emerging market countries.

Patients and methods

Forty Ph(-) MPN patients and physicians residing in the Russian Federation took part in the international Landmark Survey between September and November 2018. The criteria for engaging a physician for the survey were as follows: (1) managing of least 2 patients with MF, 5 patients with PV, and 5 patients with ET over last 12 months; (2) professional experience in hematology over 1 year; at least 25% of patients treated by the physician had to have hematological disorders. The patients with MF, PV and ET aged 18 years and older were enrolled with the physician at their routine clinic visits. Patients were eligible to complete the survey, being, however, excluded if they were participating in any clinical trials.

The survey checklists consisted of the following sections: for patients – patient demographics, patient awareness and perception of symptoms, impact of disease on daily living, work productivity/activity impairment, disease history and treatment, patient satisfaction, disease information availability; for physicians – physician demographics and caseload, patient disease burden, patient management and treatment decisions, physician perceptions [11]. This was an exploratory survey; no any special standardized questionnaires were applied during the survey.

Before completing the survey, patients and physicians consented to participate in the project. Both patients and physicians participated in the online survey independently of each other. To keep confidentiality, all physicians and patients were assigned identification numbers. Before the start of the survey, all the participants were given instructions on the procedure and principles of electronic questionnaire completion. The survey took 25-30 minutes.

The results survey are presented as descriptive statistics with estimation of mean values, standard deviations, and percentages for each position tested. Analyses were conducted in Stata statistical software version 16.0 or later (StataCorp, 2015. Stata statistical software: Release 16 (College Station, TX, StataCorp LP)). Where missing values were found in a particular variable, any participant with missing values was removed from all pieces of analysis where that variable was used. However, patients and physicians removed from one piece of analysis were still eligible for inclusion in other analyses. It was expected that the base of patients and physicians would vary from variable to variable for this reason.

Results

Characteristics of the patients and attending physicians

Overall, 40 patients with Ph(-) MPNs and 30 physicians completed the online survey. The characteristics of the patients included in the survey are summarized in Table 1. The distribution by diagnosis was as follows: PV, 42.5%; MF, 37.5%, and ET, 20% of patients. Twelve (80%) of the 15 MF patients were diagnosed with primary MF. Mean age of the patients at the time of diagnosis was 54.9 ± 9.7 years, duration of the disorder was 3.0 ± 2.2 years. Hence, their mean age at the survey was 57.9 ± 10.4 years. Diabetes mellitus (38% of ET patients), congestive heart failure (20% of MF patients), peptic ulcer (18% of PV patients), deep vein thrombosis (18% of PV patients) and liver disease (18% of PV patients) were the most common comorbidities in this group.

It is worth of note that over a half of the patients (55%) exhibited symptoms for a year prior to diagnosis, 17.5% during two years, and almost 1/3 of patients (27.5%) felt them over two years prior to the clinical diagnosis.

Of 30 physicians participating in the survey, 24 (80%) were hematologists, and 6 (20%) were hematologists-oncologists. Approximately half of the physicians (47%) had 3 to 15 years of professional experience, 40% had 15 to 25 years, and 13% had experience of 25 to 33 years. Over the period of 12 months preceding the survey, each of the physicians treated, on average, 10 MF cases, 16 PV patients, and 14 ET cases. 63% of physicians worked in regional clinic hospitals, 30% in specialized referral centers, and 7%, at the University clinics.

Table 1. Clinical and demographic characteristics of the patients

Symptoms in Ph(-) MPN patients

At diagnosis, the patients reported fatigue (63%) and weakness (53%) as the most common Ph(-) MPN symptoms. Other symptoms post-diagnosis included pruritus (33%) and night sweats (30%). On average, Ph(-) MPN patients mentioned seven symptoms ever experienced during their illness. The MF patients complained about eight symptoms, compared with six symptoms usually reported by PV and ET patients.

The five most common symptoms reported by MF, PV and ET patients over the past 12 months are listed in Figure 1. Over half of the MF patients reported fatigue (80%), weakness (67%), and night sweats (60%). Worth of note, not all patients believed these symptoms were related to the disease. In particular, the patients did not associate fatigue, weakness, and night sweats with the disease in 33%, 40% and 56% cases, respectively. As for PV symptoms, 59% of patients felt weakness, and 41% experienced fatigue and pruritus. Hence, 20% and 14% of the patients did not relate weakness and fatigue, respectively, to specific symptoms of their disease. Meanwhile, all the patients believed that pruritus was associated with the disease. 50% of ET patients experienced fatigue and numbness/tingling. Of note, all the patients associated fatigue with the disease; as for numbness/tingling, 12.5% of patients did not associate this symptom with the disease. At the same time, most physicians (69%) believed that the vast majority of the patients associated their symptoms with myeloproliferative disease.

The patients also evaluated severity of their symptoms in the past 12 months using a 10-point numerical rating scale (NRS). Some symptoms were severe: ≥7 points on the NRS scale. Patients with Ph(-) MPN reported the following severe symptoms: fatigue (n=18), weakness (n=15), headache (n=9), night sweats (n=8), abdominal pain (n=7), fever (n=5), dizziness (n=5), bone pain (n=2), nose bleeding (n=2) and facial flushing (n=2).

Attending physicians also answered some questions about symptoms in their patients. They were asked to list five most significant symptoms for the patients with each type of Ph(-) MPNs. For MF, the physicians mentioned fatigue (72%), unintentional weight loss (59%), weakness (45%), abdominal discomfort (34%), and night sweats (31%). Of note, only half of the physicians, when compared to their patients, reported night sweats in these cases. In PV, physicians pointed to itching (59%), headaches (45%), hypertension (41%), facial flushing and numbness/tingling in hands and feet (38%). Moreover, as opposed to patients, none of the physicians mentioned weakness or fatigue. For ET, the physicians noted fatigue (59%), nasal bleeding and thrombotic events clot (48%), headaches (37%), and weakness (33%). Unlike patients, physicians did not mention numbness/tingling. As evidenced by the above data, there are discrepancies in the patient and physician perception of the most significant symptoms experienced by Ph(-) MPN patients, while 77% of physicians believed that they have correctly assessed the symptom burden.

As a separate task, both physicians and patients were asked to choose from the list of symptoms experienced by patients those traits that, according to the patient, were most likely to be resolved (1 to 3). The MF patients mentioned fatigue (47%) and pruritus (33%); physicians chose weakness (45%) and fatigue (31%). Patients with PV pointed to pruritus (41%), whereas, in opinion of physicians, pruritus (52%) and hypertension (48%) were most likely to be resolved. As for ET, the patients chose fatigue (38%), while physicians highlighted fatigue, tingling in the hands/feet, and predisposal for thrombosis (44%).

These discrepancies in the physician and patient description of the symptoms that are most significant to patients can be partially explained using the survey data, with regard of the physician’s strategies when discussing symptoms and general well-being during the patients’ clinical visit. The majority of patients mentioned in the survey that the physicians were interested in their symptoms and overall well-being. Patients noticed the following: during the clinic visit, attending physician was actively interested in their well-being and symptoms (55% of patients); the doctor asked them about specific, most important symptoms (25%); the physician expected patients to report their concerns (15%); the physician asked them to fill out questionnaires and discussed existing problems with them on the basis of their answers (5%). All the patients stated that the physician was interested in their well-being and existing symptoms.

In addition, significant differences between physicians and patients were revealed, regarding the time that physicians spent discussing blood test results and well-being with the patients. The vast majority of patients (93%) believed that during the visit the physician spent most of the time discussing blood test results with them. At the same time, only 43% of physicians believed that they spent more time discussing blood test results with the patient rather than their well-being.

According to the survey of physicians, they received information about the patient’s symptoms and overall well-being in the following way: 43% of physicians were actively interested in the patient’s problems during the visit; 37% discussed the most important symptoms with the patient, and 13% expected reporting of any alarming symptoms from patients. Only 7% of physicians told that they asked patients to fill out questionnaires to record their symptoms. At the same time, 83% of physicians stated that they assessed patient's symptoms at each visit. When evaluating the severity of symptoms, 43% of physicians considered the impact of disease on the daily life of the patient, and 27% of physicians based it on their own assessment. Only 20% of physicians used questionnaires for standard assessment of the symptoms.

Disease impact on the quality of life in Ph(-) MPN patients

The list of questions in the patient’s and physician’s survey checklists focused on the impact of symptoms on patient’s quality of life and daily activities [9, 11]. Most Ph(-) MPN patients (81%) believed that the symptoms reduced their quality of life (Table 2). All the MF patients, 65% of PV patients, and 75% of ET patients agreed with this statement. Physicians also shared the view that the disease symptoms lead to worsening of quality of life of patients. Furthermore, 77% of physicians believed that even mild or moderate symptoms in patients could be associated with reduced quality of life.

Table 2. Symptom interference with quality of life in Ph(-) MPN patients

As a special point, the effect of symptoms on daily life activities was evaluated by the survey. Figure 2 shows the distribution of the patient’s and physician’s answers about impact of the symptoms upon daily activities of patients, their family and social life, relationships with caregivers, as well as limitations of activities caused by pain/discomfort. As evidenced in the Figure 2, most patients and physicians believed that disease symptoms affect the mentioned daily activities of patients. Most patients and physicians also indicated that pain/discomfort limits patient's daily activities, especially in MF patients, compared to PV and ET. In MF, the reported symptoms had a higher impact on their daily activities, family and social life. Pain/discomfort also significantly limited their daily activities. In general, the discrepancy between physicians and patients in assessing the impact of disease symptoms on daily life was not significant.

Figure 2. Patient and physician perceptions of the disease symptom burden on daily activities in Ph(-) MPN patients; A, myelofibrosis; B polycythemia vera; C, essential thrombocythemia

The patients were also asked in what way the disease affected various aspects of their quality of life (Figure 3). For the vast majority of Ph(-) MPN patients, the disease had a significant impact on physical (95%) and emotional (87%) functioning. Almost all of the patients (95%) experienced anxiety, because of their condition and were worried that their condition would worsen. It is noteworthy that 80% of patients believed that their health was worse, if compared to their condition evaluated by treating physician, and 77% felt helpless.

Figure 3. Disease impact on various aspects of quality of life as assessed by Ph(-) MPN patients

As for different forms of Ph(-) MPNs, all the patients with MF and ET, as well as 88% of patients with PV, experienced some degree of physical problems caused by their condition. All the ET patients, 87% of MF patients, and 82% of PV patients reported emotional burden associated with the disease. All the MF patients, 94% of PV patients and 87% of ET patients experienced anxiety related to their condition. At the same time, 93%, 71% and 75% of patients with MF, PV and ET, respectively, believed that they felt worse than perceived by their treating physician. Moreover, 93%, 71% and 62% of patients with MF, IP and ET, respectively, indicated that they felt helpless.

All surveyed physicians believed that MF and PV patients had physical and emotional limitations; 7% of physicians believed that ET patients did not experience such restrictions.

Disease impact on work productivity in Ph(-) MPN patients

The patient survey contained questions about employment, disability, limitations in overall activity and support from caregivers. From the proposed list of employment options, over one-third of patients (35%) stated that they worked full time, 13% were in part-time employment, and 5% were on sick leave. Other patients claimed they were pensioners (43%) or unemployed (6%). Overall, 53% of patients reported that they continued to work at the time of the survey. Over past 7 days, the patients had to miss, on average, 2.8 hours of working time, due to their disease. To assess the impact of the disease on productivity at work and overall activity, patients were asked to choose a number on a scale from 0 to 10, where 0 means "no effect of the disease on work/overall activity" and 10 means "completely unable to work/illness completely interferes with overall activity". According to the survey results, 32% of patients indicated that their disease significantly (score 7-10) limited their productivity at work; the disease significantly affected overall activity in 48% of patients.

Overall, 48% of Ph(-) MPN patients reported requiring assistance from a caregiver, with 46% of MF patients, 36% of PV patients and 13% of ET patients needed for support often or sometimes. Half of these patients were supported by their children. In 47% of cases, a support for the patients was provided by the people who continued to work. Assistance with housework (79%) and transportation (74%) were the main forms of support.

Treatment of Ph(-) MPNs and physician’s and patient’s perspectives on treatment goals

The surveys for physicians contained the following questions regarding treatment: 1) treatment strategy at the time of diagnosis; 2) therapy prescribed anytime in the past; 3) treatment that physicians currently prescribed for their patients. Physicians had to choose the answers from the proposed list of treatment options separately for patients with MF, PV and ET. According to their answers, the physicians chose a strategy of waiting and observation in 12% of MF patients, in 15% of PV cases, and in 18% of ET patients at the time of diagnosis. Details of previous treatment for patients with MF, PV and ET, and currently prescribed therapies, as well as reasons for changing therapy are summarized in Table 3. In general, there is no much difference between the past and current therapies prescribed by physicians to treat specific MF, PV and ET patients. Some differences between the past and current therapies were observed for MF treatment with epoetin-α, androgens and glucocorticosteroids, for PV treatment with epoetin-α, for ET treatment with glucocorticosteroids and BMT/HSCT.

Table 3. Treatment prescribed in the past, currently prescribed therapy, and the reasons for changing therapy in patients with MF, IP and ET

Worth of note, half of the physicians reported an increase in symptoms of a specific Ph(-) MPN as the reason for the change of treatment.

The questionnaire for physicians also included questions concerning prognostic risk assessment in patients with Ph(-) MPN, and criteria for assessing the disease progression. According to the survey, 70% of physicians used different tools to calculate prognostic risk scores in their practice. IPSS was the most commonly used scale for assessing prognostic risk (43%). Among those physicians who did not use the available risk assessment tools, 33% considered these methods useful, but did not have enough time to use them in clinical practice; the same number of physicians (33%) were familiar with these assessment tools, but did not consider them practically useful; 11% of physicians stated that they were not familiar with these tools. The physicians pointed to the following main criteria for the disease progression: in MF, deterioration of the patient's condition (86%), increasing splenomegaly (86%), and continued weight loss (79%); in PV, changes of hemoglobin levels (83%), changing severity of symptoms (79%), evolving new symptom(s) (72%); in ET, changes in platelet levels (85%), development of new symptom(s) (78%), and deterioration of the patient's condition (70%).

Both physicians and patients were given a separate block of questions related to the main treatment goals. Physicians and patients were asked to select the main treatment goals (except for a curation) from a list of statements. The physician and patient survey results regarding goals for MF, PV and ET treatment are shown in Figure 4. Information is shown as the percentages of patients and physicians who have chosen the definite treatment goals. As seen in Figure 4, the MF, PV and ET patients have selected the following main treatment goals: better quality of life (60%, 76%, and 75%, respectively), reduction of symptoms (60%, 47%, and 50%, respectively), normal blood counts (53%, 53%, and 50%, respectively), and slower progression of the disease (47%, 41%, 50%, respectively). Physicians indicated the following main treatment goals (except for a cure) in Ph(-) MPN patients: in MF, improved quality of life (66%), slower disease progression (55%) and reduction in spleen size (52%); in PV and ET, better quality of life (69% and 59%, respectively), prevention of thrombotic events (48% and 67%), retarded disease progression (48% and 48%), and reduced frequency of phlebotomies in the PV patients (48%).

Figure 4. Ph(-) MPN treatment goals (other than cure), as reported by physicians and patients

In addition, the patients filled a list of supplementary statements on how successful or unsuccessful the treatment could be. When evaluating the success of treatment, patients used the following criteria: quality of life improvement or relief of symptoms (68%), reduced number of the symptoms (48%), physician’s conclusion (48%), and blood testing results (43%).

Moreover, the physicians were also given a list of statements describing challenges in Ph(-) MPN treatment. With regard to the treatment of MF, PV and ET patients, physicians selected the following unresolved issues: chances for cure (41%, 31% and 41%, respectively), and ability to delay progression of the disease (21%, 21% and 19%, respectively). Furthermore, 22% of physicians stated that a search for new effective drugs is an important aspect of ET treatment.

Perception of the physician-patient relationship by physicians and Ph(-) MPN patients

Both physician’s and patient’s surveys contained questions about patient satisfaction with the treatment, effectiveness of the physician in management of the disease, as well as the physician-patient relationship. In terms of treatment satisfaction, 98% of Ph(-) MPN patients were generally satisfied with the treatment (65% were completely satisfied and 33% were somewhat satisfied). Overall, 85% of patients were satisfied with efficiency of the disease control achieved by their physician (75% were completely satisfied and 10% were somewhat satisfied). As for physicians, 90% of them were satisfied with their management of the disease. Similarly, 90% of physicians reported that their priority goals concerning treatment agreed with the patients' perspectives: 37% believed that they completely agreed, 53% agreed to some extent. In general, all the patients were satisfied with the communication with their physician. When asked about the physician-patient relationship, 84% of physicians stated that they were satisfied with their communication with patients. Whereas 95% of patients indicated that they were generally satisfied with the awareness of various aspects of the disease, 5% were not satisfied. When asked about patient awareness of the disease, 87% of physicians believed that patients were well informed.

The majority of patients (95%) reported that they received information about their disease directly from their physician; 20% of patients indicated that they had difficulties with finding information about their disease.

Discussion

This paper presents data on survey of Russian patients and physicians evaluating the impact of chronic Ph(-) MPNs on various aspects of patients' well-being, conducted as a part of the international Landmark Survey. One of the main aims of the Landmark Survey is to study the symptoms experienced by Ph(-) MPN patients and their impact on daily activities as assessed by patients and physicians. The survey was also designed to investigate how the disease affects the patient’s quality of life and work productivity, both from the patient’s and physician's perspective. The analysis was based on the survey completed by 40 patients with Ph(-) MPN and 30 attending physicians.

The results of the survey revealed a significant impact of Ph(-) MPNs on quality of life of the patients. Accordingly, the disease symptoms in majority of Ph(-) MPN patients (100% of MF cases, 65% of PV cases, and 75% of ET patients), led to impairment of their quality of life. In general, these data are consistent with results of the original Landmark study conducted in the USA, where 81% of MF patients, 66% of PV patients and 56% of ET patients reported worsening of their quality of life due to the disease [8]. However, compared with the original study, a higher number of MF (100% versus 81%) and ET (75% versus 56%) patients in the Russian sample reported the negative effect of the disease symptoms on their quality of life.

In terms of the most common symptoms after diagnosis, Ph(-), the MPN patients noted fatigue (63%) and weakness (53%), thus being consistent with the data from the Landmark Survey in other countries [8-11]. It is worth of note that over a half of the patients (54%) experienced symptoms for a year prior to diagnosis, and the remaining patients had symptoms for two or more years before receiving the diagnosis, which is significantly more than in other countries [8-10].

When analyzing the symptoms exhibited by Ph(-) MPN patients over the past 12 months, it was shown that most patients, regardless of the disease, noted weakness or fatigue. Other common symptoms were different, depending on the specific Ph(-) MPN subtype. It is important to note that not all patients believed these symptoms were related to the disease.

This data is in line with the published results of Landmark survey in the countries with development markets according to which many patients also did not recognize that their symptoms could be MPN-related. For example, in this study 18% MF and 25% PV did not think their fatigue/tiredness resulted from MPNs [10]. According to our data, 33% and 14% of MF and PV patients, respectively, did not recognize fatigue as a symptom of the disease. It should also be noted that the analysis of the physician’s and patient’s responses regarding the most important patient’s symptoms revealed a discrepancy in their assessments. To some extent, these differences can be explained by the fact that only a half of the physicians actively discussed well-being and symptoms with patients during clinic visits. Moreover, the results show that only 20% of asked physicians use standardized questionnaires to assess the severity of symptoms, i.e., a significantly smaller proportion compared to their colleagues in other countries [8-10].

The analyzed results of the patient’s and physician’s surveys evaluating the effect of disease symptoms on daily lives of patients, including their everyday activities, family or social life, relationships with caregivers, and pain/discomfort that limits activity, revealed that, in the opinion of most patients and physicians, the disease burden affects daily lives of patients. It is worth of note that, in general, the discrepancy between physicians and patients in assessing the impact of disease symptoms on daily life was not significant. These results are consistent with previous reports that included non-US patients [12-14], as well as the recent US Landmark survey [6].

In a separate subset of questions, patients and physicians evaluated how the disease affected various aspects of their physical and emotional functioning. In the overwhelming majority of cases both patients and physicians reported that the disease caused significant physical and emotional hardship for Ph(-) MPN patients. The following data requires a special consideration: almost all the patients experienced anxiety because of their condition and were worried that their condition would worsen; moreover, 80% believed that their health was worse than what their treating physician perceived.

It was also shown that Ph(-) MPNs affect working ability and overall activity of patients. Thus, 32% of patients indicated that their disease significantly (score 7-10) limited their productivity at work; the disease had a significant impact on the overall activity of 48% of patients. Similar data was collected by the Landmark Survey in other countries [11].

Overall, almost a half of Ph(-) MPN patients reported requiring assistance from a caregiver, with 46% of MF patients, 36% of PV patients and 13% of ET patients needing support often or sometimes. These results are consistent with data obtained in other countries [11].

A separate analysis was conducted on the responses of physicians regarding treatment strategies at the time of diagnosis, treatments that were prescribed in the past, and treatments currently prescribed for their patients. It is interesting to note that half of the physicians reported an increase in symptoms as the reason for changing treatment, which emphasizes the importance of improving approaches to symptom management in Ph(-) MPN patients.

Responses of physicians on the approaches of Ph(-) MPN prognostic risk assessment were also analyzed. It should be noted that 70% of physicians used different tools to assess prognostic risk in their practice, but a third of physicians did not resort to their use due to lack of time, doubts about the usefulness of these tools or simply due to insufficient information about them.

Patient’s and physician’s responses regarding the MF, PV and ET therapy goals are of particular interest. It is important to note that both patients and physicians chose the improvement of the quality of life and symptom relief, as well as slowing the progression of the disease as the main treatment goals. In terms of evaluating treatment success, most patients (68%) mentioned the improvement in quality of life and symptom relief. This fact highlights the relevance of patient quality of life assessments as one of the important treatment outcomes. Besides, the international guidelines on assessing clinical response of Ph(-) MPN patients to treatment suggest the use of information on patient’s quality of life and symptoms [15, 16].

Satisfaction with the treatment as well as with the physician-patient relationship was also analyzed. With regard to the physician-patient relationship, 84% of physicians and 100% of patients were satisfied with it. According to the majority of the physicians (87%), patient awareness of the disease was rather high. Overall, 95% of patients were satisfied with their knowledge of the various aspects of the disease. At the same time, the issues identified in the survey of physicians and patients in relation to significant discrepancies between physician’s and patient’s assessment of burdensome symptoms, and specific perception of certain symptoms as not related to their disease by the patients highlight the importance of further improvement of symptom assessment strategies in Ph(-) MPN patients and raising awareness about the disease among the medical community, Ph(-) MPN patients and their relatives.

Despite the fact that the results were obtained in a limited sample of respondents (40 patients with Ph(-) MPN and 30 physicians), it is the first comprehensive analysis of the problems associated with the disease and treatment of Ph(-) MPN obtained in the Russian population of these patients, and the information is presented from the viewpoint of both patients and physicians. In general, the results of our survey demonstrate that patients with Ph(-) MPN feel a significant negative impact of the disease on various aspects of their life, have impaired quality of life and reduced work productivity. This data confirm the previously published results of the Landmark Survey conducted in other countries [6-11]. At the same time, this analysis enabled us to identify features of the disease impact and treatment upon various aspects of daily life of Ph(-) MPN patients in Russia, to describe their perceptions of the treatment goals, to assess the degree of satisfaction with treatment and disease control, and also to gain an insight into the physician-patient relationship and the strategies that physicians use in real clinical practice to obtain information about the impact of the disease and treatment on various aspects of the patient’s life. Overall, the results obtained support the value of patient’s perspective about the disease and its treatment for Ph(-) MPN to improve quality of care of this patients’ population [17-19].

Conclusion

Evaluation and synthesis of the survey data collected among Russian Ph(-)MPN patients and their attending physicians as part of the Landmark Survey constitute an important contribution to this project conducted in different countries. This data revealed that the patients with different Ph(-) MPNs have serious disease-related restrictions in everyday life, altered quality of life and reduced work productivity. In addition, the survey has revealed discordance in physician’s and patient’s assessment of the problems that patients face in relation to the disease and treatment. These differences indicate a need for new approaches, in order to improve of quality of care for this patients’ population, as well as for raising knowledge on the Ph(-) MPNs among the medical community and patients. Further clinical research is required to substantiate the development of patient-centered treatment programs for chronic Ph-negative myeloproliferative neoplasms in Russian Federation, as well as to provide detailed information for the patients and their relatives about the disease and its treatment.

Acknowledgements

No conflict of interest declared.

References

1. Melikyan AL, Kovrigina AM, Subortseva IN, Shuvaev VA. National clinical recommendations on diagnostics of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocytemia, primary myelofibrosis), revised 2018. Gematologiya I Transfuziologiya. 2018; 3:275-315 (In Russian).
2. Geyer JT, Orazi A. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates. Int J Lab Hematol. 2016; 38 Suppl 1: 12-19.
3. Pemmaraju N, Clementi T, Qiao W, Peterson SK, Zoeller V, Schorr AJ, Verstovsek S. Myeloproliferative neoplasm (MPN) patient online questionnaire: assessing patients' disease knowledge in a rare hematologic malignancy in the modern digital information era. Blood. 2019; 134 (Supplement 1): 1670.
4. Kurtin S, Lyle L. The role of advanced practitioners in optimizing clinical management and support of patients with polycythemia vera. J Adv Pract Oncol. 2018; 9(1): 56-66.
5. Mesa RA, Passamonti F. Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden. 2016 ASCO Educational Book: e324-e335.
6. Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S. et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016; 16: 167.
7. Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. Differences in teatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark Survey. Cancer. 2017; 123(3): 449-458.
8. Yu J, Parasuraman S, Paranagama D, Bai A, Naim A, Dubinski D, Mesa R. Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018; 18(1): 420. DOI: 10.1186/s12885-018-4322-9.
9. Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M. Mathias JP, Komatsu N, Boothroyd RN, Spierer A, Ronco JP, Taylor-Stokes G, Waller J, Mesa R. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017; 96 (10): 1653-1665. doi: 10.1007/s00277-017-3082-y.
10. Xiao Z, Chang CS, Morozova E, Bang SM, Alzahrani M, Mycock K, Rajkovic I, Siddiqui A, Saydam G. Impact of myeloproliferative neoplasms (MPNs) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey. HemaSphere. 2019; Volume 3 (S1): 294-295. DOI: 10.1097/01.HS9.0000561008.75001.e7.
11. Saydam G, Chang C, Morozova E, Bang S, Alzahrani M, Mycock K, Rajkovic I, Siddiqui A, Xiao Z. Impact of myeloproliferative neoplasms (MPNs) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey. Leukemia Res; 2019; 85 (Suppl 1): S60-S61.
12. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PAV, Commandeur S, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012; 30(33): 4098-4103.
13. Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukemia & lymphoma. 2013; 54(10): 2226-2230.
14. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CL, Radia DH, Mesa R. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011; 118(2): 401-408.
15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)/Myeloproliferative Neoplasms. Version 2.2019 – October 29, 2018. NCCN.org
16. Barosi G, Mesa R, Finazzi G, Harrison CN, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121 (23): 4778-4781.
17. Guidelines. Patient-reported outcomes in hematology. EHA SWG "Quality of life and Symptoms". Forum Service Editore. Genoa, 2012. 206 p.
18. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JE, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007; 109 (1): 68-76.
19. Zander AR. Stem cell transplantation for myeloproliferative diseases in the era of molecular therapy. Cell Ther Transplant. 2017; 6(4):21-27.

" ["~DETAIL_TEXT"]=> string(44099) "

Introduction

Over the past decade, international hematological community has been actively engaged in clinical research to standardize medical treatment of patients with chronic Ph-negative myeloproliferative neoplasms (MPNs) and improve the quality of care for this category of patients [1–5].

To identify the problems and areas of concern in management of the Ph(-) MPN patients, a large-scale Landmark Survey of patients and physicians was initiated in USA in 2014 [6, 7]. A total of 813 Ph(-) MPN patients and 457 physicians who treated this cohort participated in this survey. The results of this study were reported for each of the most common Ph(-) MPNs, i.e., myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) in the following sections: understanding of the disease diagnosis by patients and physicians; symptoms experienced by patients and their impact on daily activities, as reported by patients and physicians; disease burden with relation to the patient's quality of life and work productivity reported by patients and physicians; patient’s and physician’s attitudes to the treatment goals; and perception of bilateral physician-patient relationships [8]. The independent responses submitted by patients and physicians were used to find distinct similarities or differences between MF, PV, and ET. In 2016, the project became international, and the electronic survey forms were completed by Ph(-) MPN patients and hematologists who treated these diseases in Australia, Japan, Canada, Germany, Italy, and the UK [9]. The data collected in this survey enabled the researchers to evaluate perception of the physical, psychological, social and other problems that Ph(-) MPN patients face in their daily life, and to improve the awareness of hematologists about these problems.

The next stage of this project took place in 2018, as a research program, to conduct an online survey of 560 Ph(-) MPN patients and 260 hematologists in the emerging market countries: China, Turkey, Russia, Taiwan, South Korea, and Saudi Arabia [10, 11] The results of this survey, along with previous studies conducted in 2014-2016, are of importance for improving Ph(-) MPN medical care and developing standardized approaches to diagnosis and treatment of these chronic disorders. The project could potentially promote the multidisciplinary efforts, working together with patients and their relatives, in order to maximize effects of the Ph(-) MPN therapy.

The aim of this paper is to analyze and systematize the data from the Russian patient and physician survey arranged as part of the Landmark Survey in the emerging market countries.

Patients and methods

Forty Ph(-) MPN patients and physicians residing in the Russian Federation took part in the international Landmark Survey between September and November 2018. The criteria for engaging a physician for the survey were as follows: (1) managing of least 2 patients with MF, 5 patients with PV, and 5 patients with ET over last 12 months; (2) professional experience in hematology over 1 year; at least 25% of patients treated by the physician had to have hematological disorders. The patients with MF, PV and ET aged 18 years and older were enrolled with the physician at their routine clinic visits. Patients were eligible to complete the survey, being, however, excluded if they were participating in any clinical trials.

The survey checklists consisted of the following sections: for patients – patient demographics, patient awareness and perception of symptoms, impact of disease on daily living, work productivity/activity impairment, disease history and treatment, patient satisfaction, disease information availability; for physicians – physician demographics and caseload, patient disease burden, patient management and treatment decisions, physician perceptions [11]. This was an exploratory survey; no any special standardized questionnaires were applied during the survey.

Before completing the survey, patients and physicians consented to participate in the project. Both patients and physicians participated in the online survey independently of each other. To keep confidentiality, all physicians and patients were assigned identification numbers. Before the start of the survey, all the participants were given instructions on the procedure and principles of electronic questionnaire completion. The survey took 25-30 minutes.

The results survey are presented as descriptive statistics with estimation of mean values, standard deviations, and percentages for each position tested. Analyses were conducted in Stata statistical software version 16.0 or later (StataCorp, 2015. Stata statistical software: Release 16 (College Station, TX, StataCorp LP)). Where missing values were found in a particular variable, any participant with missing values was removed from all pieces of analysis where that variable was used. However, patients and physicians removed from one piece of analysis were still eligible for inclusion in other analyses. It was expected that the base of patients and physicians would vary from variable to variable for this reason.

Results

Characteristics of the patients and attending physicians

Overall, 40 patients with Ph(-) MPNs and 30 physicians completed the online survey. The characteristics of the patients included in the survey are summarized in Table 1. The distribution by diagnosis was as follows: PV, 42.5%; MF, 37.5%, and ET, 20% of patients. Twelve (80%) of the 15 MF patients were diagnosed with primary MF. Mean age of the patients at the time of diagnosis was 54.9 ± 9.7 years, duration of the disorder was 3.0 ± 2.2 years. Hence, their mean age at the survey was 57.9 ± 10.4 years. Diabetes mellitus (38% of ET patients), congestive heart failure (20% of MF patients), peptic ulcer (18% of PV patients), deep vein thrombosis (18% of PV patients) and liver disease (18% of PV patients) were the most common comorbidities in this group.

It is worth of note that over a half of the patients (55%) exhibited symptoms for a year prior to diagnosis, 17.5% during two years, and almost 1/3 of patients (27.5%) felt them over two years prior to the clinical diagnosis.

Of 30 physicians participating in the survey, 24 (80%) were hematologists, and 6 (20%) were hematologists-oncologists. Approximately half of the physicians (47%) had 3 to 15 years of professional experience, 40% had 15 to 25 years, and 13% had experience of 25 to 33 years. Over the period of 12 months preceding the survey, each of the physicians treated, on average, 10 MF cases, 16 PV patients, and 14 ET cases. 63% of physicians worked in regional clinic hospitals, 30% in specialized referral centers, and 7%, at the University clinics.

Table 1. Clinical and demographic characteristics of the patients

Symptoms in Ph(-) MPN patients

At diagnosis, the patients reported fatigue (63%) and weakness (53%) as the most common Ph(-) MPN symptoms. Other symptoms post-diagnosis included pruritus (33%) and night sweats (30%). On average, Ph(-) MPN patients mentioned seven symptoms ever experienced during their illness. The MF patients complained about eight symptoms, compared with six symptoms usually reported by PV and ET patients.

The five most common symptoms reported by MF, PV and ET patients over the past 12 months are listed in Figure 1. Over half of the MF patients reported fatigue (80%), weakness (67%), and night sweats (60%). Worth of note, not all patients believed these symptoms were related to the disease. In particular, the patients did not associate fatigue, weakness, and night sweats with the disease in 33%, 40% and 56% cases, respectively. As for PV symptoms, 59% of patients felt weakness, and 41% experienced fatigue and pruritus. Hence, 20% and 14% of the patients did not relate weakness and fatigue, respectively, to specific symptoms of their disease. Meanwhile, all the patients believed that pruritus was associated with the disease. 50% of ET patients experienced fatigue and numbness/tingling. Of note, all the patients associated fatigue with the disease; as for numbness/tingling, 12.5% of patients did not associate this symptom with the disease. At the same time, most physicians (69%) believed that the vast majority of the patients associated their symptoms with myeloproliferative disease.

The patients also evaluated severity of their symptoms in the past 12 months using a 10-point numerical rating scale (NRS). Some symptoms were severe: ≥7 points on the NRS scale. Patients with Ph(-) MPN reported the following severe symptoms: fatigue (n=18), weakness (n=15), headache (n=9), night sweats (n=8), abdominal pain (n=7), fever (n=5), dizziness (n=5), bone pain (n=2), nose bleeding (n=2) and facial flushing (n=2).

Attending physicians also answered some questions about symptoms in their patients. They were asked to list five most significant symptoms for the patients with each type of Ph(-) MPNs. For MF, the physicians mentioned fatigue (72%), unintentional weight loss (59%), weakness (45%), abdominal discomfort (34%), and night sweats (31%). Of note, only half of the physicians, when compared to their patients, reported night sweats in these cases. In PV, physicians pointed to itching (59%), headaches (45%), hypertension (41%), facial flushing and numbness/tingling in hands and feet (38%). Moreover, as opposed to patients, none of the physicians mentioned weakness or fatigue. For ET, the physicians noted fatigue (59%), nasal bleeding and thrombotic events clot (48%), headaches (37%), and weakness (33%). Unlike patients, physicians did not mention numbness/tingling. As evidenced by the above data, there are discrepancies in the patient and physician perception of the most significant symptoms experienced by Ph(-) MPN patients, while 77% of physicians believed that they have correctly assessed the symptom burden.

As a separate task, both physicians and patients were asked to choose from the list of symptoms experienced by patients those traits that, according to the patient, were most likely to be resolved (1 to 3). The MF patients mentioned fatigue (47%) and pruritus (33%); physicians chose weakness (45%) and fatigue (31%). Patients with PV pointed to pruritus (41%), whereas, in opinion of physicians, pruritus (52%) and hypertension (48%) were most likely to be resolved. As for ET, the patients chose fatigue (38%), while physicians highlighted fatigue, tingling in the hands/feet, and predisposal for thrombosis (44%).

These discrepancies in the physician and patient description of the symptoms that are most significant to patients can be partially explained using the survey data, with regard of the physician’s strategies when discussing symptoms and general well-being during the patients’ clinical visit. The majority of patients mentioned in the survey that the physicians were interested in their symptoms and overall well-being. Patients noticed the following: during the clinic visit, attending physician was actively interested in their well-being and symptoms (55% of patients); the doctor asked them about specific, most important symptoms (25%); the physician expected patients to report their concerns (15%); the physician asked them to fill out questionnaires and discussed existing problems with them on the basis of their answers (5%). All the patients stated that the physician was interested in their well-being and existing symptoms.

In addition, significant differences between physicians and patients were revealed, regarding the time that physicians spent discussing blood test results and well-being with the patients. The vast majority of patients (93%) believed that during the visit the physician spent most of the time discussing blood test results with them. At the same time, only 43% of physicians believed that they spent more time discussing blood test results with the patient rather than their well-being.

According to the survey of physicians, they received information about the patient’s symptoms and overall well-being in the following way: 43% of physicians were actively interested in the patient’s problems during the visit; 37% discussed the most important symptoms with the patient, and 13% expected reporting of any alarming symptoms from patients. Only 7% of physicians told that they asked patients to fill out questionnaires to record their symptoms. At the same time, 83% of physicians stated that they assessed patient's symptoms at each visit. When evaluating the severity of symptoms, 43% of physicians considered the impact of disease on the daily life of the patient, and 27% of physicians based it on their own assessment. Only 20% of physicians used questionnaires for standard assessment of the symptoms.

Disease impact on the quality of life in Ph(-) MPN patients

The list of questions in the patient’s and physician’s survey checklists focused on the impact of symptoms on patient’s quality of life and daily activities [9, 11]. Most Ph(-) MPN patients (81%) believed that the symptoms reduced their quality of life (Table 2). All the MF patients, 65% of PV patients, and 75% of ET patients agreed with this statement. Physicians also shared the view that the disease symptoms lead to worsening of quality of life of patients. Furthermore, 77% of physicians believed that even mild or moderate symptoms in patients could be associated with reduced quality of life.

Table 2. Symptom interference with quality of life in Ph(-) MPN patients

As a special point, the effect of symptoms on daily life activities was evaluated by the survey. Figure 2 shows the distribution of the patient’s and physician’s answers about impact of the symptoms upon daily activities of patients, their family and social life, relationships with caregivers, as well as limitations of activities caused by pain/discomfort. As evidenced in the Figure 2, most patients and physicians believed that disease symptoms affect the mentioned daily activities of patients. Most patients and physicians also indicated that pain/discomfort limits patient's daily activities, especially in MF patients, compared to PV and ET. In MF, the reported symptoms had a higher impact on their daily activities, family and social life. Pain/discomfort also significantly limited their daily activities. In general, the discrepancy between physicians and patients in assessing the impact of disease symptoms on daily life was not significant.

Figure 2. Patient and physician perceptions of the disease symptom burden on daily activities in Ph(-) MPN patients; A, myelofibrosis; B polycythemia vera; C, essential thrombocythemia

The patients were also asked in what way the disease affected various aspects of their quality of life (Figure 3). For the vast majority of Ph(-) MPN patients, the disease had a significant impact on physical (95%) and emotional (87%) functioning. Almost all of the patients (95%) experienced anxiety, because of their condition and were worried that their condition would worsen. It is noteworthy that 80% of patients believed that their health was worse, if compared to their condition evaluated by treating physician, and 77% felt helpless.

Figure 3. Disease impact on various aspects of quality of life as assessed by Ph(-) MPN patients

As for different forms of Ph(-) MPNs, all the patients with MF and ET, as well as 88% of patients with PV, experienced some degree of physical problems caused by their condition. All the ET patients, 87% of MF patients, and 82% of PV patients reported emotional burden associated with the disease. All the MF patients, 94% of PV patients and 87% of ET patients experienced anxiety related to their condition. At the same time, 93%, 71% and 75% of patients with MF, PV and ET, respectively, believed that they felt worse than perceived by their treating physician. Moreover, 93%, 71% and 62% of patients with MF, IP and ET, respectively, indicated that they felt helpless.

All surveyed physicians believed that MF and PV patients had physical and emotional limitations; 7% of physicians believed that ET patients did not experience such restrictions.

Disease impact on work productivity in Ph(-) MPN patients

The patient survey contained questions about employment, disability, limitations in overall activity and support from caregivers. From the proposed list of employment options, over one-third of patients (35%) stated that they worked full time, 13% were in part-time employment, and 5% were on sick leave. Other patients claimed they were pensioners (43%) or unemployed (6%). Overall, 53% of patients reported that they continued to work at the time of the survey. Over past 7 days, the patients had to miss, on average, 2.8 hours of working time, due to their disease. To assess the impact of the disease on productivity at work and overall activity, patients were asked to choose a number on a scale from 0 to 10, where 0 means "no effect of the disease on work/overall activity" and 10 means "completely unable to work/illness completely interferes with overall activity". According to the survey results, 32% of patients indicated that their disease significantly (score 7-10) limited their productivity at work; the disease significantly affected overall activity in 48% of patients.

Overall, 48% of Ph(-) MPN patients reported requiring assistance from a caregiver, with 46% of MF patients, 36% of PV patients and 13% of ET patients needed for support often or sometimes. Half of these patients were supported by their children. In 47% of cases, a support for the patients was provided by the people who continued to work. Assistance with housework (79%) and transportation (74%) were the main forms of support.

Treatment of Ph(-) MPNs and physician’s and patient’s perspectives on treatment goals

The surveys for physicians contained the following questions regarding treatment: 1) treatment strategy at the time of diagnosis; 2) therapy prescribed anytime in the past; 3) treatment that physicians currently prescribed for their patients. Physicians had to choose the answers from the proposed list of treatment options separately for patients with MF, PV and ET. According to their answers, the physicians chose a strategy of waiting and observation in 12% of MF patients, in 15% of PV cases, and in 18% of ET patients at the time of diagnosis. Details of previous treatment for patients with MF, PV and ET, and currently prescribed therapies, as well as reasons for changing therapy are summarized in Table 3. In general, there is no much difference between the past and current therapies prescribed by physicians to treat specific MF, PV and ET patients. Some differences between the past and current therapies were observed for MF treatment with epoetin-α, androgens and glucocorticosteroids, for PV treatment with epoetin-α, for ET treatment with glucocorticosteroids and BMT/HSCT.

Table 3. Treatment prescribed in the past, currently prescribed therapy, and the reasons for changing therapy in patients with MF, IP and ET

Worth of note, half of the physicians reported an increase in symptoms of a specific Ph(-) MPN as the reason for the change of treatment.

The questionnaire for physicians also included questions concerning prognostic risk assessment in patients with Ph(-) MPN, and criteria for assessing the disease progression. According to the survey, 70% of physicians used different tools to calculate prognostic risk scores in their practice. IPSS was the most commonly used scale for assessing prognostic risk (43%). Among those physicians who did not use the available risk assessment tools, 33% considered these methods useful, but did not have enough time to use them in clinical practice; the same number of physicians (33%) were familiar with these assessment tools, but did not consider them practically useful; 11% of physicians stated that they were not familiar with these tools. The physicians pointed to the following main criteria for the disease progression: in MF, deterioration of the patient's condition (86%), increasing splenomegaly (86%), and continued weight loss (79%); in PV, changes of hemoglobin levels (83%), changing severity of symptoms (79%), evolving new symptom(s) (72%); in ET, changes in platelet levels (85%), development of new symptom(s) (78%), and deterioration of the patient's condition (70%).

Both physicians and patients were given a separate block of questions related to the main treatment goals. Physicians and patients were asked to select the main treatment goals (except for a curation) from a list of statements. The physician and patient survey results regarding goals for MF, PV and ET treatment are shown in Figure 4. Information is shown as the percentages of patients and physicians who have chosen the definite treatment goals. As seen in Figure 4, the MF, PV and ET patients have selected the following main treatment goals: better quality of life (60%, 76%, and 75%, respectively), reduction of symptoms (60%, 47%, and 50%, respectively), normal blood counts (53%, 53%, and 50%, respectively), and slower progression of the disease (47%, 41%, 50%, respectively). Physicians indicated the following main treatment goals (except for a cure) in Ph(-) MPN patients: in MF, improved quality of life (66%), slower disease progression (55%) and reduction in spleen size (52%); in PV and ET, better quality of life (69% and 59%, respectively), prevention of thrombotic events (48% and 67%), retarded disease progression (48% and 48%), and reduced frequency of phlebotomies in the PV patients (48%).

Figure 4. Ph(-) MPN treatment goals (other than cure), as reported by physicians and patients

In addition, the patients filled a list of supplementary statements on how successful or unsuccessful the treatment could be. When evaluating the success of treatment, patients used the following criteria: quality of life improvement or relief of symptoms (68%), reduced number of the symptoms (48%), physician’s conclusion (48%), and blood testing results (43%).

Moreover, the physicians were also given a list of statements describing challenges in Ph(-) MPN treatment. With regard to the treatment of MF, PV and ET patients, physicians selected the following unresolved issues: chances for cure (41%, 31% and 41%, respectively), and ability to delay progression of the disease (21%, 21% and 19%, respectively). Furthermore, 22% of physicians stated that a search for new effective drugs is an important aspect of ET treatment.

Perception of the physician-patient relationship by physicians and Ph(-) MPN patients

Both physician’s and patient’s surveys contained questions about patient satisfaction with the treatment, effectiveness of the physician in management of the disease, as well as the physician-patient relationship. In terms of treatment satisfaction, 98% of Ph(-) MPN patients were generally satisfied with the treatment (65% were completely satisfied and 33% were somewhat satisfied). Overall, 85% of patients were satisfied with efficiency of the disease control achieved by their physician (75% were completely satisfied and 10% were somewhat satisfied). As for physicians, 90% of them were satisfied with their management of the disease. Similarly, 90% of physicians reported that their priority goals concerning treatment agreed with the patients' perspectives: 37% believed that they completely agreed, 53% agreed to some extent. In general, all the patients were satisfied with the communication with their physician. When asked about the physician-patient relationship, 84% of physicians stated that they were satisfied with their communication with patients. Whereas 95% of patients indicated that they were generally satisfied with the awareness of various aspects of the disease, 5% were not satisfied. When asked about patient awareness of the disease, 87% of physicians believed that patients were well informed.

The majority of patients (95%) reported that they received information about their disease directly from their physician; 20% of patients indicated that they had difficulties with finding information about their disease.

Discussion

This paper presents data on survey of Russian patients and physicians evaluating the impact of chronic Ph(-) MPNs on various aspects of patients' well-being, conducted as a part of the international Landmark Survey. One of the main aims of the Landmark Survey is to study the symptoms experienced by Ph(-) MPN patients and their impact on daily activities as assessed by patients and physicians. The survey was also designed to investigate how the disease affects the patient’s quality of life and work productivity, both from the patient’s and physician's perspective. The analysis was based on the survey completed by 40 patients with Ph(-) MPN and 30 attending physicians.

The results of the survey revealed a significant impact of Ph(-) MPNs on quality of life of the patients. Accordingly, the disease symptoms in majority of Ph(-) MPN patients (100% of MF cases, 65% of PV cases, and 75% of ET patients), led to impairment of their quality of life. In general, these data are consistent with results of the original Landmark study conducted in the USA, where 81% of MF patients, 66% of PV patients and 56% of ET patients reported worsening of their quality of life due to the disease [8]. However, compared with the original study, a higher number of MF (100% versus 81%) and ET (75% versus 56%) patients in the Russian sample reported the negative effect of the disease symptoms on their quality of life.

In terms of the most common symptoms after diagnosis, Ph(-), the MPN patients noted fatigue (63%) and weakness (53%), thus being consistent with the data from the Landmark Survey in other countries [8-11]. It is worth of note that over a half of the patients (54%) experienced symptoms for a year prior to diagnosis, and the remaining patients had symptoms for two or more years before receiving the diagnosis, which is significantly more than in other countries [8-10].

When analyzing the symptoms exhibited by Ph(-) MPN patients over the past 12 months, it was shown that most patients, regardless of the disease, noted weakness or fatigue. Other common symptoms were different, depending on the specific Ph(-) MPN subtype. It is important to note that not all patients believed these symptoms were related to the disease.

This data is in line with the published results of Landmark survey in the countries with development markets according to which many patients also did not recognize that their symptoms could be MPN-related. For example, in this study 18% MF and 25% PV did not think their fatigue/tiredness resulted from MPNs [10]. According to our data, 33% and 14% of MF and PV patients, respectively, did not recognize fatigue as a symptom of the disease. It should also be noted that the analysis of the physician’s and patient’s responses regarding the most important patient’s symptoms revealed a discrepancy in their assessments. To some extent, these differences can be explained by the fact that only a half of the physicians actively discussed well-being and symptoms with patients during clinic visits. Moreover, the results show that only 20% of asked physicians use standardized questionnaires to assess the severity of symptoms, i.e., a significantly smaller proportion compared to their colleagues in other countries [8-10].

The analyzed results of the patient’s and physician’s surveys evaluating the effect of disease symptoms on daily lives of patients, including their everyday activities, family or social life, relationships with caregivers, and pain/discomfort that limits activity, revealed that, in the opinion of most patients and physicians, the disease burden affects daily lives of patients. It is worth of note that, in general, the discrepancy between physicians and patients in assessing the impact of disease symptoms on daily life was not significant. These results are consistent with previous reports that included non-US patients [12-14], as well as the recent US Landmark survey [6].

In a separate subset of questions, patients and physicians evaluated how the disease affected various aspects of their physical and emotional functioning. In the overwhelming majority of cases both patients and physicians reported that the disease caused significant physical and emotional hardship for Ph(-) MPN patients. The following data requires a special consideration: almost all the patients experienced anxiety because of their condition and were worried that their condition would worsen; moreover, 80% believed that their health was worse than what their treating physician perceived.

It was also shown that Ph(-) MPNs affect working ability and overall activity of patients. Thus, 32% of patients indicated that their disease significantly (score 7-10) limited their productivity at work; the disease had a significant impact on the overall activity of 48% of patients. Similar data was collected by the Landmark Survey in other countries [11].

Overall, almost a half of Ph(-) MPN patients reported requiring assistance from a caregiver, with 46% of MF patients, 36% of PV patients and 13% of ET patients needing support often or sometimes. These results are consistent with data obtained in other countries [11].

A separate analysis was conducted on the responses of physicians regarding treatment strategies at the time of diagnosis, treatments that were prescribed in the past, and treatments currently prescribed for their patients. It is interesting to note that half of the physicians reported an increase in symptoms as the reason for changing treatment, which emphasizes the importance of improving approaches to symptom management in Ph(-) MPN patients.

Responses of physicians on the approaches of Ph(-) MPN prognostic risk assessment were also analyzed. It should be noted that 70% of physicians used different tools to assess prognostic risk in their practice, but a third of physicians did not resort to their use due to lack of time, doubts about the usefulness of these tools or simply due to insufficient information about them.

Patient’s and physician’s responses regarding the MF, PV and ET therapy goals are of particular interest. It is important to note that both patients and physicians chose the improvement of the quality of life and symptom relief, as well as slowing the progression of the disease as the main treatment goals. In terms of evaluating treatment success, most patients (68%) mentioned the improvement in quality of life and symptom relief. This fact highlights the relevance of patient quality of life assessments as one of the important treatment outcomes. Besides, the international guidelines on assessing clinical response of Ph(-) MPN patients to treatment suggest the use of information on patient’s quality of life and symptoms [15, 16].

Satisfaction with the treatment as well as with the physician-patient relationship was also analyzed. With regard to the physician-patient relationship, 84% of physicians and 100% of patients were satisfied with it. According to the majority of the physicians (87%), patient awareness of the disease was rather high. Overall, 95% of patients were satisfied with their knowledge of the various aspects of the disease. At the same time, the issues identified in the survey of physicians and patients in relation to significant discrepancies between physician’s and patient’s assessment of burdensome symptoms, and specific perception of certain symptoms as not related to their disease by the patients highlight the importance of further improvement of symptom assessment strategies in Ph(-) MPN patients and raising awareness about the disease among the medical community, Ph(-) MPN patients and their relatives.

Despite the fact that the results were obtained in a limited sample of respondents (40 patients with Ph(-) MPN and 30 physicians), it is the first comprehensive analysis of the problems associated with the disease and treatment of Ph(-) MPN obtained in the Russian population of these patients, and the information is presented from the viewpoint of both patients and physicians. In general, the results of our survey demonstrate that patients with Ph(-) MPN feel a significant negative impact of the disease on various aspects of their life, have impaired quality of life and reduced work productivity. This data confirm the previously published results of the Landmark Survey conducted in other countries [6-11]. At the same time, this analysis enabled us to identify features of the disease impact and treatment upon various aspects of daily life of Ph(-) MPN patients in Russia, to describe their perceptions of the treatment goals, to assess the degree of satisfaction with treatment and disease control, and also to gain an insight into the physician-patient relationship and the strategies that physicians use in real clinical practice to obtain information about the impact of the disease and treatment on various aspects of the patient’s life. Overall, the results obtained support the value of patient’s perspective about the disease and its treatment for Ph(-) MPN to improve quality of care of this patients’ population [17-19].

Conclusion

Evaluation and synthesis of the survey data collected among Russian Ph(-)MPN patients and their attending physicians as part of the Landmark Survey constitute an important contribution to this project conducted in different countries. This data revealed that the patients with different Ph(-) MPNs have serious disease-related restrictions in everyday life, altered quality of life and reduced work productivity. In addition, the survey has revealed discordance in physician’s and patient’s assessment of the problems that patients face in relation to the disease and treatment. These differences indicate a need for new approaches, in order to improve of quality of care for this patients’ population, as well as for raising knowledge on the Ph(-) MPNs among the medical community and patients. Further clinical research is required to substantiate the development of patient-centered treatment programs for chronic Ph-negative myeloproliferative neoplasms in Russian Federation, as well as to provide detailed information for the patients and their relatives about the disease and its treatment.

Acknowledgements

No conflict of interest declared.

References

1. Melikyan AL, Kovrigina AM, Subortseva IN, Shuvaev VA. National clinical recommendations on diagnostics of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocytemia, primary myelofibrosis), revised 2018. Gematologiya I Transfuziologiya. 2018; 3:275-315 (In Russian).
2. Geyer JT, Orazi A. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates. Int J Lab Hematol. 2016; 38 Suppl 1: 12-19.
3. Pemmaraju N, Clementi T, Qiao W, Peterson SK, Zoeller V, Schorr AJ, Verstovsek S. Myeloproliferative neoplasm (MPN) patient online questionnaire: assessing patients' disease knowledge in a rare hematologic malignancy in the modern digital information era. Blood. 2019; 134 (Supplement 1): 1670.
4. Kurtin S, Lyle L. The role of advanced practitioners in optimizing clinical management and support of patients with polycythemia vera. J Adv Pract Oncol. 2018; 9(1): 56-66.
5. Mesa RA, Passamonti F. Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden. 2016 ASCO Educational Book: e324-e335.
6. Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S. et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016; 16: 167.
7. Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. Differences in teatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark Survey. Cancer. 2017; 123(3): 449-458.
8. Yu J, Parasuraman S, Paranagama D, Bai A, Naim A, Dubinski D, Mesa R. Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018; 18(1): 420. DOI: 10.1186/s12885-018-4322-9.
9. Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M. Mathias JP, Komatsu N, Boothroyd RN, Spierer A, Ronco JP, Taylor-Stokes G, Waller J, Mesa R. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017; 96 (10): 1653-1665. doi: 10.1007/s00277-017-3082-y.
10. Xiao Z, Chang CS, Morozova E, Bang SM, Alzahrani M, Mycock K, Rajkovic I, Siddiqui A, Saydam G. Impact of myeloproliferative neoplasms (MPNs) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey. HemaSphere. 2019; Volume 3 (S1): 294-295. DOI: 10.1097/01.HS9.0000561008.75001.e7.
11. Saydam G, Chang C, Morozova E, Bang S, Alzahrani M, Mycock K, Rajkovic I, Siddiqui A, Xiao Z. Impact of myeloproliferative neoplasms (MPNs) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey. Leukemia Res; 2019; 85 (Suppl 1): S60-S61.
12. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PAV, Commandeur S, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012; 30(33): 4098-4103.
13. Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukemia & lymphoma. 2013; 54(10): 2226-2230.
14. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CL, Radia DH, Mesa R. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011; 118(2): 401-408.
15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)/Myeloproliferative Neoplasms. Version 2.2019 – October 29, 2018. NCCN.org
16. Barosi G, Mesa R, Finazzi G, Harrison CN, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121 (23): 4778-4781.
17. Guidelines. Patient-reported outcomes in hematology. EHA SWG "Quality of life and Symptoms". Forum Service Editore. Genoa, 2012. 206 p.
18. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JE, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007; 109 (1): 68-76.
19. Zander AR. Stem cell transplantation for myeloproliferative diseases in the era of molecular therapy. Cell Ther Transplant. 2017; 6(4):21-27.

" ["DETAIL_TEXT_TYPE"]=> string(4) "html" ["~DETAIL_TEXT_TYPE"]=> string(4) "html" ["PREVIEW_TEXT"]=> string(0) "" ["~PREVIEW_TEXT"]=> string(0) "" ["PREVIEW_TEXT_TYPE"]=> string(4) "text" ["~PREVIEW_TEXT_TYPE"]=> string(4) "text" ["PREVIEW_PICTURE"]=> NULL ["~PREVIEW_PICTURE"]=> NULL ["LANG_DIR"]=> string(4) "/ru/" ["~LANG_DIR"]=> string(4) "/ru/" ["SORT"]=> string(3) "500" ["~SORT"]=> string(3) "500" ["CODE"]=> string(100) "otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu" ["~CODE"]=> string(100) "otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu" ["EXTERNAL_ID"]=> string(4) "1855" ["~EXTERNAL_ID"]=> string(4) "1855" ["IBLOCK_TYPE_ID"]=> string(7) "journal" ["~IBLOCK_TYPE_ID"]=> string(7) "journal" ["IBLOCK_CODE"]=> string(7) "volumes" ["~IBLOCK_CODE"]=> string(7) "volumes" ["IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["~IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["LID"]=> string(2) "s2" ["~LID"]=> string(2) "s2" ["EDIT_LINK"]=> NULL ["DELETE_LINK"]=> NULL ["DISPLAY_ACTIVE_FROM"]=> string(0) "" ["IPROPERTY_VALUES"]=> array(18) { ["ELEMENT_META_TITLE"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["ELEMENT_META_KEYWORDS"]=> string(0) "" ["ELEMENT_META_DESCRIPTION"]=> string(536) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования LandmarkAttitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study" ["ELEMENT_PREVIEW_PICTURE_FILE_ALT"]=> string(3388) "<p style="text-align: justify;">Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).</p> <p style="text-align: justify;">Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы. </p>" ["ELEMENT_PREVIEW_PICTURE_FILE_TITLE"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["ELEMENT_DETAIL_PICTURE_FILE_ALT"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["ELEMENT_DETAIL_PICTURE_FILE_TITLE"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_META_TITLE"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_META_KEYWORDS"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_META_DESCRIPTION"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_PICTURE_FILE_ALT"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_PICTURE_FILE_TITLE"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_PICTURE_FILE_NAME"]=> string(100) "otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu" ["SECTION_DETAIL_PICTURE_FILE_ALT"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_DETAIL_PICTURE_FILE_TITLE"]=> string(336) "Отношение к заболеванию и лечению у пациентов с хроническими Ph-негативными неоплазиями: результаты опросов врачей и их пациентов в России, как часть международного исследования Landmark" ["SECTION_DETAIL_PICTURE_FILE_NAME"]=> string(100) "otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu" ["ELEMENT_PREVIEW_PICTURE_FILE_NAME"]=> string(100) "otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu" ["ELEMENT_DETAIL_PICTURE_FILE_NAME"]=> string(100) "otnoshenie-k-zabolevaniyu-i-lecheniyu-u-patsientov-s-khronicheskimi-ph-negativnymi-neoplaziyami-rezu" } ["FIELDS"]=> array(1) { ["IBLOCK_SECTION_ID"]=> string(3) "149" } ["PROPERTIES"]=> array(18) { ["KEYWORDS"]=> array(36) { ["ID"]=> string(2) "19" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:46:01" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(27) "Ключевые слова" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "KEYWORDS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "19" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "4" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "Y" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "Y" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(27) "Ключевые слова" ["~DEFAULT_VALUE"]=> string(0) "" } ["SUBMITTED"]=> array(36) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26468" ["VALUE"]=> string(10) "07.05.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "07.05.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL } ["ACCEPTED"]=> array(36) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26469" ["VALUE"]=> string(10) "05.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "05.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL } ["PUBLISHED"]=> array(36) { ["ID"]=> string(2) "22" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Дата публикации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "PUBLISHED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "22" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Дата публикации" ["~DEFAULT_VALUE"]=> NULL } ["CONTACT"]=> array(36) { ["ID"]=> string(2) "23" ["TIMESTAMP_X"]=> string(19) "2015-09-03 14:43:05" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(14) "Контакт" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "CONTACT" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "23" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(14) "Контакт" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHORS"]=> array(36) { ["ID"]=> string(2) "24" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:45:07" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "AUTHORS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "24" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_RU"]=> array(36) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26470" ["VALUE"]=> array(2) { ["TEXT"]=> string(354) "<p>Елена В. Морозова¹, Мария В. Барабанщикова¹, Татьяна И. Ионова², <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Борис В. Афанасьев¹</span></p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(272) "

Елена В. Морозова¹, Мария В. Барабанщикова¹, Татьяна И. Ионова², Борис В. Афанасьев¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_RU"]=> array(36) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26471" ["VALUE"]=> array(2) { ["TEXT"]=> string(592) "<p>¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ² Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(550) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_RU"]=> array(36) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26472" ["VALUE"]=> array(2) { ["TEXT"]=> string(3388) "<p style="text-align: justify;">Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).</p> <p style="text-align: justify;">Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(3310) "

Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).

Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.

Ключевые слова

Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["DOI"]=> array(36) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26473" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-28-39" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-28-39" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_EN"]=> array(36) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26476" ["VALUE"]=> array(2) { ["TEXT"]=> string(295) "<p>Elena V. Morozova¹, Maria V. Barabanshchikova¹, Tatyana I. Ionova², <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Boris V. Afanasyev¹</span></p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(213) "

Elena V. Morozova¹, Maria V. Barabanshchikova¹, Tatyana I. Ionova², Boris V. Afanasyev¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_EN"]=> array(36) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26477" ["VALUE"]=> array(2) { ["TEXT"]=> string(550) "<p>¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br> ² Saint Petersburg State University Hospital, St. Petersburg, Russia</p><br> <p><b>Correspondence</b><br> Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia<br> Phone: +7 (962) 710 1711<br> E-mail: tation16@gmail.com</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(460) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Saint Petersburg State University Hospital, St. Petersburg, Russia

Correspondence
Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia
Phone: +7 (962) 710 1711
E-mail: tation16@gmail.com

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_EN"]=> array(36) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26479" ["VALUE"]=> array(2) { ["TEXT"]=> string(1894) "<p style="text-align: justify;">The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation. </p> <h2>Keywords</h2> <p style="text-align: justify;">Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(1838) "

The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation.

Keywords

Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["NAME_EN"]=> array(36) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26474" ["VALUE"]=> string(200) "Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(200) "Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" } ["FULL_TEXT_RU"]=> array(36) { ["ID"]=> string(2) "42" ["TIMESTAMP_X"]=> string(19) "2015-09-07 20:29:18" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(23) "Полный текст" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(12) "FULL_TEXT_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "42" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(23) "Полный текст" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["PDF_RU"]=> array(36) { ["ID"]=> string(2) "43" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF RUS" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_RU" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "43" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26475" ["VALUE"]=> string(4) "2019" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2019" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF RUS" ["~DEFAULT_VALUE"]=> string(0) "" } ["PDF_EN"]=> array(36) { ["ID"]=> string(2) "44" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF ENG" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "44" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26478" ["VALUE"]=> string(4) "2020" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2020" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF ENG" ["~DEFAULT_VALUE"]=> string(0) "" } ["NAME_LONG"]=> array(36) { ["ID"]=> string(2) "45" ["TIMESTAMP_X"]=> string(19) "2023-04-13 00:55:00" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(72) "Название (для очень длинных заголовков)" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "NAME_LONG" ["DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "45" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(80) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(72) "Название (для очень длинных заголовков)" ["~DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } } } ["DISPLAY_PROPERTIES"]=> array(10) { ["AUTHOR_EN"]=> array(37) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26476" ["VALUE"]=> array(2) { ["TEXT"]=> string(295) "<p>Elena V. Morozova¹, Maria V. Barabanshchikova¹, Tatyana I. Ionova², <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Boris V. Afanasyev¹</span></p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(213) "

Elena V. Morozova¹, Maria V. Barabanshchikova¹, Tatyana I. Ionova², Boris V. Afanasyev¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(213) "

Elena V. Morozova¹, Maria V. Barabanshchikova¹, Tatyana I. Ionova², Boris V. Afanasyev¹

" } ["SUMMARY_EN"]=> array(37) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26479" ["VALUE"]=> array(2) { ["TEXT"]=> string(1894) "<p style="text-align: justify;">The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation. </p> <h2>Keywords</h2> <p style="text-align: justify;">Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(1838) "

The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation.

Keywords

Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(1838) "

The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation.

Keywords

Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs.

" } ["DOI"]=> array(37) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26473" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-28-39" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-28-39" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-28-39" } ["NAME_EN"]=> array(37) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26474" ["VALUE"]=> string(200) "Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(200) "Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(200) "Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study" } ["ORGANIZATION_EN"]=> array(37) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26477" ["VALUE"]=> array(2) { ["TEXT"]=> string(550) "<p>¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br> ² Saint Petersburg State University Hospital, St. Petersburg, Russia</p><br> <p><b>Correspondence</b><br> Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia<br> Phone: +7 (962) 710 1711<br> E-mail: tation16@gmail.com</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(460) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Saint Petersburg State University Hospital, St. Petersburg, Russia

Correspondence
Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia
Phone: +7 (962) 710 1711
E-mail: tation16@gmail.com

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(460) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Saint Petersburg State University Hospital, St. Petersburg, Russia

Correspondence
Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia
Phone: +7 (962) 710 1711
E-mail: tation16@gmail.com

" } ["AUTHOR_RU"]=> array(37) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26470" ["VALUE"]=> array(2) { ["TEXT"]=> string(354) "<p>Елена В. Морозова¹, Мария В. Барабанщикова¹, Татьяна И. Ионова², <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Борис В. Афанасьев¹</span></p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(272) "

Елена В. Морозова¹, Мария В. Барабанщикова¹, Татьяна И. Ионова², Борис В. Афанасьев¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(272) "

Елена В. Морозова¹, Мария В. Барабанщикова¹, Татьяна И. Ионова², Борис В. Афанасьев¹

" } ["SUBMITTED"]=> array(37) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26468" ["VALUE"]=> string(10) "07.05.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "07.05.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "07.05.2020" } ["ACCEPTED"]=> array(37) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26469" ["VALUE"]=> string(10) "05.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "05.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "05.06.2020" } ["SUMMARY_RU"]=> array(37) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26472" ["VALUE"]=> array(2) { ["TEXT"]=> string(3388) "<p style="text-align: justify;">Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).</p> <p style="text-align: justify;">Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(3310) "

Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).

Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.

Ключевые слова

Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(3310) "

Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).

Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.

Ключевые слова

Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы.

" } ["ORGANIZATION_RU"]=> array(37) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26471" ["VALUE"]=> array(2) { ["TEXT"]=> string(592) "<p>¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ² Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(550) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(550) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия

" } } } [2]=> array(49) { ["IBLOCK_SECTION_ID"]=> string(3) "149" ["~IBLOCK_SECTION_ID"]=> string(3) "149" ["ID"]=> string(4) "1856" ["~ID"]=> string(4) "1856" ["IBLOCK_ID"]=> string(1) "2" ["~IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["~NAME"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["ACTIVE_FROM"]=> NULL ["~ACTIVE_FROM"]=> NULL ["TIMESTAMP_X"]=> string(19) "03.08.2020 14:47:28" ["~TIMESTAMP_X"]=> string(19) "03.08.2020 14:47:28" ["DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-/" ["~DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-/" ["LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["~LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["DETAIL_TEXT"]=> string(20840) "

Introduction

Engraftment-related fever and engraftment syndrome are well-known phenomenon post autologous HSCT. Engraftment syndrome refers to the constellation of features associated with engraftment including fever, skin rash, fluid retention, weight gain, and non-cardiogenic pulmonary edema. These features constitute the major criteria of the proposed definition of engraftment syndrome [1]. However, some studies have defined this syndrome differently and its reported incidence varies widely from 7% to as high as 59% in some studies [2-7]. The period of onset of engraftment-related fever often coincides with the time when the patients are likely to have fungal and bacterial infections. Hence, antibiotics are often escalated at the time of onset of breakthrough fever. This leads to increased use of antimicrobials and consequently adds significantly to health care costs.

There is no reliable clinical or laboratory parameter which helps to differentiate engraftment related fever from infectious fever. One study has shown that the ratio of Interleukin-12 to Interleukin-6 could reliably distinguish infectious from non-infectious fever following autologous HSCT [8]. However, measurement of interleukin levels is not available in most transplant centres. Our study stemmed from personal observations that the relative increase in total leukocyte count (TLC) is greater than the relative increase in C-reactive protein (CRP) in patients with engraftment fever whereas the reverse is, generally, seen in infectious fever. With this observation, we aimed to study whether the TLC/CRP ratio helps to distinguish infectious fever from engraftment-related fever in the patients undergoing autologous HSCT.

Patients and methods

Patient characteristics

This is a retrospective analysis of all autologous transplants from March 2011 to September 2013 at a single centre. One hundred and nine consecutive autologous transplants were included in the analysis (Table 1). Fifty-three patients had Hodgkin lymphoma, 19 had Non Hodgkin lymphoma, 34 had multiple myeloma and 3 had neuroblastoma. The median age was 32 years (range 2-63 years). Eighty four patients were males. At the time of transplant, 67 (61%) patients were in complete remission and 37 (34%) were in partial remission.

Chemotherapy and granulocyte colony stimulating factor (G-CSF) were used for stem cell mobilization in 100 (92%) patients while only G-CSF was used in 4 (4%) patients. G-CSF with plerixafor was used in 1 patient. Four (4%) patients did not receive any form of mobilizing drug. All these 4 patients received marrow grafts. All patients with multiple myeloma received melphalan based conditioning regimen, either melphalan alone (n=31) or with bortezomib (n=3). Lymphoma patients received conditioning with lomustine + cytarabine + cyclophosphamide + etoposide [LACE (n=69)], lomustine + etoposide + cytarabine + melphalan [LEAM (n=1)] or carmustine + etoposide + cytarabine + melphalan [BEAM (n=2)] regimen. Patients with neuroblastoma received busulfan + melphalan conditioning. Peripheral blood stem cells graft was used in 103 (95%) patients and bone marrow graft was used in 5 (5%) patients. One patient received a combined marrow and PBSC graft. Stem cells were cryopreserved for a median of 43 days (17-301 days). The median dose of CD34 cells infused was 4.6×10⁶ per kg. Neutrophil and platelet engraftment occurred at a median of 11 days and 13 days, respectively.

Table 1. Patient characteristics

TLC and CRP were measured in the frames of routine blood analyses daily in the morning for all patients from the day of admission to the day of discharge and TLC/CRP ratio was calculated. Complete blood counts were done by Beckman HMX coulter. CRP was measured by the particle-enhanced turbidimetric immunoassay (PETIA) technique. Appropriate clinical and laboratory data were retrieved from patients’ files.

Clinical definitions

Engraftment: Myeloid engraftment was defined as TLC >1×10⁹/L for 3 consecutive days or absolute neutrophil count greater than or equal to 0.5×10⁹/L for 2 consecutive days, whichever was earlier. Platelet engraftment was defined as the first day of consecutive 7 days when platelet count remained about 20×10⁹/L without need for platelet transfusion.

Peri-engraftment period: Peri-engraftment period was defined as period of 72 hours prior to myeloid engraftment to 96 hours after engraftment.

Breakthrough fever: Fever >38°C with onset in peri-engraftment period (usually during the 2^nd week post-transplant) after being afebrile for at least 48 hours. Episodes of breakthrough fever were classified as either infectious fever, or engraftment-related fever.

Continuous fever: Patients with fever persisting over 2^nd week post-transplant without an afebrile period, or with afebrile period of <48 hours were classified as having continuous fever.

Infectious fever: The condition was classified as infectious fever if blood culture (or culture from any other normally sterile site) was positive, or in case of radiological signs of infection or if fever subsided within 48 hours after change of antibiotics.

Engraftment fever: Engraftment fever was defined as fever with onset in the peri-engraftment period, without any evidence of associated infectious cause, and responding to systemic steroid therapy.

Anti-infective prophylaxis

All the patients received prophylaxis with an anti-fungal agent (voriconazole or posaconazole) and acyclovir. Antifungal prophylaxis was started on day -1 and continued till resolution of neutropenia. In patients receiving systemic steroids for engraftment fever, antifungal prophylaxis was continued until the steroids were stopped. Acyclovir was given for up to 6 months post HSCT. Patients receiving systemic steroids for engraftment fever also received cotrimoxazole prophylaxis. No antibacterial prophylaxis was performed for the period of neutropenia.

Use of growth factors

Filgrastim (G-CSF) was used in all autologous transplants. In patients with lymphomas and neuroblastoma, it started on the next day after stem cell infusion (Day +1). In patients with myeloma, it was started on day +5 post-transplant. In all the patients, it continued until myeloid engraftment.

Treatment strategy for breakthrough fever

Treatment-related decisions were made at the discretion of treating physician. In general, antibacterial or antifungal drugs were added at the onset of breakthrough fever. The antibiotics were continued if the patient became afebrile by 48 hours. If the patient remained febrile beyond 48 hours and blood culture had grown an organism, then antibiotics were modified according to the sensitivity reports. If the fever persisted beyond 48 hours, and there was no evidence of any infective cause, then systemic steroids were started. In few patients with high clinical suspicion of engraftment fever, systemic steroids were started at the onset of breakthrough fever. Initially methylprednisolone was started at a dose of 1-2 mg per kg per day and subsequently changed to oral prednisolone. Prednisolone was tapered every 3^rd to 7^th day as per discretion of the attending clinician.

Statistical analysis

We studied the trends of TLC:CRP ratio during the course of HSCT. We studied the absolute value of this ratio on the day of breakthrough fever to determine if it helps in distinguishing engraftment-related fever from infectious fever. Optimal cut-off value of the ratio on the day of breakthrough was obtained by plotting a receiver operating characteristic (ROC) curve. Sensitivity and specificity indices were calculated from this value. We also calculated the absolute rise of the ratio from its nadir to post-nadir value (i.e the lowest value and the value on the next day) and studied, whether this absolute rise helps to predict the occurrence of engraftment fever. Categorical data were analysed with chi-square test; continuous data with Mann-Whitney test. Analysis was done by SPSS software (version 18).

Results

Among the 109 patients subjected to autologous HSCT, seventy patients (64%) developed breakthrough fever in the 2^nd week post-transplant. Fourteen patients (13%) had continuous fever while 22 (20%) patients did not have fever at any time in the 2^nd week. Three patients (3%) expired prior to day 7 (all 3 due to pneumonia with sepsis). Of the 70 patients with breakthrough fever, 19 had multiple myeloma, 36 suffered with Hodgkin lymphoma, 14 had non-Hodgkin lymphoma, and one patient had neuroblastoma. The characteristics and engraftment kinetics of the cohort with breakthrough fever were not different from the entire cohort (Table 1).

The median day of the breakthrough fever onset was day +9 (ranges, day +7 to day+15). Sixty-two patients had engraftment-related fever; 15 of these had a full-blown engraftment syndrome. The overall incidence of engraftment fever was 57% (62 of 109 patients). Among the 62 patients with engraftment fever, one patient died due to full-blown engraftment syndrome. All others recovered. Peri-engraftment hepatic and renal dysfunction was seen in 2 patients each. Antibiotics were escalated in 35 of 62 (56%) patients with engraftment fever at the time of onset of breakthrough fever. All the patients with infectious fever got well (Table 2).

Table 2. Breakthrough fever and clinical outcomes

Trend of TLC-to-CRP ratio following HSCT in myeloma patients

The ratio of TLC (expressed in 109/ml) to CRP (expressed in mg/dl) followed a parabolic curve. It had a median value of 12.35 (range 2.34-60) at day -3 of HSCT and gradually declined to a median nadir value of 0.02 (range 0 to 0.16) (Fig. 1). The nadir was attained at a median of 9 days post-transplant. A rising trend of the ratio was first evident at a median of 10 days. This was followed by a gradual rise in ratio towards baseline.

Trend of TLC-to-CRP ratio after HSCT in lymphoma patients

The curve of TLC:CRP ratio was also parabolic in the patients with lymphoma. The median value of the ratio when starting the conditioning chemotherapy (on day -8) was 5.35 (range 0.41 to 83). It reached a nadir median value of 0.01 (range 0-7.55) on day +2. It remained at the nadir level till day +5. Rising trend of the radio was first evident on day +6. A rising trend of the ratio preceded neutrophil engraftment by a median term of 5 days (Fig. 2).

Absolute value of the TLC:CRP ratio on the day of breakthrough fever

We also examined, whether the absolute value of the TLC:CRP ratio on the day of breakthrough fever may help in identifying the cause of fever. The median value of this ratio in patients with engraftment fever was significantly higher than among the patients with infectious fever (0.139 vs 0.038, p=0.013). A ROC curve was constructed for TLC:CRP ratio. The area under the ROC curve was 0.78 (95% CI – 0.66 to 0.89, p <0.0001). This indicates that the test has potentially good diagnostic usefulness. The curve provided an optimum cut off value of 0.056 to discriminate between engraftment and infective fever (Fig. 3).

A ratio greater than or equal to 0.056 on the day of breakthrough fever had sensitivity of 63% (95% CI 50 – 75%) and specificity of 100% (95% CI 63 – 100%) for detecting engraftment fever. The positive and negative predictive values of ratio >0.056 for engraftment related fever were 100% (95% CI 89 – 100%) and 26% (95% CI – 13-45%). Thus, a TLC:CRP ratio of >0.056 is absolutely specific for engraftment fever.

Absolute rise in ratio from nadir value to predict risk of engraftment fever

We studied the rise in ratio from its nadir value to the post nadir value (i.e. value on the next day) and attempted to see if a cut-off could be found, thus helping to predict increased risk of developing engraftment related fever. However, at various cut-off values ranging from 0.001 to 0.01, approximately 60% of the patients developed engraftment fever. Thus, no particular cut-off value predicting an increased risk of developing engraftment fever could be determined in our patient cohort (p=NS) (Table 3). The median increase from the nadir to the post-nadir value was not different in patients with and without engraftment related fever (0.008 vs 0.010, p=0.72).

Discussion

Engraftment fever is a well-known entity post autologous HSCT and occurs in the peri-engraftment period [1]. However, this is also the time when transplant patients may develop fungal and bacterial infections. Unfortunately, there is no laboratory marker or test in routine clinical use which helps to distinguish engraftment related fever versus infectious fever. The distinction is largely based on clinical judgement. Antimicrobials are often escalated in patients who develop breakthrough fever during peri-engraftment period, since it is not always possible to discriminate it from infective fever.

Few studies have tried to differentiate engraftment fever from infectious fever. A study from Memorial Sloan-Kettering Institute suggested that ratio of serum interleukin 12 to interleukin 6 at the time of breakthrough fever helps to discriminate between engraftment and infectious fever [8]. This group studied the levels of various cytokines in serum at various time points following autologous HSCT and found that value of ratio >4.1 at the time of breakthrough fever has a sensitivity of 95% and specificity of 75% for detecting engraftment fever. Although several functions of interleukin 12 are known, one of the important functions is to enhance the proliferation of hematopoietic progenitor cells [9-11]. Also, it is well established that interleukin-6 is the major stimulator of C-reactive protein [12, 13]. Hence, from a biological perspective, the ratio of TLC to CRP could be used as a surrogate marker for the ratio of serum IL-12 to IL-6.

A major problem with the use of serum cytokine levels is the lack of availability of these at most centres. On the other hand, measurements of TLC and CRP values are available at most centres and are relatively inexpensive. The cut-off value of TLC/CRP ratio 0.056 identified in our study has a higher specificity, but lower sensitivity than the IL-12 to IL-6 ratio reported in the previous study [8]. In this study, 17% of episodes of breakthrough fever occurring after neutrophil engraftment were associated with infection. This value is similar to that found in our study (8 of 70 episodes, 11%). Similar to our study, the median value of IL-12 to IL-6 ratio was significantly higher in patients with non-infectious fever compared to those with infectious episodes. The study reported a sensitivity and specificity of 95% and 75% at a cut-off of 4.1. The area under the ROC curve was 0.88 for the IL-12 to IL-6 ratio with 95% CI being 0.79-0.97.

To conclude, a rising trend of the ratio of TLC:CRP is detected prior to neutrophil engraftment. An absolute value of the ratio greater than or equal to 0.056 at the time of breakthrough fever is highly specific for engraftment fever. Further prospective studies are warranted to confirm the findings of this small study. If the findings are confirmed, they could help to prevent unnecessary use of anti-bacterials and anti-fungals in post-transplant period.

Conflicts of interest

None declared.

References

1. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.
2. Lee C, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 1995; 16: 175-182.
3. Ravoet C, Feremans W, Husson B, Majois F, Kentos A, Lambermont M, Wallef G, Capel P, Beauduin M, Delannoy A. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant 1996; 18: 943-947.
4. Edenfield W, Moores LK, Goodwin G, Lee N. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant 2000; 25: 405-409.
5. Cahill R, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-184.
6. Nurnberger W, Willers R, Burdach S, Gobel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 1997; 74: 221-224.
7. Moreb JS, Kubilis PS, Mullins DL, Myers L, Youngblood M, Hutcheson C. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients. Bone Marrow Transplant 1997; 19: 101-106.
8. Tuma R, Almyroudis N, Sohn S, Panageas K, Rice R, Galinkin D, Blain M, Montefusco M, Pamer E, Nimer Sd, Kewalramani T. The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation. Cytotherapy. 2006; 8: 327-334.
9. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
10. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3: 133-146.
11. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 194; 12: 154-168.
12. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999; 189: 599-604.
13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-1812.

" ["~DETAIL_TEXT"]=> string(20840) "

Introduction

Engraftment-related fever and engraftment syndrome are well-known phenomenon post autologous HSCT. Engraftment syndrome refers to the constellation of features associated with engraftment including fever, skin rash, fluid retention, weight gain, and non-cardiogenic pulmonary edema. These features constitute the major criteria of the proposed definition of engraftment syndrome [1]. However, some studies have defined this syndrome differently and its reported incidence varies widely from 7% to as high as 59% in some studies [2-7]. The period of onset of engraftment-related fever often coincides with the time when the patients are likely to have fungal and bacterial infections. Hence, antibiotics are often escalated at the time of onset of breakthrough fever. This leads to increased use of antimicrobials and consequently adds significantly to health care costs.

There is no reliable clinical or laboratory parameter which helps to differentiate engraftment related fever from infectious fever. One study has shown that the ratio of Interleukin-12 to Interleukin-6 could reliably distinguish infectious from non-infectious fever following autologous HSCT [8]. However, measurement of interleukin levels is not available in most transplant centres. Our study stemmed from personal observations that the relative increase in total leukocyte count (TLC) is greater than the relative increase in C-reactive protein (CRP) in patients with engraftment fever whereas the reverse is, generally, seen in infectious fever. With this observation, we aimed to study whether the TLC/CRP ratio helps to distinguish infectious fever from engraftment-related fever in the patients undergoing autologous HSCT.

Patients and methods

Patient characteristics

This is a retrospective analysis of all autologous transplants from March 2011 to September 2013 at a single centre. One hundred and nine consecutive autologous transplants were included in the analysis (Table 1). Fifty-three patients had Hodgkin lymphoma, 19 had Non Hodgkin lymphoma, 34 had multiple myeloma and 3 had neuroblastoma. The median age was 32 years (range 2-63 years). Eighty four patients were males. At the time of transplant, 67 (61%) patients were in complete remission and 37 (34%) were in partial remission.

Chemotherapy and granulocyte colony stimulating factor (G-CSF) were used for stem cell mobilization in 100 (92%) patients while only G-CSF was used in 4 (4%) patients. G-CSF with plerixafor was used in 1 patient. Four (4%) patients did not receive any form of mobilizing drug. All these 4 patients received marrow grafts. All patients with multiple myeloma received melphalan based conditioning regimen, either melphalan alone (n=31) or with bortezomib (n=3). Lymphoma patients received conditioning with lomustine + cytarabine + cyclophosphamide + etoposide [LACE (n=69)], lomustine + etoposide + cytarabine + melphalan [LEAM (n=1)] or carmustine + etoposide + cytarabine + melphalan [BEAM (n=2)] regimen. Patients with neuroblastoma received busulfan + melphalan conditioning. Peripheral blood stem cells graft was used in 103 (95%) patients and bone marrow graft was used in 5 (5%) patients. One patient received a combined marrow and PBSC graft. Stem cells were cryopreserved for a median of 43 days (17-301 days). The median dose of CD34 cells infused was 4.6×10⁶ per kg. Neutrophil and platelet engraftment occurred at a median of 11 days and 13 days, respectively.

Table 1. Patient characteristics

TLC and CRP were measured in the frames of routine blood analyses daily in the morning for all patients from the day of admission to the day of discharge and TLC/CRP ratio was calculated. Complete blood counts were done by Beckman HMX coulter. CRP was measured by the particle-enhanced turbidimetric immunoassay (PETIA) technique. Appropriate clinical and laboratory data were retrieved from patients’ files.

Clinical definitions

Engraftment: Myeloid engraftment was defined as TLC >1×10⁹/L for 3 consecutive days or absolute neutrophil count greater than or equal to 0.5×10⁹/L for 2 consecutive days, whichever was earlier. Platelet engraftment was defined as the first day of consecutive 7 days when platelet count remained about 20×10⁹/L without need for platelet transfusion.

Peri-engraftment period: Peri-engraftment period was defined as period of 72 hours prior to myeloid engraftment to 96 hours after engraftment.

Breakthrough fever: Fever >38°C with onset in peri-engraftment period (usually during the 2^nd week post-transplant) after being afebrile for at least 48 hours. Episodes of breakthrough fever were classified as either infectious fever, or engraftment-related fever.

Continuous fever: Patients with fever persisting over 2^nd week post-transplant without an afebrile period, or with afebrile period of <48 hours were classified as having continuous fever.

Infectious fever: The condition was classified as infectious fever if blood culture (or culture from any other normally sterile site) was positive, or in case of radiological signs of infection or if fever subsided within 48 hours after change of antibiotics.

Engraftment fever: Engraftment fever was defined as fever with onset in the peri-engraftment period, without any evidence of associated infectious cause, and responding to systemic steroid therapy.

Anti-infective prophylaxis

All the patients received prophylaxis with an anti-fungal agent (voriconazole or posaconazole) and acyclovir. Antifungal prophylaxis was started on day -1 and continued till resolution of neutropenia. In patients receiving systemic steroids for engraftment fever, antifungal prophylaxis was continued until the steroids were stopped. Acyclovir was given for up to 6 months post HSCT. Patients receiving systemic steroids for engraftment fever also received cotrimoxazole prophylaxis. No antibacterial prophylaxis was performed for the period of neutropenia.

Use of growth factors

Filgrastim (G-CSF) was used in all autologous transplants. In patients with lymphomas and neuroblastoma, it started on the next day after stem cell infusion (Day +1). In patients with myeloma, it was started on day +5 post-transplant. In all the patients, it continued until myeloid engraftment.

Treatment strategy for breakthrough fever

Treatment-related decisions were made at the discretion of treating physician. In general, antibacterial or antifungal drugs were added at the onset of breakthrough fever. The antibiotics were continued if the patient became afebrile by 48 hours. If the patient remained febrile beyond 48 hours and blood culture had grown an organism, then antibiotics were modified according to the sensitivity reports. If the fever persisted beyond 48 hours, and there was no evidence of any infective cause, then systemic steroids were started. In few patients with high clinical suspicion of engraftment fever, systemic steroids were started at the onset of breakthrough fever. Initially methylprednisolone was started at a dose of 1-2 mg per kg per day and subsequently changed to oral prednisolone. Prednisolone was tapered every 3^rd to 7^th day as per discretion of the attending clinician.

Statistical analysis

We studied the trends of TLC:CRP ratio during the course of HSCT. We studied the absolute value of this ratio on the day of breakthrough fever to determine if it helps in distinguishing engraftment-related fever from infectious fever. Optimal cut-off value of the ratio on the day of breakthrough was obtained by plotting a receiver operating characteristic (ROC) curve. Sensitivity and specificity indices were calculated from this value. We also calculated the absolute rise of the ratio from its nadir to post-nadir value (i.e the lowest value and the value on the next day) and studied, whether this absolute rise helps to predict the occurrence of engraftment fever. Categorical data were analysed with chi-square test; continuous data with Mann-Whitney test. Analysis was done by SPSS software (version 18).

Results

Among the 109 patients subjected to autologous HSCT, seventy patients (64%) developed breakthrough fever in the 2^nd week post-transplant. Fourteen patients (13%) had continuous fever while 22 (20%) patients did not have fever at any time in the 2^nd week. Three patients (3%) expired prior to day 7 (all 3 due to pneumonia with sepsis). Of the 70 patients with breakthrough fever, 19 had multiple myeloma, 36 suffered with Hodgkin lymphoma, 14 had non-Hodgkin lymphoma, and one patient had neuroblastoma. The characteristics and engraftment kinetics of the cohort with breakthrough fever were not different from the entire cohort (Table 1).

The median day of the breakthrough fever onset was day +9 (ranges, day +7 to day+15). Sixty-two patients had engraftment-related fever; 15 of these had a full-blown engraftment syndrome. The overall incidence of engraftment fever was 57% (62 of 109 patients). Among the 62 patients with engraftment fever, one patient died due to full-blown engraftment syndrome. All others recovered. Peri-engraftment hepatic and renal dysfunction was seen in 2 patients each. Antibiotics were escalated in 35 of 62 (56%) patients with engraftment fever at the time of onset of breakthrough fever. All the patients with infectious fever got well (Table 2).

Table 2. Breakthrough fever and clinical outcomes

Trend of TLC-to-CRP ratio following HSCT in myeloma patients

The ratio of TLC (expressed in 109/ml) to CRP (expressed in mg/dl) followed a parabolic curve. It had a median value of 12.35 (range 2.34-60) at day -3 of HSCT and gradually declined to a median nadir value of 0.02 (range 0 to 0.16) (Fig. 1). The nadir was attained at a median of 9 days post-transplant. A rising trend of the ratio was first evident at a median of 10 days. This was followed by a gradual rise in ratio towards baseline.

Trend of TLC-to-CRP ratio after HSCT in lymphoma patients

The curve of TLC:CRP ratio was also parabolic in the patients with lymphoma. The median value of the ratio when starting the conditioning chemotherapy (on day -8) was 5.35 (range 0.41 to 83). It reached a nadir median value of 0.01 (range 0-7.55) on day +2. It remained at the nadir level till day +5. Rising trend of the radio was first evident on day +6. A rising trend of the ratio preceded neutrophil engraftment by a median term of 5 days (Fig. 2).

Absolute value of the TLC:CRP ratio on the day of breakthrough fever

We also examined, whether the absolute value of the TLC:CRP ratio on the day of breakthrough fever may help in identifying the cause of fever. The median value of this ratio in patients with engraftment fever was significantly higher than among the patients with infectious fever (0.139 vs 0.038, p=0.013). A ROC curve was constructed for TLC:CRP ratio. The area under the ROC curve was 0.78 (95% CI – 0.66 to 0.89, p <0.0001). This indicates that the test has potentially good diagnostic usefulness. The curve provided an optimum cut off value of 0.056 to discriminate between engraftment and infective fever (Fig. 3).

A ratio greater than or equal to 0.056 on the day of breakthrough fever had sensitivity of 63% (95% CI 50 – 75%) and specificity of 100% (95% CI 63 – 100%) for detecting engraftment fever. The positive and negative predictive values of ratio >0.056 for engraftment related fever were 100% (95% CI 89 – 100%) and 26% (95% CI – 13-45%). Thus, a TLC:CRP ratio of >0.056 is absolutely specific for engraftment fever.

Absolute rise in ratio from nadir value to predict risk of engraftment fever

We studied the rise in ratio from its nadir value to the post nadir value (i.e. value on the next day) and attempted to see if a cut-off could be found, thus helping to predict increased risk of developing engraftment related fever. However, at various cut-off values ranging from 0.001 to 0.01, approximately 60% of the patients developed engraftment fever. Thus, no particular cut-off value predicting an increased risk of developing engraftment fever could be determined in our patient cohort (p=NS) (Table 3). The median increase from the nadir to the post-nadir value was not different in patients with and without engraftment related fever (0.008 vs 0.010, p=0.72).

Discussion

Engraftment fever is a well-known entity post autologous HSCT and occurs in the peri-engraftment period [1]. However, this is also the time when transplant patients may develop fungal and bacterial infections. Unfortunately, there is no laboratory marker or test in routine clinical use which helps to distinguish engraftment related fever versus infectious fever. The distinction is largely based on clinical judgement. Antimicrobials are often escalated in patients who develop breakthrough fever during peri-engraftment period, since it is not always possible to discriminate it from infective fever.

Few studies have tried to differentiate engraftment fever from infectious fever. A study from Memorial Sloan-Kettering Institute suggested that ratio of serum interleukin 12 to interleukin 6 at the time of breakthrough fever helps to discriminate between engraftment and infectious fever [8]. This group studied the levels of various cytokines in serum at various time points following autologous HSCT and found that value of ratio >4.1 at the time of breakthrough fever has a sensitivity of 95% and specificity of 75% for detecting engraftment fever. Although several functions of interleukin 12 are known, one of the important functions is to enhance the proliferation of hematopoietic progenitor cells [9-11]. Also, it is well established that interleukin-6 is the major stimulator of C-reactive protein [12, 13]. Hence, from a biological perspective, the ratio of TLC to CRP could be used as a surrogate marker for the ratio of serum IL-12 to IL-6.

A major problem with the use of serum cytokine levels is the lack of availability of these at most centres. On the other hand, measurements of TLC and CRP values are available at most centres and are relatively inexpensive. The cut-off value of TLC/CRP ratio 0.056 identified in our study has a higher specificity, but lower sensitivity than the IL-12 to IL-6 ratio reported in the previous study [8]. In this study, 17% of episodes of breakthrough fever occurring after neutrophil engraftment were associated with infection. This value is similar to that found in our study (8 of 70 episodes, 11%). Similar to our study, the median value of IL-12 to IL-6 ratio was significantly higher in patients with non-infectious fever compared to those with infectious episodes. The study reported a sensitivity and specificity of 95% and 75% at a cut-off of 4.1. The area under the ROC curve was 0.88 for the IL-12 to IL-6 ratio with 95% CI being 0.79-0.97.

To conclude, a rising trend of the ratio of TLC:CRP is detected prior to neutrophil engraftment. An absolute value of the ratio greater than or equal to 0.056 at the time of breakthrough fever is highly specific for engraftment fever. Further prospective studies are warranted to confirm the findings of this small study. If the findings are confirmed, they could help to prevent unnecessary use of anti-bacterials and anti-fungals in post-transplant period.

Conflicts of interest

None declared.

References

1. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.
2. Lee C, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 1995; 16: 175-182.
3. Ravoet C, Feremans W, Husson B, Majois F, Kentos A, Lambermont M, Wallef G, Capel P, Beauduin M, Delannoy A. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant 1996; 18: 943-947.
4. Edenfield W, Moores LK, Goodwin G, Lee N. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant 2000; 25: 405-409.
5. Cahill R, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-184.
6. Nurnberger W, Willers R, Burdach S, Gobel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol 1997; 74: 221-224.
7. Moreb JS, Kubilis PS, Mullins DL, Myers L, Youngblood M, Hutcheson C. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients. Bone Marrow Transplant 1997; 19: 101-106.
8. Tuma R, Almyroudis N, Sohn S, Panageas K, Rice R, Galinkin D, Blain M, Montefusco M, Pamer E, Nimer Sd, Kewalramani T. The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation. Cytotherapy. 2006; 8: 327-334.
9. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
10. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3: 133-146.
11. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 194; 12: 154-168.
12. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999; 189: 599-604.
13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-1812.

" ["DETAIL_TEXT_TYPE"]=> string(4) "html" ["~DETAIL_TEXT_TYPE"]=> string(4) "html" ["PREVIEW_TEXT"]=> string(0) "" ["~PREVIEW_TEXT"]=> string(0) "" ["PREVIEW_TEXT_TYPE"]=> string(4) "text" ["~PREVIEW_TEXT_TYPE"]=> string(4) "text" ["PREVIEW_PICTURE"]=> NULL ["~PREVIEW_PICTURE"]=> NULL ["LANG_DIR"]=> string(4) "/ru/" ["~LANG_DIR"]=> string(4) "/ru/" ["SORT"]=> string(3) "500" ["~SORT"]=> string(3) "500" ["CODE"]=> string(100) "sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-" ["~CODE"]=> string(100) "sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-" ["EXTERNAL_ID"]=> string(4) "1856" ["~EXTERNAL_ID"]=> string(4) "1856" ["IBLOCK_TYPE_ID"]=> string(7) "journal" ["~IBLOCK_TYPE_ID"]=> string(7) "journal" ["IBLOCK_CODE"]=> string(7) "volumes" ["~IBLOCK_CODE"]=> string(7) "volumes" ["IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["~IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["LID"]=> string(2) "s2" ["~LID"]=> string(2) "s2" ["EDIT_LINK"]=> NULL ["DELETE_LINK"]=> NULL ["DISPLAY_ACTIVE_FROM"]=> string(0) "" ["IPROPERTY_VALUES"]=> array(18) { ["ELEMENT_META_TITLE"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["ELEMENT_META_KEYWORDS"]=> string(0) "" ["ELEMENT_META_DESCRIPTION"]=> string(621) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?" ["ELEMENT_PREVIEW_PICTURE_FILE_ALT"]=> string(4284) "<p style="text-align: justify;">«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов. </p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная. </p>" ["ELEMENT_PREVIEW_PICTURE_FILE_TITLE"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["ELEMENT_DETAIL_PICTURE_FILE_ALT"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["ELEMENT_DETAIL_PICTURE_FILE_TITLE"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_META_TITLE"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_META_KEYWORDS"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_META_DESCRIPTION"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_PICTURE_FILE_ALT"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_PICTURE_FILE_TITLE"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_PICTURE_FILE_NAME"]=> string(100) "sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-" ["SECTION_DETAIL_PICTURE_FILE_ALT"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_DETAIL_PICTURE_FILE_TITLE"]=> string(428) "Соотношение количества лейкоцитов и С-реактивного белка в крови: поможет ли это дифференциации между инфекционной лихорадкой и синдромом приживления у пациентов после аутологичной трансплантации гемопоэтических стволовых клеток?" ["SECTION_DETAIL_PICTURE_FILE_NAME"]=> string(100) "sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-" ["ELEMENT_PREVIEW_PICTURE_FILE_NAME"]=> string(100) "sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-" ["ELEMENT_DETAIL_PICTURE_FILE_NAME"]=> string(100) "sootnoshenie-kolichestva-leykotsitov-i-s-reaktivnogo-belka-v-krovi-pomozhet-li-eto-differentsiatsii-" } ["FIELDS"]=> array(1) { ["IBLOCK_SECTION_ID"]=> string(3) "149" } ["PROPERTIES"]=> array(18) { ["KEYWORDS"]=> array(36) { ["ID"]=> string(2) "19" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:46:01" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(27) "Ключевые слова" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "KEYWORDS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "19" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "4" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "Y" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "Y" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(27) "Ключевые слова" ["~DEFAULT_VALUE"]=> string(0) "" } ["SUBMITTED"]=> array(36) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26480" ["VALUE"]=> string(10) "20.04.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "20.04.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL } ["ACCEPTED"]=> array(36) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26481" ["VALUE"]=> string(10) "26.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "26.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL } ["PUBLISHED"]=> array(36) { ["ID"]=> string(2) "22" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Дата публикации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "PUBLISHED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "22" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Дата публикации" ["~DEFAULT_VALUE"]=> NULL } ["CONTACT"]=> array(36) { ["ID"]=> string(2) "23" ["TIMESTAMP_X"]=> string(19) "2015-09-03 14:43:05" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(14) "Контакт" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "CONTACT" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "23" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(14) "Контакт" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHORS"]=> array(36) { ["ID"]=> string(2) "24" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:45:07" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "AUTHORS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "24" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_RU"]=> array(36) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26482" ["VALUE"]=> array(2) { ["TEXT"]=> string(590) "<p>Сачин Пунатар^1,2, Лингарадж Наяк^1,2, Авинаш Бонда^1,2, Анант Гокарн^1,2, Аникет Мохите¹, Картик Шанмугам¹, Дипан Раджаманикам¹, Алок Гупта¹, Либин Мэтью¹, Садхана Каннан³, Навин Хаттри^1,2</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(446) "

Сачин Пунатар^1,2, Лингарадж Наяк^1,2, Авинаш Бонда^1,2, Анант Гокарн^1,2, Аникет Мохите¹, Картик Шанмугам¹, Дипан Раджаманикам¹, Алок Гупта¹, Либин Мэтью¹, Садхана Каннан³, Навин Хаттри^1,2

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_RU"]=> array(36) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26483" ["VALUE"]=> array(2) { ["TEXT"]=> string(570) "<p>¹ Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия<br> ² Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия<br> ³ Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(510) "

¹ Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия
² Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия
³ Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_RU"]=> array(36) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26484" ["VALUE"]=> array(2) { ["TEXT"]=> string(4284) "<p style="text-align: justify;">«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов. </p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(4219) "

«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов.

Ключевые слова

Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["DOI"]=> array(36) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26485" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-40-46" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-40-46" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_EN"]=> array(36) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26488" ["VALUE"]=> array(2) { ["TEXT"]=> string(464) "<p>Sachin Punatar^1,2, Lingaraj Nayak^1,2, Avinash Bonda^1,2, Anant Gokarn^1,2, Aniket Mohite¹, Karthik Shanmugam¹, Deepan Rajamanickam¹, Alok Gupta¹, Libin Mathew¹, Sadhana Kannan³, Navin Khattry^1,2</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(320) "

Sachin Punatar^1,2, Lingaraj Nayak^1,2, Avinash Bonda^1,2, Anant Gokarn^1,2, Aniket Mohite¹, Karthik Shanmugam¹, Deepan Rajamanickam¹, Alok Gupta¹, Libin Mathew¹, Sadhana Kannan³, Navin Khattry^1,2

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_EN"]=> array(36) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26489" ["VALUE"]=> array(2) { ["TEXT"]=> string(738) "<p>¹ HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India<br> ² Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India<br> ³ Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India</p> <br> <p><b>Correspondence</b><br> Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India<br> Phone +91 989 2501 884<br> E mail: nkhattry@gmail.com</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(630) "

¹ HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India
² Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India
³ Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India

Correspondence
Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India
Phone +91 989 2501 884
E mail: nkhattry@gmail.com

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_EN"]=> array(36) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26490" ["VALUE"]=> array(2) { ["TEXT"]=> string(2028) "<p style="text-align: justify;">Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value. </p> <p style="text-align: justify;">Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 <i>vs</i> 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings. </p> <h2>Keywords</h2> <p style="text-align: justify;">Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(1929) "

Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value.

Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 vs 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings.

Keywords

Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["NAME_EN"]=> array(36) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26486" ["VALUE"]=> string(193) "Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(193) "Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" } ["FULL_TEXT_RU"]=> array(36) { ["ID"]=> string(2) "42" ["TIMESTAMP_X"]=> string(19) "2015-09-07 20:29:18" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(23) "Полный текст" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(12) "FULL_TEXT_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "42" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(23) "Полный текст" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["PDF_RU"]=> array(36) { ["ID"]=> string(2) "43" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF RUS" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_RU" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "43" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26487" ["VALUE"]=> string(4) "2031" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2031" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF RUS" ["~DEFAULT_VALUE"]=> string(0) "" } ["PDF_EN"]=> array(36) { ["ID"]=> string(2) "44" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF ENG" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "44" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26491" ["VALUE"]=> string(4) "2032" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2032" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF ENG" ["~DEFAULT_VALUE"]=> string(0) "" } ["NAME_LONG"]=> array(36) { ["ID"]=> string(2) "45" ["TIMESTAMP_X"]=> string(19) "2023-04-13 00:55:00" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(72) "Название (для очень длинных заголовков)" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "NAME_LONG" ["DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "45" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(80) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(72) "Название (для очень длинных заголовков)" ["~DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } } } ["DISPLAY_PROPERTIES"]=> array(10) { ["AUTHOR_EN"]=> array(37) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26488" ["VALUE"]=> array(2) { ["TEXT"]=> string(464) "<p>Sachin Punatar^1,2, Lingaraj Nayak^1,2, Avinash Bonda^1,2, Anant Gokarn^1,2, Aniket Mohite¹, Karthik Shanmugam¹, Deepan Rajamanickam¹, Alok Gupta¹, Libin Mathew¹, Sadhana Kannan³, Navin Khattry^1,2</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(320) "

Sachin Punatar^1,2, Lingaraj Nayak^1,2, Avinash Bonda^1,2, Anant Gokarn^1,2, Aniket Mohite¹, Karthik Shanmugam¹, Deepan Rajamanickam¹, Alok Gupta¹, Libin Mathew¹, Sadhana Kannan³, Navin Khattry^1,2

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(320) "

Sachin Punatar^1,2, Lingaraj Nayak^1,2, Avinash Bonda^1,2, Anant Gokarn^1,2, Aniket Mohite¹, Karthik Shanmugam¹, Deepan Rajamanickam¹, Alok Gupta¹, Libin Mathew¹, Sadhana Kannan³, Navin Khattry^1,2

" } ["SUMMARY_EN"]=> array(37) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26490" ["VALUE"]=> array(2) { ["TEXT"]=> string(2028) "<p style="text-align: justify;">Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value. </p> <p style="text-align: justify;">Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 <i>vs</i> 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings. </p> <h2>Keywords</h2> <p style="text-align: justify;">Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(1929) "

Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value.

Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 vs 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings.

Keywords

Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(1929) "

Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value.

Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 vs 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings.

Keywords

Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous.

" } ["DOI"]=> array(37) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26485" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-40-46" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-40-46" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-40-46" } ["NAME_EN"]=> array(37) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26486" ["VALUE"]=> string(193) "Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(193) "Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(193) "Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?" } ["ORGANIZATION_EN"]=> array(37) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26489" ["VALUE"]=> array(2) { ["TEXT"]=> string(738) "<p>¹ HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India<br> ² Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India<br> ³ Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India</p> <br> <p><b>Correspondence</b><br> Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India<br> Phone +91 989 2501 884<br> E mail: nkhattry@gmail.com</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(630) "

¹ HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India
² Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India
³ Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India

Correspondence
Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India
Phone +91 989 2501 884
E mail: nkhattry@gmail.com

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(630) "

¹ HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India
² Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India
³ Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India

Correspondence
Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India
Phone +91 989 2501 884
E mail: nkhattry@gmail.com

" } ["AUTHOR_RU"]=> array(37) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26482" ["VALUE"]=> array(2) { ["TEXT"]=> string(590) "<p>Сачин Пунатар^1,2, Лингарадж Наяк^1,2, Авинаш Бонда^1,2, Анант Гокарн^1,2, Аникет Мохите¹, Картик Шанмугам¹, Дипан Раджаманикам¹, Алок Гупта¹, Либин Мэтью¹, Садхана Каннан³, Навин Хаттри^1,2</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(446) "

Сачин Пунатар^1,2, Лингарадж Наяк^1,2, Авинаш Бонда^1,2, Анант Гокарн^1,2, Аникет Мохите¹, Картик Шанмугам¹, Дипан Раджаманикам¹, Алок Гупта¹, Либин Мэтью¹, Садхана Каннан³, Навин Хаттри^1,2

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(446) "

Сачин Пунатар^1,2, Лингарадж Наяк^1,2, Авинаш Бонда^1,2, Анант Гокарн^1,2, Аникет Мохите¹, Картик Шанмугам¹, Дипан Раджаманикам¹, Алок Гупта¹, Либин Мэтью¹, Садхана Каннан³, Навин Хаттри^1,2

" } ["SUBMITTED"]=> array(37) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26480" ["VALUE"]=> string(10) "20.04.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "20.04.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "20.04.2020" } ["ACCEPTED"]=> array(37) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26481" ["VALUE"]=> string(10) "26.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "26.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "26.06.2020" } ["SUMMARY_RU"]=> array(37) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26484" ["VALUE"]=> array(2) { ["TEXT"]=> string(4284) "<p style="text-align: justify;">«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов. </p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(4219) "

«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов.

Ключевые слова

Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(4219) "

«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов.

Ключевые слова

Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная.

" } ["ORGANIZATION_RU"]=> array(37) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26483" ["VALUE"]=> array(2) { ["TEXT"]=> string(570) "<p>¹ Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия<br> ² Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия<br> ³ Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(510) "

¹ Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия
² Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия
³ Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(510) "

¹ Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия
² Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия
³ Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия

" } } } [3]=> array(49) { ["IBLOCK_SECTION_ID"]=> string(3) "149" ["~IBLOCK_SECTION_ID"]=> string(3) "149" ["ID"]=> string(4) "1857" ["~ID"]=> string(4) "1857" ["IBLOCK_ID"]=> string(1) "2" ["~IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["~NAME"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["ACTIVE_FROM"]=> NULL ["~ACTIVE_FROM"]=> NULL ["TIMESTAMP_X"]=> string(19) "03.08.2020 17:18:33" ["~TIMESTAMP_X"]=> string(19) "03.08.2020 17:18:33" ["DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy/" ["~DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy/" ["LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["~LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["DETAIL_TEXT"]=> string(39357) "

Introduction

Fecal microbiome contains hundreds types of bacteria, with only minority of, mostly, aerobic gut bacteria having been detectable in bacteriological cultures. However, conventional microbiological cultures are able to detect only a limited number of aerobic and, to lesser degree, anaerobic bacteria in fecal samples. In this respect, a gene-specific DNA diagnostics, e.g., multiplex PCR aimed for detection of potentially pathogenic microbes, is a more sensitive technique for detection and quantification of distinct microbial species and families at different microbiotes of human body [1].

Moreover, major bacterial classes and families became available for studies and comparisons, due to development of the next-generation sequencing (NGS). Bacteroides and Clostridia comprise the majority of normal intestinal flora as suggested by several NGS studies performed in different parts of the world [2, 3]. These microbial types are susceptible to massive antibiotic treatment which is usually applied in immunocompromised patients after bone marrow transplantation [4].

Still there are no generally approved reference biodiversity values, or marker microorganisms for assessment of gut microbiome in immunocompromised patients following severe cytostatic and antimicrobial therapy. Severe intestinal affection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a useful clinical model for evaluation of gut microbiome shifts and its correction after fecal microbiota transplantation (FMT) [5]. An FMT protocol for clinical trials in severe graft-versus-host disease (GvHD) was applied quite recently [6].

Despite numerous clinical studies on FMT, there are only few bacterial markers for monitoring its efficiency. Appropriate guidelines are limited to bacteriological screening of the third-party donors of fecal transplants [7]. To our knowledge, there are no clear recommendations on screening of fecal microbiota in the patients. Except of time- and labor-consuming NGS analysis, some multiplex PCR-based approaches may be used that detect distinct gut pathogens [8, 9]. A quite recent approach is based on determination of relative proportions for the dominant phyla in human gut microbiome [10].

To evaluate real biodiversity of intestinal microbiome, most recent works are performed by sequencing of 16S rRNA fragments from multiple bacterial species, with subsequent detection of species-specific genes. The results of NGS assays provide a big number of 16S rRNA nucleotide sequences which correspond to relative representation of distinct bacterial classes in the given sample. The best reliable data derived from NGS analysis concern biological diversity for big taxonomic classes of microbiota, down to the family level. More exact species-specific diagnostics is less robust, due to only marginal interspecies differences in nucleotide sequences detectable by the current NGS technique.

Therefore, some more simple and cost-effective microbial markers are required for evaluation and screening of human microbiota after massive antibiotic therapy and in the course of gut recolonization. Hence, the aim of our study was a search for microbial species detectable by molecular biology techniques that could correlate with clinical results of FMT performed in severe resistant GvHD after allo-HSCT.

Patients and methods

The prospective single-center study included 27 patients at the age of 1 to 52 years old (median, 25 years) after allo-HSCT at the Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation over a period of 2017 to 2019 (Table 1). The main group included 19 post-HSCT patients who developed acute intestinal GvHD. All the patients were in remission state for their primary disease. These patients received FMT due to severe GvHD resistant to standard treatment. The inclusion criterion was steroid-refractory acute or chronic GvHD (overlap-syndrome) accompanied by intestinal affection. Intestinal GvHD has been confirmed by pathological examination of colonic mucosa biopsies. FMT was performed at a median of 110 (37-909) days post-HSCT. The comparison group with similar GvHD symptoms included eight patients who received placebo preparations instead of FMT applied on a median of 56 (34-120) days after HSCT.

Table 1. Clinical characteristics of the FMT patients

Antimicrobial prophylaxis was canceled 3 days before and during TFM treatment. Systemic antibacterial drugs were administered by common clinical indications (local infection, septicemia) to 8 patients (37%) before FMT, and in 18 cases (95%), after the procedure. Seven placebo-treated patients out of 8 (88%) were also exposed to systemic antimicrobial therapy. The patients with proven intestinal affection with HHV6 or EBV herpes viruses received gancyclovir: 11 (58%) in FMT-treated, 8 (100%) in the placebo group.

All the patients received immunosuppressive therapy as the first-line GvHD treatment, by means glucocorticosteroids (methylprednisolone, 1 mg/kg/d). The second-line therapy was performed with Ruxolitinib at the dose of 10-15mg/d (for children 0.25mg/kg/d). The patients underwent clinical and laboratory screening at the following terms: before FMT/placebo treatment D -1-3, D+3, D+16, D+30, D+60, and D+120 after FMT. The next day after last FMT was considered D+1. Primary endpoints were determined on the D+30 following FMT or placebo administration.

Routine laboratory studies at the ICU included daily blood cell and differential leukocyte counts, routine serum biochemistry, serum markers of inflammation (procalcitonine, С-reactive protein). In cases of acute intestinal syndrome, the aerobic microbial cultures of stool samples were routinely seeded, and C.difficile toxins A and B were checked by a simple immune chromatography test (VEDALAB, France).

In four cases (21%), the fecal transplant donation was performed from related donors (mother, 1; father, 2; brother, 1). FMT from unrelated donors was carried out in 15 patients.

Fecal transplants were administered by the following methods: via gastroduodenoscope, in 3 patients (16%); via nasointestinal catheter, in 7cases (3 TFM+ and 4 placebo); 13 patients (68%) ingested gelatin capsules with frozen microbiota. Placebo capsules were used in 4 patients (50%).

The single-center prospective study "Treatment of children and adult patients with inflammatory and infectious gut lesions after allogeneic transplantation of hematopoietic stem cells using transplantation of normal human microbiota" was approved by the Local Review Board at the First I. Pavlov Saint-Petersburg State Medical University №192 от 30.01.2017. The trial was performed in accordance with Good Clinical Practice and Declaration of Helsinki, i.e., full awareness of the study purpose, procedures and possible adverse effects from treatment, as stated by appropriate written informed consent signed by each patient or his (her) competent relative.

Fecal microbiota encapsulation procedure

Preparation of fecal transplants and their storage at -80°C was performed at the specialized microbiological laboratory. In brief, the donor material was supplemented with 10% glycerol and 50% sterile dextrose syrup (v/v), then homogenized with a disposable blender. The material, placed on ice, was then packed up in solid Coni-Snap® Size 0 gelatin capsules using the ProFiller 1100 device. The bar-coded capsules were placed into individual sterile containers. The fecal transplants (FT) were transferred to a freezing chamber (-80°C) and stored until use. The capsules were administered at a dose of 10 (3-15) capsules for 2 or 3 subsequent days. The total dose per single TFM course was 22 g (30 capsules) corresponding to 0.41 (0.29-1.67 g/kg body mass), independent on age and weight of the subjects.

The patients from comparison group were treated with 5 mL of 0.9% physiological saline delivered during diagnostic gastroscopy, or frozen capsules with physiological saline.

Laboratory screening of gut microbiota

Semi-quantitative assessment of fecal microbiota profile was performed with real-time PCR technique using commercial Colonoflor-16test system (Alpha-Lab, Saint Petersburg, Russia). Total bacterial mass, as well most represented microbial species, including strictly anaerobic species, could be detected by this DNA-based technique (Table 2). A set of gene-specific primers is used in this test kit, exploiting the differences in 16S rDNA sequences (see Table 3).

The same fecal DNA samples were used for detailed 16S rDNA sequencing by means of NGS technique, as elsewhere described [11]. The serial microbiome sequencing procedure was carried out with Illumina™ HiSeq 2500 system.

Table 2. Reference values for different microbial species detected by multiplex real-time PCR kit (Colonoflor-16)

Table 3. Gene-specific primers for detection of distinct microbes in fecal material (Colonoflor test system)

Clinical evaluation

Clinical examination of the patients along the observation period until D+120 was performed by the well-validated scales: GvHD severity score [12]; evaluation of clinical response of GvHD patients to therapy [13]; Bristol scale of stool [14].

All the patients (or their parents) filled a special diary with notices on their actual daily condition and severity of distinct symptoms by scoring the adverse treatment effects, according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE), version 5.0 of November 27 2017) [15], as follows: anorexia (1-5 points), nausea (1-3 points), lower intestinal bleeding (1-5 points). Pain syndrome (abdominal pains) was evaluated by the 10-point visual analogue scale for adults and children (VAS), according to WHO criteria [16, 17]. Number of defecations, daily volumes of diarrhea and vomiting were registered. The stool properties were evaluated according to the Bristol scale (1 to 7 points).

Aiming for a more objective evaluation of clinical response, the patients from main group were divided in two sub-groups, i.e., patients who showed full clinical response (CR), and those who responded only partially or lacked any positive response (PLR). These and other parameters were introduced into a common database.

The stool consistence was evaluated by the seven-point Bristol scale [14] (Lewis, Heaton, 1997). Volumes of water lost with stool and vomiting was also registered. A validated toxicity scale was used to evaluate bloody and mucous admixtures, loss of appetite, and other side effects (CTCAE Version 5.0 Published: November 27, 2017), using a 4-point scoring of its intensity (0, the symptom absent; 1, mild degree or periodic; 2, intermediate (often); 3, severe (permanent), requiring proper therapy). To evaluate abdominal pain, a 10-point VAS was applied [16, 17].

To specify rates of clinical response a, we classified the patients in 2 groups, i.e., the FMT outcomes were classified as the main group with complete response (CR), partial response (PR), or treatment failure (NR) in the patients. Full response was registered by 2 criteria, i.e., gut GvHD improvement (stool volume <10 mL/kg/day, absence of abdominal pains and bloody stool, no signs of gut paresis), and stool consistence of <4 points at Bristol scale should be registered. Partial response was documented in cases of complete response for intestinal GvHD, and stool consistence of >4 points by Bristol scale (stool volume >10 ml/kg/day). Absence of clinical response was documented if no complete recovery for intestinal GvHD, along with liquid stool (Bristol scale, 6 to 7 points, daily stool volume >10 mL/kg weight).

On the days before FMT/placebo administration, and by the days +3, +16, +30, +60, +120 after FMT, the mean sum values for preceding time period were calculated, beginning from the next day after last control point until the target point of the study. When analyzing clinical results, the last day of TFM treatment was assumed as day 0 for the observation period.

Statistical evaluation

All clinical and laboratory data obtained during the follow-up examinations were analyzed with R programming language v.3.6.2 in Rstudio v. 1.2.5033. Shannon index for 16S sequencing results was calculated as follows:

where n is a number of detected bacterial groups, p_i, frequency of i-th group occurrence. Comparison of samples was performed with non-parametric statistical methods: Wilcoxon test for two-sample comparisons, and Kruskal-Wallis test for three-sample comparison. Visualization was performed by means of R packages ggplot2 [18] and ggpubr [19].

Results

In the whole group of patients, some grade of response (disregarding Bristol scale) was achieved in 23 patients (85%), at D+120, including 18 cases after FMT (95%), and 5 placebo-treated patients (63%) (р=0.0646). Whole response was achieved in 16 patients (84%) after FMT, versus in 5 cases (63%) from placebo group (p=0.3191). One patient deceased without response to FMT (5%) versus 3 patients (38%) in the placebo group.

When evaluating clinical response to GvHD therapy, with regard of stool consistence by Bristol scale, we observed whole clinical response 120 days after FMT in 9 cases (47% with Bristol score of ≤4 points), and 9 patients (47%) showed improvement stool consistence (>4 points). In the placebo group, a complete or partial response was revealed, respectively, in 1 (13%) and 4 (50%) of the patients by the day +120.

Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase in the patients with complete clinical response (Fig. 1). In patients with full clinical response after FMT, or placebo, we have detected increased amounts of some major microbial groups by means of Colonoflor testing, i.e., Bacteroides fragilis group, Bifidobacterium spp., Faecalibacterium prausnitzii, along with decrease in Enterococcus spp. and Lactobacillus spp.

Figure 1. Relative contents of dominant fecal microbial species in the total set of samples from all the study terms (A), and on day +30 of observation (B) in the patients with complete response (red), partial/absent response (blue) including the placebo group. Abscissa, type of response after FMT. Ordinate, number of genocopies, log₁₀ per standard sample (0.1 g)

E.g., such shifts in total group of samples were demonstrable for B.fragilis group (p=2.1×10^-7); F.prausnitzii (p=9.8×10^-8) during the observation terms (Fig. 1A). Similar increase in B.fragilis group (p=0.028), and F.prausnitzii (p=0.027) was detectable by the D+30 in FMT-treated or placebo patients (Fig. 1B).

Moreover, a stable and significant increase of B.fragilis group and F.prausnitzii was revealed since early terms in FMT-treated patients compared to placebo-treated patients (Table 4).

Meanwhile, the numbers of Enterococcus, Lactobacillus spp., and Bacteroides thetaiotaomicron, generally, were not changed over this time period (Table 4). In the control group (placebo) we have not found significant changes of fecal microbiota against initial levels over 120 days of monitoring.

Table 4. Significance of differences (p values) between initial (pre-TFM/placebo) and post-FMT levels of certain microorganisms in fecal microbiota of total patient group (19 FMT cases and 8 placebo-treated patients)

Note: The differences significant at P<0.05 are shown in bold-face type.

Mean values of Bifidobacterium spp., E.coli, B.fragilis group and F.prausnitzii were significantly different for the studied groups (р<0.003; р<0.012; р<0.016; р<0.12, respectively), as seen in Fig. 2. We have also found some differences of the microbiota dynamics for the subgroups with complete response, partial/no response: Bifidobacterium spp. (р<0.047), E.coli (р<0.00047), B.fragilis gr. (р<5.6×10^-5), F.prausnitzii (р<0.0062).

In the placebo group, we did not detect any cases of C.difficile-associated infections. Meanwhile, three cases of C.difficile infection were detected in the FMT group. However, both A and B toxins of C.difficile became negative by day +16, +30 and +45 s after FMT.

Figure 2. Time-dependent changes of total bacterial mass and four selected bacterial classes are presented over 120 days of observation. Abscissa, subgroups of patients; Ordinate, number of genocopies, log₁₀ per standard sample (0.1 g)

Note: the groups with different response include FMT- and placebo-treated patients.

Hence, relative contents of B.fragilis group in fecal microbiota was selected as a bacterial marker increased upon recolonization, due to sufficient difference between complete and no/partial response to the FMT (p=2.1×10^-7), and pronounced dynamics of changes (p=5.6×10^-5) over 120 days of observation. Therefore, was selected for further studies, i.e. search for correlations with NGS results on Bacteroidia class.

Correlations between the ratios of specific microbial DNA extracted from fecal samples determined by the 16S rRNA NGS technique were assessed at phylogenetic levels of Bacteroidetes (Phylum), Bacteroidia (Class), and Bacteroidales (Order). Among all microbial specificities detectable by quantitative PCR (Colonoflor test set), only Bacteroides fragilis group showed strong correlation with the ratios of Bacteroidetes phylum and Bacteroidia class revealed NGS approach. When applying NGS technique for detection of gut bacteria, we revealed high correlation only between the general types of bacteroides, i.e. phylum (Bacteroidetes); class (Bacteroidia); order (Bacteroidales); family (Bacteroidaceae), genus (Bacteroides) (Table 5).

Table 5. Correlations between the main types of Bacteroidetes and B.fragilis group determined by NGS approach

B.fragilis contents in fecal microbiota from healthy donors proved to be significantly higher than in the patients with GvHD before FMT (Table 6), thus potentially requiring enhancement of these microorganisms in the patients after HSCT with immune complications. After FMT, the median levels of B.fragilis group are sufficiently increasing in parallel to complete clinical response, being, however, at lower levels in cases with partial or zero response.

Table 6. B.fragilis contents in the fecal microbiota samples (log₁₀ of genocopy numbers) in healthy donors and patients with differential response to FMT

Hence, the evaluation of B.fragilis group using real-time PCR, generally correlates with data on broader Bacteroides class obtained by 16SrRNA sequencing performed by much more complex and costly NGS technique. Meanwhile, multiplex PCR allows to get semi-quantitative results which could be used for routine monitoring of gut dysbiosis and its recovery.

In this series, D+30 proved to be the most informative time point for discerning differences between FMT and placebo-treated patients. I.e., on D+30 (a control point of study), we have found an increase over the D0 ratios in Bacteroidetes phylum; Bacteroidia (Class); Bacteroidales (Order) when studied by NGS approach. A strong correlation was found at all the time points with copy numbers of B.fragilis (PCR technique), as shown in Fig. 3.

Figure 3. Parallel changes of B.fragilis copy numbers (multiplex PCR) and Shannon index of genomic bacterial diversity determined by 16S rRNA sequencing for the groups with complete response (CR) versus partial/lacking response after FMT or placebo on D+30

The numbers of fecal B.fragilis genocopies in all the patients (FMT and placebo) with complete response were increased on D+30, and differed from the groups with partial/zero response after FMT procedure, or after placebo treatment (Fig. 3).

We have revealed a statistically significant correlation between the Shannon index (16 S rRNA sequencing) and B.fragilis levels (multiplex) PCR in the patients after FMT and/or placebo, either with complete response (CR), being significant at p=0.028, or partial/absent response (PR/NR), at p=8×10^-4 (Fig. 4).

Hence, on the basis of B.fragilis contents in fecal microbiota, its diversity (by Shannon index), and extent of clinical response for differently treated groups, we have obtained sufficient correlations between the subgroups with complete response, suboptimal response to FMT treatment, and placebo-treated patients.

Discussion

In this study we searched for microbiological correlates of clinical effect produced by FMT. We were able to compare the results of multiplex PCR technique and NGS gene analysis that were performed in parallel in the same fecal samples. Both molecular biology approaches proved to be effective when detecting shifts in gross classes of microbiota, e.g., Bacteroides, Clostridia and Enterobacter.

Using NGS approach, the proportions of some major microbiome classes are revealed, as follows: Bacteroidia, Clostridia, Gammaproteobacteria, Bacilli, Actinobacteria (Bifidobacterium spp). The main classes discerned by the NGS approach are represented by distinct microbial species detected by Colonoflor multiplex PCR (Table 7).

Table 7. Phylogenetic assignment of the bacteria revealed by 16S rRNA-based Colonoflor PCR system, and NGS approach (Illumina, MySeq)

As determined by next-generation sequencing and subsequent bioinformatics mining of resulting data bases for gut bacteria, we revealed high correlation only between gross types of bacteroides, i.e. phylum (Bacteroidetes); class (Bacteroidia); order (Bacteroidales); family (Bacteroidaceae), genus (Bacteroides) (Table 5). However, this correlation becomes much lower, when B.fragilis group is concerned, thus suggesting lesser precision of NGS diagnostics at the species level. Higher accuracy of the multiplex PCR for the B.fragilis group quantification could be explained by better specificity of appropriate primers, and due to presence of a reference gene marker for the total bacterial mass, thus allowing semi-quantitative determination.

To evaluate real biodiversity of intestinal microbiome, most recent works are performed by sequencing of 16S rRNA fragments from multiple bacterial species, with subsequent detection of species-specific genes. The results of NGS assays provide a big number of 16S rRNA nucleotide sequences which correspond to relative representation of distinct bacterial classes in the given sample. The best reliable data derived from NGS analysis concern biological diversity for big taxonomic classes of microbiota, down to the family level. More exact species-specific diagnostics is less robust, due to only marginal interspecies differences in nucleotide sequences detectable by the current NGS technique.

Therefore, some more simple and cost-effective microbial markers are required for evaluation and screening of human microbiota after massive antibiotic therapy and in the course of gut recolonization.

16S RNA gene polymorphism is a good method for control of ratios between the major classes of fecal microbiota. Moreover, drastic shifts of gut microbiota are revealed in several gut infections (mostly, C.difficile) and local immune affection, e.g., GvHD [20]. A conventional multiplex PCR approach allows performing a more specific, cheap and fast detection of major fecal microorganisms which is especially informative when using quantitative PCR (qPCR) after FMT, as shown in our study.

As seen from the presented data, one may recommend detection of the main bacterial groups (Bifidobacterium spp., Escherichia coli, B.fragilis group, Faecalibacterium prausnitzii) as potential markers for assessment of fecal microbiota shifts after FMT. It should be, however, noted that this correlation does not extend to other microbial groups (e.g., Lactobacillus spp., Citrobacter with absence of good correlation with 16S rRNA sequencing for Lactobacillus spp. and Citrobacter, probably, due to suboptimal sensitivity of the given test system for Lactobacillus spp. (<10⁵CFU/sample).

According to the qPCR data, the majority of microbial species sufficiently differed from the initial values on D+16 to D+30 after FMT, as seen for Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii. Therefore, one should presume engraftment of main fecal microorganisms after FMT over this period. Bacteroides compose 99% of normal microbiota, with quite important functional potential, being among promising probiotics [21].

Meanwhile, qPCR determination of B.fragilis group has shown a strong correlation with clinical response in the patients after FMT, thus allowing to consider this bacterial marker a potential laboratory correlate of efficient clinical response after FMT. An increase in Bacteroides quantities detected with qPCR and higher relative amounts found by means of NGS-based typing of 16S rDNA may, therefore, reflect engraftment of the major gut bacterial population. Decreased B.fragilis contents in the patients with partial or poor clinical response after D+30 post-FMT may be a non-engraftment marker, whereas increasing B.fragilis levels with a maximum about D+30 are revealed in complete clinical response. Meanwhile, other findings presume pronounced changes in Clostridiales (e.g., Blautia) as possible index of microbiota maintenance, thus deserving their further pathogenetic significance [4]. E.g., the qPCR system for Clostridium spp. should be also applied for additional testing of the gut microbiota restoration, along with testing for pathogenic C.difficile toxins, as a negative prognostic marker.

Monitoring of gut bacterial markers to assess gut microbiota recovery may effectively improve clinical assessment in gastroenterology. The currently used clinical criteria are mostly indirect, including stool volume and quality, intestinal motility, fecal blood and calprotectin tests, thus requiring additional microbial markers aimed for quantitative evaluation of the disease state. Certain bacterial families may serve as semi-quantitative markers of the disease-associated shifts and recovery of the microbiota. We have shown that quantitative PCR of distinct gut microorganisms is quite available and cheaper option for routine follow-up of intestinal dysbiosis [22].

However, the 16S rDNA sequencing by means of NGS approach remain indispensable for research in the field, looking for novel markers of human microbiota in health and disease.

Conclusions

1. Quantitative real-time PCR of the major bacteria groups of gut microbiota, e.g., Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii could be used as microbiological marker for evaluation of changing fecal microbiota following fecal transplantation as a routine molecular biology technique.

2. The genocopy counts of B.fragilis group correlate with clinical response in the patients with severe GvHD after allo-HSCT.

3. The time course of B.fragilis group contents could be considered an index of fecal microbiota engraftment following FMT.

4. B.fragilis contents in fecal microbiota measured by multiplex PCR show high positive correlation with Shannon index of bacterial diversity, determined by 16S rRNA gene sequencing.

Conflict of interest

The authors state that they have no conflict of interests.

Acknowledgements

The study was in part supported by a research contract with Russian Ministry of Healthcare effective as of January 2018 to December 2020.

References

1. Chukhlovin A.B., Pankratova O.S. Opportunistic microflora at unusual sites: marker pathogens in severe posttransplant immune deficiency. Cell Ther Transplant. 2017; 6(4): 28-41.
2. Fujio-Vejar S, Vasquez Y, Morales P, Magne F, Vera-Wolf P, Ugalde JA, Navarrete P, Gotteland M. The gut microbiota of healthy Chilean subjects reveals a high abundance of the phylum Verrucomicrobia. Front Microbiol, 30 June 2017, https://doi.org/10.3389/fmicb.2017.01221.
3. Senghor B, Sokhna C, Ruimy R, Lagier J-C. Gut microbiota diversity according to dietary habits and geographical provenance. Hum Microbiome J. 2018; 7-8: 1-9.
4. Taur Y. Intestinal microbiome changes and stem cell transplantation: Lessons learned. Virulence. 2016, 7(8), 930-938. doi: 10.1080/21505594.2016.1250982.
5. Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020; 382:822-834.
6. Shouval R, Geva M, Nagler A, Youngster I. Fecal microbiota transplantation for treatment of acute graft-versus-host disease. Clin Hematol Int. 2019; 1(1): 28-35.
7. Cammarota G, Ianiro G, Kelly CR, Mullish B, Allegretti JR, Kassam Z et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019;68:2111-2121.
8. Becker SL, Chatigre JK, Gohou JP, Coulibaly JT, Leuppi R, Polmans K, Chappuis F, Mertens P, Herrmann M, Goran EKN, Utzinger J, von Müller L. Combined stool-based multiplex PCR and microscopy for enhanced pathogen detection in patients with persistent diarrhoea and asymptomatic controls from Côte d’Ivoire. Clin Microbiol Infect. 2015;21:591.e1-591.e10.
9. Zitomersky NL, Coyne MJ, Comstock LE. Longitudinal analysis of the prevalence, maintenance, and IgA response to species of the order Bacteroidales in the human gut. Infect Immunity, 2011, 79, 2012-2020.
10. Jo YJ, Tagele SB, Pham HQ, Jung YG, Ibal JC, Choi SD, Kang GU, Park S, Kang Y, Kim S, Koh H, Shin JH. In Situ profiling of the three dominant phyla within the human gut using TaqMan PCR for pre-hospital diagnosis of gut dysbiosis. Int J Mol Sci. 2020; 21(6): 1916. doi: 10.3390/ijms21061916.
11. Goloshchapov OV, Olekhnovich EI, Sidorenko SV, MoiseevIS, Kucher MA, Fedorov DE, Pavlenko AV, Manolov AI, Gostev VV, Veselovsky VA, Klimina KM, Kostryukova ES, Bakin EA, Shvetcov AN, Gumbatova ED, Klementeva RV, Shcherbakov AA, Gorchakova MV, J Egozcue JJ, Pawlowsky-Glahn V, Suvorova MA, Chukhlovin AB, Govorun VM, Ilina EN, Afanasyev BV. Long-term impact of fecal transplantation in healthy volunteers. BMC Microbiology. 2019; vol. 19, Article No.: 312.
12. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
13. Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a consensus document. Biol Blood Marrow Transplant. 2009; 15(7): 777. doi:10.1016/j.bbmt.2009.03.012.
14. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9): 920-924.
15. Common terminology criteria for adverse events (CTCAE). Version 5.0. Published: November 27, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.....
16. WHO guidelines on the pharmacological treatment of persistingpain in children with medical illnesses Geneva: World Health Organization; 2012. PMID: 23720867.
17. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018. https://www.who.int/ncds/management/palliative-care/cancer-pain-guidelines/en/
18. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2016. Springer-Verlag, New York.
19. Kassambara A. 2019. ggpubr: 'ggplot2' Based Publication Ready Plots. R package version 0.2.4. https://CRAN.R-project.org/package=ggpubr.
20. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Porosnicu Rodriguez KA, Xu K. Increased GvHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339): 339ra71. doi:10.1126/scitranslmed.aaf2311.
21. El Hage R, Hernandez-Sanabria E, Van de Wiele T. Emerging trends in "Smart Probiotics": functional consideration for the development of novel health and industrial applications. Front Microbiol. 2017; DOI: 10.3389/fmicb.2017.01889.
22. Jian C, Luukkonen P, Yki-Järvinen H, Salonen A, Korpela K. Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling. PLoSOne. 2020; 15(1):e0227285. DOI: 10.1371/journal.pone.0227285.

" ["~DETAIL_TEXT"]=> string(39357) "

Introduction

Fecal microbiome contains hundreds types of bacteria, with only minority of, mostly, aerobic gut bacteria having been detectable in bacteriological cultures. However, conventional microbiological cultures are able to detect only a limited number of aerobic and, to lesser degree, anaerobic bacteria in fecal samples. In this respect, a gene-specific DNA diagnostics, e.g., multiplex PCR aimed for detection of potentially pathogenic microbes, is a more sensitive technique for detection and quantification of distinct microbial species and families at different microbiotes of human body [1].

Moreover, major bacterial classes and families became available for studies and comparisons, due to development of the next-generation sequencing (NGS). Bacteroides and Clostridia comprise the majority of normal intestinal flora as suggested by several NGS studies performed in different parts of the world [2, 3]. These microbial types are susceptible to massive antibiotic treatment which is usually applied in immunocompromised patients after bone marrow transplantation [4].

Still there are no generally approved reference biodiversity values, or marker microorganisms for assessment of gut microbiome in immunocompromised patients following severe cytostatic and antimicrobial therapy. Severe intestinal affection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a useful clinical model for evaluation of gut microbiome shifts and its correction after fecal microbiota transplantation (FMT) [5]. An FMT protocol for clinical trials in severe graft-versus-host disease (GvHD) was applied quite recently [6].

Despite numerous clinical studies on FMT, there are only few bacterial markers for monitoring its efficiency. Appropriate guidelines are limited to bacteriological screening of the third-party donors of fecal transplants [7]. To our knowledge, there are no clear recommendations on screening of fecal microbiota in the patients. Except of time- and labor-consuming NGS analysis, some multiplex PCR-based approaches may be used that detect distinct gut pathogens [8, 9]. A quite recent approach is based on determination of relative proportions for the dominant phyla in human gut microbiome [10].

To evaluate real biodiversity of intestinal microbiome, most recent works are performed by sequencing of 16S rRNA fragments from multiple bacterial species, with subsequent detection of species-specific genes. The results of NGS assays provide a big number of 16S rRNA nucleotide sequences which correspond to relative representation of distinct bacterial classes in the given sample. The best reliable data derived from NGS analysis concern biological diversity for big taxonomic classes of microbiota, down to the family level. More exact species-specific diagnostics is less robust, due to only marginal interspecies differences in nucleotide sequences detectable by the current NGS technique.

Therefore, some more simple and cost-effective microbial markers are required for evaluation and screening of human microbiota after massive antibiotic therapy and in the course of gut recolonization. Hence, the aim of our study was a search for microbial species detectable by molecular biology techniques that could correlate with clinical results of FMT performed in severe resistant GvHD after allo-HSCT.

Patients and methods

The prospective single-center study included 27 patients at the age of 1 to 52 years old (median, 25 years) after allo-HSCT at the Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation over a period of 2017 to 2019 (Table 1). The main group included 19 post-HSCT patients who developed acute intestinal GvHD. All the patients were in remission state for their primary disease. These patients received FMT due to severe GvHD resistant to standard treatment. The inclusion criterion was steroid-refractory acute or chronic GvHD (overlap-syndrome) accompanied by intestinal affection. Intestinal GvHD has been confirmed by pathological examination of colonic mucosa biopsies. FMT was performed at a median of 110 (37-909) days post-HSCT. The comparison group with similar GvHD symptoms included eight patients who received placebo preparations instead of FMT applied on a median of 56 (34-120) days after HSCT.

Table 1. Clinical characteristics of the FMT patients

Antimicrobial prophylaxis was canceled 3 days before and during TFM treatment. Systemic antibacterial drugs were administered by common clinical indications (local infection, septicemia) to 8 patients (37%) before FMT, and in 18 cases (95%), after the procedure. Seven placebo-treated patients out of 8 (88%) were also exposed to systemic antimicrobial therapy. The patients with proven intestinal affection with HHV6 or EBV herpes viruses received gancyclovir: 11 (58%) in FMT-treated, 8 (100%) in the placebo group.

All the patients received immunosuppressive therapy as the first-line GvHD treatment, by means glucocorticosteroids (methylprednisolone, 1 mg/kg/d). The second-line therapy was performed with Ruxolitinib at the dose of 10-15mg/d (for children 0.25mg/kg/d). The patients underwent clinical and laboratory screening at the following terms: before FMT/placebo treatment D -1-3, D+3, D+16, D+30, D+60, and D+120 after FMT. The next day after last FMT was considered D+1. Primary endpoints were determined on the D+30 following FMT or placebo administration.

Routine laboratory studies at the ICU included daily blood cell and differential leukocyte counts, routine serum biochemistry, serum markers of inflammation (procalcitonine, С-reactive protein). In cases of acute intestinal syndrome, the aerobic microbial cultures of stool samples were routinely seeded, and C.difficile toxins A and B were checked by a simple immune chromatography test (VEDALAB, France).

In four cases (21%), the fecal transplant donation was performed from related donors (mother, 1; father, 2; brother, 1). FMT from unrelated donors was carried out in 15 patients.

Fecal transplants were administered by the following methods: via gastroduodenoscope, in 3 patients (16%); via nasointestinal catheter, in 7cases (3 TFM+ and 4 placebo); 13 patients (68%) ingested gelatin capsules with frozen microbiota. Placebo capsules were used in 4 patients (50%).

The single-center prospective study "Treatment of children and adult patients with inflammatory and infectious gut lesions after allogeneic transplantation of hematopoietic stem cells using transplantation of normal human microbiota" was approved by the Local Review Board at the First I. Pavlov Saint-Petersburg State Medical University №192 от 30.01.2017. The trial was performed in accordance with Good Clinical Practice and Declaration of Helsinki, i.e., full awareness of the study purpose, procedures and possible adverse effects from treatment, as stated by appropriate written informed consent signed by each patient or his (her) competent relative.

Fecal microbiota encapsulation procedure

Preparation of fecal transplants and their storage at -80°C was performed at the specialized microbiological laboratory. In brief, the donor material was supplemented with 10% glycerol and 50% sterile dextrose syrup (v/v), then homogenized with a disposable blender. The material, placed on ice, was then packed up in solid Coni-Snap® Size 0 gelatin capsules using the ProFiller 1100 device. The bar-coded capsules were placed into individual sterile containers. The fecal transplants (FT) were transferred to a freezing chamber (-80°C) and stored until use. The capsules were administered at a dose of 10 (3-15) capsules for 2 or 3 subsequent days. The total dose per single TFM course was 22 g (30 capsules) corresponding to 0.41 (0.29-1.67 g/kg body mass), independent on age and weight of the subjects.

The patients from comparison group were treated with 5 mL of 0.9% physiological saline delivered during diagnostic gastroscopy, or frozen capsules with physiological saline.

Laboratory screening of gut microbiota

Semi-quantitative assessment of fecal microbiota profile was performed with real-time PCR technique using commercial Colonoflor-16test system (Alpha-Lab, Saint Petersburg, Russia). Total bacterial mass, as well most represented microbial species, including strictly anaerobic species, could be detected by this DNA-based technique (Table 2). A set of gene-specific primers is used in this test kit, exploiting the differences in 16S rDNA sequences (see Table 3).

The same fecal DNA samples were used for detailed 16S rDNA sequencing by means of NGS technique, as elsewhere described [11]. The serial microbiome sequencing procedure was carried out with Illumina™ HiSeq 2500 system.

Table 2. Reference values for different microbial species detected by multiplex real-time PCR kit (Colonoflor-16)

Table 3. Gene-specific primers for detection of distinct microbes in fecal material (Colonoflor test system)

Clinical evaluation

Clinical examination of the patients along the observation period until D+120 was performed by the well-validated scales: GvHD severity score [12]; evaluation of clinical response of GvHD patients to therapy [13]; Bristol scale of stool [14].

All the patients (or their parents) filled a special diary with notices on their actual daily condition and severity of distinct symptoms by scoring the adverse treatment effects, according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE), version 5.0 of November 27 2017) [15], as follows: anorexia (1-5 points), nausea (1-3 points), lower intestinal bleeding (1-5 points). Pain syndrome (abdominal pains) was evaluated by the 10-point visual analogue scale for adults and children (VAS), according to WHO criteria [16, 17]. Number of defecations, daily volumes of diarrhea and vomiting were registered. The stool properties were evaluated according to the Bristol scale (1 to 7 points).

Aiming for a more objective evaluation of clinical response, the patients from main group were divided in two sub-groups, i.e., patients who showed full clinical response (CR), and those who responded only partially or lacked any positive response (PLR). These and other parameters were introduced into a common database.

The stool consistence was evaluated by the seven-point Bristol scale [14] (Lewis, Heaton, 1997). Volumes of water lost with stool and vomiting was also registered. A validated toxicity scale was used to evaluate bloody and mucous admixtures, loss of appetite, and other side effects (CTCAE Version 5.0 Published: November 27, 2017), using a 4-point scoring of its intensity (0, the symptom absent; 1, mild degree or periodic; 2, intermediate (often); 3, severe (permanent), requiring proper therapy). To evaluate abdominal pain, a 10-point VAS was applied [16, 17].

To specify rates of clinical response a, we classified the patients in 2 groups, i.e., the FMT outcomes were classified as the main group with complete response (CR), partial response (PR), or treatment failure (NR) in the patients. Full response was registered by 2 criteria, i.e., gut GvHD improvement (stool volume <10 mL/kg/day, absence of abdominal pains and bloody stool, no signs of gut paresis), and stool consistence of <4 points at Bristol scale should be registered. Partial response was documented in cases of complete response for intestinal GvHD, and stool consistence of >4 points by Bristol scale (stool volume >10 ml/kg/day). Absence of clinical response was documented if no complete recovery for intestinal GvHD, along with liquid stool (Bristol scale, 6 to 7 points, daily stool volume >10 mL/kg weight).

On the days before FMT/placebo administration, and by the days +3, +16, +30, +60, +120 after FMT, the mean sum values for preceding time period were calculated, beginning from the next day after last control point until the target point of the study. When analyzing clinical results, the last day of TFM treatment was assumed as day 0 for the observation period.

Statistical evaluation

All clinical and laboratory data obtained during the follow-up examinations were analyzed with R programming language v.3.6.2 in Rstudio v. 1.2.5033. Shannon index for 16S sequencing results was calculated as follows:

where n is a number of detected bacterial groups, p_i, frequency of i-th group occurrence. Comparison of samples was performed with non-parametric statistical methods: Wilcoxon test for two-sample comparisons, and Kruskal-Wallis test for three-sample comparison. Visualization was performed by means of R packages ggplot2 [18] and ggpubr [19].

Results

In the whole group of patients, some grade of response (disregarding Bristol scale) was achieved in 23 patients (85%), at D+120, including 18 cases after FMT (95%), and 5 placebo-treated patients (63%) (р=0.0646). Whole response was achieved in 16 patients (84%) after FMT, versus in 5 cases (63%) from placebo group (p=0.3191). One patient deceased without response to FMT (5%) versus 3 patients (38%) in the placebo group.

When evaluating clinical response to GvHD therapy, with regard of stool consistence by Bristol scale, we observed whole clinical response 120 days after FMT in 9 cases (47% with Bristol score of ≤4 points), and 9 patients (47%) showed improvement stool consistence (>4 points). In the placebo group, a complete or partial response was revealed, respectively, in 1 (13%) and 4 (50%) of the patients by the day +120.

Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase in the patients with complete clinical response (Fig. 1). In patients with full clinical response after FMT, or placebo, we have detected increased amounts of some major microbial groups by means of Colonoflor testing, i.e., Bacteroides fragilis group, Bifidobacterium spp., Faecalibacterium prausnitzii, along with decrease in Enterococcus spp. and Lactobacillus spp.

Figure 1. Relative contents of dominant fecal microbial species in the total set of samples from all the study terms (A), and on day +30 of observation (B) in the patients with complete response (red), partial/absent response (blue) including the placebo group. Abscissa, type of response after FMT. Ordinate, number of genocopies, log₁₀ per standard sample (0.1 g)

E.g., such shifts in total group of samples were demonstrable for B.fragilis group (p=2.1×10^-7); F.prausnitzii (p=9.8×10^-8) during the observation terms (Fig. 1A). Similar increase in B.fragilis group (p=0.028), and F.prausnitzii (p=0.027) was detectable by the D+30 in FMT-treated or placebo patients (Fig. 1B).

Moreover, a stable and significant increase of B.fragilis group and F.prausnitzii was revealed since early terms in FMT-treated patients compared to placebo-treated patients (Table 4).

Meanwhile, the numbers of Enterococcus, Lactobacillus spp., and Bacteroides thetaiotaomicron, generally, were not changed over this time period (Table 4). In the control group (placebo) we have not found significant changes of fecal microbiota against initial levels over 120 days of monitoring.

Table 4. Significance of differences (p values) between initial (pre-TFM/placebo) and post-FMT levels of certain microorganisms in fecal microbiota of total patient group (19 FMT cases and 8 placebo-treated patients)

Note: The differences significant at P<0.05 are shown in bold-face type.

Mean values of Bifidobacterium spp., E.coli, B.fragilis group and F.prausnitzii were significantly different for the studied groups (р<0.003; р<0.012; р<0.016; р<0.12, respectively), as seen in Fig. 2. We have also found some differences of the microbiota dynamics for the subgroups with complete response, partial/no response: Bifidobacterium spp. (р<0.047), E.coli (р<0.00047), B.fragilis gr. (р<5.6×10^-5), F.prausnitzii (р<0.0062).

In the placebo group, we did not detect any cases of C.difficile-associated infections. Meanwhile, three cases of C.difficile infection were detected in the FMT group. However, both A and B toxins of C.difficile became negative by day +16, +30 and +45 s after FMT.

Figure 2. Time-dependent changes of total bacterial mass and four selected bacterial classes are presented over 120 days of observation. Abscissa, subgroups of patients; Ordinate, number of genocopies, log₁₀ per standard sample (0.1 g)

Note: the groups with different response include FMT- and placebo-treated patients.

Hence, relative contents of B.fragilis group in fecal microbiota was selected as a bacterial marker increased upon recolonization, due to sufficient difference between complete and no/partial response to the FMT (p=2.1×10^-7), and pronounced dynamics of changes (p=5.6×10^-5) over 120 days of observation. Therefore, was selected for further studies, i.e. search for correlations with NGS results on Bacteroidia class.

Correlations between the ratios of specific microbial DNA extracted from fecal samples determined by the 16S rRNA NGS technique were assessed at phylogenetic levels of Bacteroidetes (Phylum), Bacteroidia (Class), and Bacteroidales (Order). Among all microbial specificities detectable by quantitative PCR (Colonoflor test set), only Bacteroides fragilis group showed strong correlation with the ratios of Bacteroidetes phylum and Bacteroidia class revealed NGS approach. When applying NGS technique for detection of gut bacteria, we revealed high correlation only between the general types of bacteroides, i.e. phylum (Bacteroidetes); class (Bacteroidia); order (Bacteroidales); family (Bacteroidaceae), genus (Bacteroides) (Table 5).

Table 5. Correlations between the main types of Bacteroidetes and B.fragilis group determined by NGS approach

B.fragilis contents in fecal microbiota from healthy donors proved to be significantly higher than in the patients with GvHD before FMT (Table 6), thus potentially requiring enhancement of these microorganisms in the patients after HSCT with immune complications. After FMT, the median levels of B.fragilis group are sufficiently increasing in parallel to complete clinical response, being, however, at lower levels in cases with partial or zero response.

Table 6. B.fragilis contents in the fecal microbiota samples (log₁₀ of genocopy numbers) in healthy donors and patients with differential response to FMT

Hence, the evaluation of B.fragilis group using real-time PCR, generally correlates with data on broader Bacteroides class obtained by 16SrRNA sequencing performed by much more complex and costly NGS technique. Meanwhile, multiplex PCR allows to get semi-quantitative results which could be used for routine monitoring of gut dysbiosis and its recovery.

In this series, D+30 proved to be the most informative time point for discerning differences between FMT and placebo-treated patients. I.e., on D+30 (a control point of study), we have found an increase over the D0 ratios in Bacteroidetes phylum; Bacteroidia (Class); Bacteroidales (Order) when studied by NGS approach. A strong correlation was found at all the time points with copy numbers of B.fragilis (PCR technique), as shown in Fig. 3.

Figure 3. Parallel changes of B.fragilis copy numbers (multiplex PCR) and Shannon index of genomic bacterial diversity determined by 16S rRNA sequencing for the groups with complete response (CR) versus partial/lacking response after FMT or placebo on D+30

The numbers of fecal B.fragilis genocopies in all the patients (FMT and placebo) with complete response were increased on D+30, and differed from the groups with partial/zero response after FMT procedure, or after placebo treatment (Fig. 3).

We have revealed a statistically significant correlation between the Shannon index (16 S rRNA sequencing) and B.fragilis levels (multiplex) PCR in the patients after FMT and/or placebo, either with complete response (CR), being significant at p=0.028, or partial/absent response (PR/NR), at p=8×10^-4 (Fig. 4).

Hence, on the basis of B.fragilis contents in fecal microbiota, its diversity (by Shannon index), and extent of clinical response for differently treated groups, we have obtained sufficient correlations between the subgroups with complete response, suboptimal response to FMT treatment, and placebo-treated patients.

Discussion

In this study we searched for microbiological correlates of clinical effect produced by FMT. We were able to compare the results of multiplex PCR technique and NGS gene analysis that were performed in parallel in the same fecal samples. Both molecular biology approaches proved to be effective when detecting shifts in gross classes of microbiota, e.g., Bacteroides, Clostridia and Enterobacter.

Using NGS approach, the proportions of some major microbiome classes are revealed, as follows: Bacteroidia, Clostridia, Gammaproteobacteria, Bacilli, Actinobacteria (Bifidobacterium spp). The main classes discerned by the NGS approach are represented by distinct microbial species detected by Colonoflor multiplex PCR (Table 7).

Table 7. Phylogenetic assignment of the bacteria revealed by 16S rRNA-based Colonoflor PCR system, and NGS approach (Illumina, MySeq)

As determined by next-generation sequencing and subsequent bioinformatics mining of resulting data bases for gut bacteria, we revealed high correlation only between gross types of bacteroides, i.e. phylum (Bacteroidetes); class (Bacteroidia); order (Bacteroidales); family (Bacteroidaceae), genus (Bacteroides) (Table 5). However, this correlation becomes much lower, when B.fragilis group is concerned, thus suggesting lesser precision of NGS diagnostics at the species level. Higher accuracy of the multiplex PCR for the B.fragilis group quantification could be explained by better specificity of appropriate primers, and due to presence of a reference gene marker for the total bacterial mass, thus allowing semi-quantitative determination.

To evaluate real biodiversity of intestinal microbiome, most recent works are performed by sequencing of 16S rRNA fragments from multiple bacterial species, with subsequent detection of species-specific genes. The results of NGS assays provide a big number of 16S rRNA nucleotide sequences which correspond to relative representation of distinct bacterial classes in the given sample. The best reliable data derived from NGS analysis concern biological diversity for big taxonomic classes of microbiota, down to the family level. More exact species-specific diagnostics is less robust, due to only marginal interspecies differences in nucleotide sequences detectable by the current NGS technique.

Therefore, some more simple and cost-effective microbial markers are required for evaluation and screening of human microbiota after massive antibiotic therapy and in the course of gut recolonization.

16S RNA gene polymorphism is a good method for control of ratios between the major classes of fecal microbiota. Moreover, drastic shifts of gut microbiota are revealed in several gut infections (mostly, C.difficile) and local immune affection, e.g., GvHD [20]. A conventional multiplex PCR approach allows performing a more specific, cheap and fast detection of major fecal microorganisms which is especially informative when using quantitative PCR (qPCR) after FMT, as shown in our study.

As seen from the presented data, one may recommend detection of the main bacterial groups (Bifidobacterium spp., Escherichia coli, B.fragilis group, Faecalibacterium prausnitzii) as potential markers for assessment of fecal microbiota shifts after FMT. It should be, however, noted that this correlation does not extend to other microbial groups (e.g., Lactobacillus spp., Citrobacter with absence of good correlation with 16S rRNA sequencing for Lactobacillus spp. and Citrobacter, probably, due to suboptimal sensitivity of the given test system for Lactobacillus spp. (<10⁵CFU/sample).

According to the qPCR data, the majority of microbial species sufficiently differed from the initial values on D+16 to D+30 after FMT, as seen for Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii. Therefore, one should presume engraftment of main fecal microorganisms after FMT over this period. Bacteroides compose 99% of normal microbiota, with quite important functional potential, being among promising probiotics [21].

Meanwhile, qPCR determination of B.fragilis group has shown a strong correlation with clinical response in the patients after FMT, thus allowing to consider this bacterial marker a potential laboratory correlate of efficient clinical response after FMT. An increase in Bacteroides quantities detected with qPCR and higher relative amounts found by means of NGS-based typing of 16S rDNA may, therefore, reflect engraftment of the major gut bacterial population. Decreased B.fragilis contents in the patients with partial or poor clinical response after D+30 post-FMT may be a non-engraftment marker, whereas increasing B.fragilis levels with a maximum about D+30 are revealed in complete clinical response. Meanwhile, other findings presume pronounced changes in Clostridiales (e.g., Blautia) as possible index of microbiota maintenance, thus deserving their further pathogenetic significance [4]. E.g., the qPCR system for Clostridium spp. should be also applied for additional testing of the gut microbiota restoration, along with testing for pathogenic C.difficile toxins, as a negative prognostic marker.

Monitoring of gut bacterial markers to assess gut microbiota recovery may effectively improve clinical assessment in gastroenterology. The currently used clinical criteria are mostly indirect, including stool volume and quality, intestinal motility, fecal blood and calprotectin tests, thus requiring additional microbial markers aimed for quantitative evaluation of the disease state. Certain bacterial families may serve as semi-quantitative markers of the disease-associated shifts and recovery of the microbiota. We have shown that quantitative PCR of distinct gut microorganisms is quite available and cheaper option for routine follow-up of intestinal dysbiosis [22].

However, the 16S rDNA sequencing by means of NGS approach remain indispensable for research in the field, looking for novel markers of human microbiota in health and disease.

Conclusions

1. Quantitative real-time PCR of the major bacteria groups of gut microbiota, e.g., Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii could be used as microbiological marker for evaluation of changing fecal microbiota following fecal transplantation as a routine molecular biology technique.

2. The genocopy counts of B.fragilis group correlate with clinical response in the patients with severe GvHD after allo-HSCT.

3. The time course of B.fragilis group contents could be considered an index of fecal microbiota engraftment following FMT.

4. B.fragilis contents in fecal microbiota measured by multiplex PCR show high positive correlation with Shannon index of bacterial diversity, determined by 16S rRNA gene sequencing.

Conflict of interest

The authors state that they have no conflict of interests.

Acknowledgements

The study was in part supported by a research contract with Russian Ministry of Healthcare effective as of January 2018 to December 2020.

References

1. Chukhlovin A.B., Pankratova O.S. Opportunistic microflora at unusual sites: marker pathogens in severe posttransplant immune deficiency. Cell Ther Transplant. 2017; 6(4): 28-41.
2. Fujio-Vejar S, Vasquez Y, Morales P, Magne F, Vera-Wolf P, Ugalde JA, Navarrete P, Gotteland M. The gut microbiota of healthy Chilean subjects reveals a high abundance of the phylum Verrucomicrobia. Front Microbiol, 30 June 2017, https://doi.org/10.3389/fmicb.2017.01221.
3. Senghor B, Sokhna C, Ruimy R, Lagier J-C. Gut microbiota diversity according to dietary habits and geographical provenance. Hum Microbiome J. 2018; 7-8: 1-9.
4. Taur Y. Intestinal microbiome changes and stem cell transplantation: Lessons learned. Virulence. 2016, 7(8), 930-938. doi: 10.1080/21505594.2016.1250982.
5. Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020; 382:822-834.
6. Shouval R, Geva M, Nagler A, Youngster I. Fecal microbiota transplantation for treatment of acute graft-versus-host disease. Clin Hematol Int. 2019; 1(1): 28-35.
7. Cammarota G, Ianiro G, Kelly CR, Mullish B, Allegretti JR, Kassam Z et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019;68:2111-2121.
8. Becker SL, Chatigre JK, Gohou JP, Coulibaly JT, Leuppi R, Polmans K, Chappuis F, Mertens P, Herrmann M, Goran EKN, Utzinger J, von Müller L. Combined stool-based multiplex PCR and microscopy for enhanced pathogen detection in patients with persistent diarrhoea and asymptomatic controls from Côte d’Ivoire. Clin Microbiol Infect. 2015;21:591.e1-591.e10.
9. Zitomersky NL, Coyne MJ, Comstock LE. Longitudinal analysis of the prevalence, maintenance, and IgA response to species of the order Bacteroidales in the human gut. Infect Immunity, 2011, 79, 2012-2020.
10. Jo YJ, Tagele SB, Pham HQ, Jung YG, Ibal JC, Choi SD, Kang GU, Park S, Kang Y, Kim S, Koh H, Shin JH. In Situ profiling of the three dominant phyla within the human gut using TaqMan PCR for pre-hospital diagnosis of gut dysbiosis. Int J Mol Sci. 2020; 21(6): 1916. doi: 10.3390/ijms21061916.
11. Goloshchapov OV, Olekhnovich EI, Sidorenko SV, MoiseevIS, Kucher MA, Fedorov DE, Pavlenko AV, Manolov AI, Gostev VV, Veselovsky VA, Klimina KM, Kostryukova ES, Bakin EA, Shvetcov AN, Gumbatova ED, Klementeva RV, Shcherbakov AA, Gorchakova MV, J Egozcue JJ, Pawlowsky-Glahn V, Suvorova MA, Chukhlovin AB, Govorun VM, Ilina EN, Afanasyev BV. Long-term impact of fecal transplantation in healthy volunteers. BMC Microbiology. 2019; vol. 19, Article No.: 312.
12. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
13. Martin PJ, Bachier CR, Klingemann H-G, McCarthy PL, Szabolcs P, Uberti JP et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a consensus document. Biol Blood Marrow Transplant. 2009; 15(7): 777. doi:10.1016/j.bbmt.2009.03.012.
14. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9): 920-924.
15. Common terminology criteria for adverse events (CTCAE). Version 5.0. Published: November 27, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.....
16. WHO guidelines on the pharmacological treatment of persistingpain in children with medical illnesses Geneva: World Health Organization; 2012. PMID: 23720867.
17. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018. https://www.who.int/ncds/management/palliative-care/cancer-pain-guidelines/en/
18. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2016. Springer-Verlag, New York.
19. Kassambara A. 2019. ggpubr: 'ggplot2' Based Publication Ready Plots. R package version 0.2.4. https://CRAN.R-project.org/package=ggpubr.
20. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Porosnicu Rodriguez KA, Xu K. Increased GvHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339): 339ra71. doi:10.1126/scitranslmed.aaf2311.
21. El Hage R, Hernandez-Sanabria E, Van de Wiele T. Emerging trends in "Smart Probiotics": functional consideration for the development of novel health and industrial applications. Front Microbiol. 2017; DOI: 10.3389/fmicb.2017.01889.
22. Jian C, Luukkonen P, Yki-Järvinen H, Salonen A, Korpela K. Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling. PLoSOne. 2020; 15(1):e0227285. DOI: 10.1371/journal.pone.0227285.

" ["DETAIL_TEXT_TYPE"]=> string(4) "html" ["~DETAIL_TEXT_TYPE"]=> string(4) "html" ["PREVIEW_TEXT"]=> string(0) "" ["~PREVIEW_TEXT"]=> string(0) "" ["PREVIEW_TEXT_TYPE"]=> string(4) "text" ["~PREVIEW_TEXT_TYPE"]=> string(4) "text" ["PREVIEW_PICTURE"]=> NULL ["~PREVIEW_PICTURE"]=> NULL ["LANG_DIR"]=> string(4) "/ru/" ["~LANG_DIR"]=> string(4) "/ru/" ["SORT"]=> string(3) "500" ["~SORT"]=> string(3) "500" ["CODE"]=> string(100) "bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy" ["~CODE"]=> string(100) "bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy" ["EXTERNAL_ID"]=> string(4) "1857" ["~EXTERNAL_ID"]=> string(4) "1857" ["IBLOCK_TYPE_ID"]=> string(7) "journal" ["~IBLOCK_TYPE_ID"]=> string(7) "journal" ["IBLOCK_CODE"]=> string(7) "volumes" ["~IBLOCK_CODE"]=> string(7) "volumes" ["IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["~IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["LID"]=> string(2) "s2" ["~LID"]=> string(2) "s2" ["EDIT_LINK"]=> NULL ["DELETE_LINK"]=> NULL ["DISPLAY_ACTIVE_FROM"]=> string(0) "" ["IPROPERTY_VALUES"]=> array(18) { ["ELEMENT_META_TITLE"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["ELEMENT_META_KEYWORDS"]=> string(0) "" ["ELEMENT_META_DESCRIPTION"]=> string(371) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment" ["ELEMENT_PREVIEW_PICTURE_FILE_ALT"]=> string(5852) "<p style="text-align: justify;">Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.</p> <h3>Пациенты и методы</h3> <p style="text-align: justify;">В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.</p> <h3>Результаты</h3> <p style="text-align: justify;">При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); <i>Escherichia coli</i> (p=0,001); <i>Bacteroides fragilis group</i> (p=0,05); <i>Faecalibacterium prausnitzii</i> (p=0,005). В то же время количества <i>Lactobacillus spp.</i> и <i>Bacteroides thetaiotaomicron</i>, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: <i>Bifidobacterium spp.</i> (р<0,047), <i>E.coli</i> (р<0,00047), <i>B.fragilis group</i> (p=5,6×10^-5), <i>F.prausnitzii</i> (р<0,0062).</p> <h3>Выводы</h3> <p style="text-align: justify;">Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. <i>Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii</i> может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий <i>B.fragilis group</i> коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ. </p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, <i>Bacteroides fragilis</i>, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.</p>" ["ELEMENT_PREVIEW_PICTURE_FILE_TITLE"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["ELEMENT_DETAIL_PICTURE_FILE_ALT"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["ELEMENT_DETAIL_PICTURE_FILE_TITLE"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_META_TITLE"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_META_KEYWORDS"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_META_DESCRIPTION"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_PICTURE_FILE_ALT"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_PICTURE_FILE_TITLE"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_PICTURE_FILE_NAME"]=> string(100) "bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy" ["SECTION_DETAIL_PICTURE_FILE_ALT"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_DETAIL_PICTURE_FILE_TITLE"]=> string(244) "Bacteroides fragilis – потенциальный маркер эффективной трансплантации микробиоты при лечении острой реакции «трансплантат против хозяина»" ["SECTION_DETAIL_PICTURE_FILE_NAME"]=> string(100) "bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy" ["ELEMENT_PREVIEW_PICTURE_FILE_NAME"]=> string(100) "bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy" ["ELEMENT_DETAIL_PICTURE_FILE_NAME"]=> string(100) "bacteroides-fragilis-potentsialnyy-marker-effektivnoy-transplantatsii-mikrobioty-pri-lechenii-ostroy" } ["FIELDS"]=> array(1) { ["IBLOCK_SECTION_ID"]=> string(3) "149" } ["PROPERTIES"]=> array(18) { ["KEYWORDS"]=> array(36) { ["ID"]=> string(2) "19" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:46:01" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(27) "Ключевые слова" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "KEYWORDS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "19" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "4" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "Y" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "Y" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(27) "Ключевые слова" ["~DEFAULT_VALUE"]=> string(0) "" } ["SUBMITTED"]=> array(36) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26492" ["VALUE"]=> string(10) "10.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "10.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL } ["ACCEPTED"]=> array(36) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26493" ["VALUE"]=> string(10) "26.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "26.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL } ["PUBLISHED"]=> array(36) { ["ID"]=> string(2) "22" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Дата публикации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "PUBLISHED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "22" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Дата публикации" ["~DEFAULT_VALUE"]=> NULL } ["CONTACT"]=> array(36) { ["ID"]=> string(2) "23" ["TIMESTAMP_X"]=> string(19) "2015-09-03 14:43:05" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(14) "Контакт" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "CONTACT" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "23" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(14) "Контакт" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHORS"]=> array(36) { ["ID"]=> string(2) "24" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:45:07" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "AUTHORS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "24" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_RU"]=> array(36) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26494" ["VALUE"]=> array(2) { ["TEXT"]=> string(1017) "<p>Олег В. Голощапов¹, Евгений А. Бакин¹, Максим А. Кучер¹, Оксана В. Станевич¹, Мария А. Суворова², Владимир В. Гостев³, Олег С. Глотов⁴, Юрий А. Эйсмонт⁴, Дмитрий Е. Полев⁵, Анастасия Ю. Лобенская⁵, Руслана В. Клементьева¹, Мария О. Голощапова¹, Людмила С. Зубаровская¹, Сергей В. Сидоренко³, Александр Н. Суворов⁴, Иван С. Моисеев¹, Алексей Б. Чухловин¹</p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(801) "

Олег В. Голощапов¹, Евгений А. Бакин¹, Максим А. Кучер¹, Оксана В. Станевич¹, Мария А. Суворова², Владимир В. Гостев³, Олег С. Глотов⁴, Юрий А. Эйсмонт⁴, Дмитрий Е. Полев⁵, Анастасия Ю. Лобенская⁵, Руслана В. Клементьева¹, Мария О. Голощапова¹, Людмила С. Зубаровская¹, Сергей В. Сидоренко³, Александр Н. Суворов⁴, Иван С. Моисеев¹, Алексей Б. Чухловин¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_RU"]=> array(36) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26495" ["VALUE"]=> array(2) { ["TEXT"]=> string(1097) "<p>¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ² Научная лаборатория Эксплана, Санкт-Петербург, Россия <br> ³ Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия <br> ⁴ Городская больница №40, Санкт-Петербург, Россия<br> ⁵ ООО «Сербалаб», Санкт-Петербург, Россия<br> ⁶ Институт экспериментальной медицины, Санкт-Петербург, Россия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(983) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Научная лаборатория Эксплана, Санкт-Петербург, Россия
³ Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия
⁴ Городская больница №40, Санкт-Петербург, Россия
⁵ ООО «Сербалаб», Санкт-Петербург, Россия
⁶ Институт экспериментальной медицины, Санкт-Петербург, Россия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_RU"]=> array(36) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26496" ["VALUE"]=> array(2) { ["TEXT"]=> string(5852) "<p style="text-align: justify;">Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.</p> <h3>Пациенты и методы</h3> <p style="text-align: justify;">В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.</p> <h3>Результаты</h3> <p style="text-align: justify;">При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); <i>Escherichia coli</i> (p=0,001); <i>Bacteroides fragilis group</i> (p=0,05); <i>Faecalibacterium prausnitzii</i> (p=0,005). В то же время количества <i>Lactobacillus spp.</i> и <i>Bacteroides thetaiotaomicron</i>, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: <i>Bifidobacterium spp.</i> (р<0,047), <i>E.coli</i> (р<0,00047), <i>B.fragilis group</i> (p=5,6×10^-5), <i>F.prausnitzii</i> (р<0,0062).</p> <h3>Выводы</h3> <p style="text-align: justify;">Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. <i>Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii</i> может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий <i>B.fragilis group</i> коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ. </p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, <i>Bacteroides fragilis</i>, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(5526) "

Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.

Пациенты и методы

В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.

Результаты

При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); Escherichia coli (p=0,001); Bacteroides fragilis group (p=0,05); Faecalibacterium prausnitzii (p=0,005). В то же время количества Lactobacillus spp. и Bacteroides thetaiotaomicron, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: Bifidobacterium spp. (р<0,047), E.coli (р<0,00047), B.fragilis group (p=5,6×10^-5), F.prausnitzii (р<0,0062).

Выводы

Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий B.fragilis group коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ.

Ключевые слова

Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, Bacteroides fragilis, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["DOI"]=> array(36) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26497" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-47-59" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-47-59" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_EN"]=> array(36) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26500" ["VALUE"]=> array(2) { ["TEXT"]=> string(773) "<p>Oleg V. Goloshchapov¹, Evgenyi A. Bakin¹, Maxim A. Kucher¹, Oksana V. Stanevich¹, Maria A. Suvorova², Vladimir V. Gostev³, Oleg S. Glotov⁴, Yury A. Eismont⁴, Dmitry E. Polev⁵, Anastasia Yu. Lobenskaya⁵, Ruslana V. Klementeva¹, Maria O. Goloshchapova¹, Ludmila S. Zubarovskaya¹, Sergey V. Sidorenko³, Alexander N. Suvorov⁶, Ivan S. Moiseev¹, Alexei B. Chukhlovin¹ </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(557) "

Oleg V. Goloshchapov¹, Evgenyi A. Bakin¹, Maxim A. Kucher¹, Oksana V. Stanevich¹, Maria A. Suvorova², Vladimir V. Gostev³, Oleg S. Glotov⁴, Yury A. Eismont⁴, Dmitry E. Polev⁵, Anastasia Yu. Lobenskaya⁵, Ruslana V. Klementeva¹, Maria O. Goloshchapova¹, Ludmila S. Zubarovskaya¹, Sergey V. Sidorenko³, Alexander N. Suvorov⁶, Ivan S. Moiseev¹, Alexei B. Chukhlovin¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_EN"]=> array(36) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26501" ["VALUE"]=> array(2) { ["TEXT"]=> string(917) "<p>¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br> ² Explana Research Laboratory, St. Petersburg, Russia<br> ³ Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia<br> ⁴ City Hospital No. 40, St. Petersburg, Russia<br> ⁵ Cerbalab Ltd, St. Petersburg, Russia<br> ⁶ Institute of Experimental Medicine, St. Petersburg, Russia</p> <br> <p><b>Correspondence</b><br> Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia<br> Phone: + 7 (921) 979 2913<br> E-mail: golocht@yandex.ru</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(755) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Explana Research Laboratory, St. Petersburg, Russia
³ Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia
⁴ City Hospital No. 40, St. Petersburg, Russia
⁵ Cerbalab Ltd, St. Petersburg, Russia
⁶ Institute of Experimental Medicine, St. Petersburg, Russia

Correspondence
Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: + 7 (921) 979 2913
E-mail: golocht@yandex.ru

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_EN"]=> array(36) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26502" ["VALUE"]=> array(2) { ["TEXT"]=> string(3745) "<p style="text-align: justify;">Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.</p> <h3>Patients and methods</h3> <p style="text-align: justify;">The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.</p> <h3>Results</h3> <p style="text-align: justify;">When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); <i>Escherichia coli</i> (p=0.001); <i>Bacteroides fragilis group</i> (p=0.05); <i>Faecalibacterium prausnitzii</i> (p=0.005). Meanwhile, the numbers <i>Lactobacillus spp.</i>, and <i>Bacteroides thetaiotaomicron</i>, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: <i>Bifidobacterium spp.</i> (р<0.047), <i>E.coli</i> (р<0.00047), <i>B. fragilis group</i> (p=5.6×10^-5), <i>F.prausnitzii</i> (р<0.0062). <h3>Conclusions</h3> <p style="text-align: justify;">1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., <i>Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii</i> could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.</p> <h2>Keywords</h2> <p style="text-align: justify;">Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, <i>Bacteroides fragilis</i>, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(3437) "

Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.

Patients and methods

The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.

Results

When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); Escherichia coli (p=0.001); Bacteroides fragilis group (p=0.05); Faecalibacterium prausnitzii (p=0.005). Meanwhile, the numbers Lactobacillus spp., and Bacteroides thetaiotaomicron, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: Bifidobacterium spp. (р<0.047), E.coli (р<0.00047), B. fragilis group (p=5.6×10^-5), F.prausnitzii (р<0.0062).

Conclusions

1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.

Keywords

Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, Bacteroides fragilis, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["NAME_EN"]=> array(36) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26498" ["VALUE"]=> string(127) "Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(127) "Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" } ["FULL_TEXT_RU"]=> array(36) { ["ID"]=> string(2) "42" ["TIMESTAMP_X"]=> string(19) "2015-09-07 20:29:18" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(23) "Полный текст" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(12) "FULL_TEXT_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "42" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(23) "Полный текст" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["PDF_RU"]=> array(36) { ["ID"]=> string(2) "43" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF RUS" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_RU" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "43" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26499" ["VALUE"]=> string(4) "2039" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2039" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF RUS" ["~DEFAULT_VALUE"]=> string(0) "" } ["PDF_EN"]=> array(36) { ["ID"]=> string(2) "44" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF ENG" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "44" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26503" ["VALUE"]=> string(4) "2040" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2040" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF ENG" ["~DEFAULT_VALUE"]=> string(0) "" } ["NAME_LONG"]=> array(36) { ["ID"]=> string(2) "45" ["TIMESTAMP_X"]=> string(19) "2023-04-13 00:55:00" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(72) "Название (для очень длинных заголовков)" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "NAME_LONG" ["DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "45" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(80) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(72) "Название (для очень длинных заголовков)" ["~DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } } } ["DISPLAY_PROPERTIES"]=> array(10) { ["AUTHOR_EN"]=> array(37) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26500" ["VALUE"]=> array(2) { ["TEXT"]=> string(773) "<p>Oleg V. Goloshchapov¹, Evgenyi A. Bakin¹, Maxim A. Kucher¹, Oksana V. Stanevich¹, Maria A. Suvorova², Vladimir V. Gostev³, Oleg S. Glotov⁴, Yury A. Eismont⁴, Dmitry E. Polev⁵, Anastasia Yu. Lobenskaya⁵, Ruslana V. Klementeva¹, Maria O. Goloshchapova¹, Ludmila S. Zubarovskaya¹, Sergey V. Sidorenko³, Alexander N. Suvorov⁶, Ivan S. Moiseev¹, Alexei B. Chukhlovin¹ </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(557) "

Oleg V. Goloshchapov¹, Evgenyi A. Bakin¹, Maxim A. Kucher¹, Oksana V. Stanevich¹, Maria A. Suvorova², Vladimir V. Gostev³, Oleg S. Glotov⁴, Yury A. Eismont⁴, Dmitry E. Polev⁵, Anastasia Yu. Lobenskaya⁵, Ruslana V. Klementeva¹, Maria O. Goloshchapova¹, Ludmila S. Zubarovskaya¹, Sergey V. Sidorenko³, Alexander N. Suvorov⁶, Ivan S. Moiseev¹, Alexei B. Chukhlovin¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(557) "

Oleg V. Goloshchapov¹, Evgenyi A. Bakin¹, Maxim A. Kucher¹, Oksana V. Stanevich¹, Maria A. Suvorova², Vladimir V. Gostev³, Oleg S. Glotov⁴, Yury A. Eismont⁴, Dmitry E. Polev⁵, Anastasia Yu. Lobenskaya⁵, Ruslana V. Klementeva¹, Maria O. Goloshchapova¹, Ludmila S. Zubarovskaya¹, Sergey V. Sidorenko³, Alexander N. Suvorov⁶, Ivan S. Moiseev¹, Alexei B. Chukhlovin¹

" } ["SUMMARY_EN"]=> array(37) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26502" ["VALUE"]=> array(2) { ["TEXT"]=> string(3745) "<p style="text-align: justify;">Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.</p> <h3>Patients and methods</h3> <p style="text-align: justify;">The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.</p> <h3>Results</h3> <p style="text-align: justify;">When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); <i>Escherichia coli</i> (p=0.001); <i>Bacteroides fragilis group</i> (p=0.05); <i>Faecalibacterium prausnitzii</i> (p=0.005). Meanwhile, the numbers <i>Lactobacillus spp.</i>, and <i>Bacteroides thetaiotaomicron</i>, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: <i>Bifidobacterium spp.</i> (р<0.047), <i>E.coli</i> (р<0.00047), <i>B. fragilis group</i> (p=5.6×10^-5), <i>F.prausnitzii</i> (р<0.0062). <h3>Conclusions</h3> <p style="text-align: justify;">1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., <i>Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii</i> could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.</p> <h2>Keywords</h2> <p style="text-align: justify;">Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, <i>Bacteroides fragilis</i>, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(3437) "

Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.

Patients and methods

The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.

Results

When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); Escherichia coli (p=0.001); Bacteroides fragilis group (p=0.05); Faecalibacterium prausnitzii (p=0.005). Meanwhile, the numbers Lactobacillus spp., and Bacteroides thetaiotaomicron, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: Bifidobacterium spp. (р<0.047), E.coli (р<0.00047), B. fragilis group (p=5.6×10^-5), F.prausnitzii (р<0.0062).

Conclusions

1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.

Keywords

Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, Bacteroides fragilis, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(3437) "

Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.

Patients and methods

The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.

Results

When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); Escherichia coli (p=0.001); Bacteroides fragilis group (p=0.05); Faecalibacterium prausnitzii (p=0.005). Meanwhile, the numbers Lactobacillus spp., and Bacteroides thetaiotaomicron, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: Bifidobacterium spp. (р<0.047), E.coli (р<0.00047), B. fragilis group (p=5.6×10^-5), F.prausnitzii (р<0.0062).

Conclusions

1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.

Keywords

Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, Bacteroides fragilis, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.

" } ["DOI"]=> array(37) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26497" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-47-59" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-47-59" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-47-59" } ["NAME_EN"]=> array(37) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26498" ["VALUE"]=> string(127) "Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(127) "Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(127) "Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment" } ["ORGANIZATION_EN"]=> array(37) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26501" ["VALUE"]=> array(2) { ["TEXT"]=> string(917) "<p>¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br> ² Explana Research Laboratory, St. Petersburg, Russia<br> ³ Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia<br> ⁴ City Hospital No. 40, St. Petersburg, Russia<br> ⁵ Cerbalab Ltd, St. Petersburg, Russia<br> ⁶ Institute of Experimental Medicine, St. Petersburg, Russia</p> <br> <p><b>Correspondence</b><br> Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia<br> Phone: + 7 (921) 979 2913<br> E-mail: golocht@yandex.ru</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(755) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Explana Research Laboratory, St. Petersburg, Russia
³ Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia
⁴ City Hospital No. 40, St. Petersburg, Russia
⁵ Cerbalab Ltd, St. Petersburg, Russia
⁶ Institute of Experimental Medicine, St. Petersburg, Russia

Correspondence
Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: + 7 (921) 979 2913
E-mail: golocht@yandex.ru

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(755) "

¹ RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
² Explana Research Laboratory, St. Petersburg, Russia
³ Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia
⁴ City Hospital No. 40, St. Petersburg, Russia
⁵ Cerbalab Ltd, St. Petersburg, Russia
⁶ Institute of Experimental Medicine, St. Petersburg, Russia

Correspondence
Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: + 7 (921) 979 2913
E-mail: golocht@yandex.ru

" } ["AUTHOR_RU"]=> array(37) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26494" ["VALUE"]=> array(2) { ["TEXT"]=> string(1017) "<p>Олег В. Голощапов¹, Евгений А. Бакин¹, Максим А. Кучер¹, Оксана В. Станевич¹, Мария А. Суворова², Владимир В. Гостев³, Олег С. Глотов⁴, Юрий А. Эйсмонт⁴, Дмитрий Е. Полев⁵, Анастасия Ю. Лобенская⁵, Руслана В. Клементьева¹, Мария О. Голощапова¹, Людмила С. Зубаровская¹, Сергей В. Сидоренко³, Александр Н. Суворов⁴, Иван С. Моисеев¹, Алексей Б. Чухловин¹</p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(801) "

Олег В. Голощапов¹, Евгений А. Бакин¹, Максим А. Кучер¹, Оксана В. Станевич¹, Мария А. Суворова², Владимир В. Гостев³, Олег С. Глотов⁴, Юрий А. Эйсмонт⁴, Дмитрий Е. Полев⁵, Анастасия Ю. Лобенская⁵, Руслана В. Клементьева¹, Мария О. Голощапова¹, Людмила С. Зубаровская¹, Сергей В. Сидоренко³, Александр Н. Суворов⁴, Иван С. Моисеев¹, Алексей Б. Чухловин¹

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(801) "

Олег В. Голощапов¹, Евгений А. Бакин¹, Максим А. Кучер¹, Оксана В. Станевич¹, Мария А. Суворова², Владимир В. Гостев³, Олег С. Глотов⁴, Юрий А. Эйсмонт⁴, Дмитрий Е. Полев⁵, Анастасия Ю. Лобенская⁵, Руслана В. Клементьева¹, Мария О. Голощапова¹, Людмила С. Зубаровская¹, Сергей В. Сидоренко³, Александр Н. Суворов⁴, Иван С. Моисеев¹, Алексей Б. Чухловин¹

" } ["SUBMITTED"]=> array(37) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26492" ["VALUE"]=> string(10) "10.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "10.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "10.06.2020" } ["ACCEPTED"]=> array(37) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26493" ["VALUE"]=> string(10) "26.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "26.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "26.06.2020" } ["SUMMARY_RU"]=> array(37) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26496" ["VALUE"]=> array(2) { ["TEXT"]=> string(5852) "<p style="text-align: justify;">Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.</p> <h3>Пациенты и методы</h3> <p style="text-align: justify;">В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.</p> <h3>Результаты</h3> <p style="text-align: justify;">При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); <i>Escherichia coli</i> (p=0,001); <i>Bacteroides fragilis group</i> (p=0,05); <i>Faecalibacterium prausnitzii</i> (p=0,005). В то же время количества <i>Lactobacillus spp.</i> и <i>Bacteroides thetaiotaomicron</i>, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: <i>Bifidobacterium spp.</i> (р<0,047), <i>E.coli</i> (р<0,00047), <i>B.fragilis group</i> (p=5,6×10^-5), <i>F.prausnitzii</i> (р<0,0062).</p> <h3>Выводы</h3> <p style="text-align: justify;">Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. <i>Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii</i> может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий <i>B.fragilis group</i> коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ. </p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, <i>Bacteroides fragilis</i>, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(5526) "

Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.

Пациенты и методы

В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.

Результаты

При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); Escherichia coli (p=0,001); Bacteroides fragilis group (p=0,05); Faecalibacterium prausnitzii (p=0,005). В то же время количества Lactobacillus spp. и Bacteroides thetaiotaomicron, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: Bifidobacterium spp. (р<0,047), E.coli (р<0,00047), B.fragilis group (p=5,6×10^-5), F.prausnitzii (р<0,0062).

Выводы

Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий B.fragilis group коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ.

Ключевые слова

Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, Bacteroides fragilis, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(5526) "

Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.

Пациенты и методы

В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.

Результаты

При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); Escherichia coli (p=0,001); Bacteroides fragilis group (p=0,05); Faecalibacterium prausnitzii (p=0,005). В то же время количества Lactobacillus spp. и Bacteroides thetaiotaomicron, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: Bifidobacterium spp. (р<0,047), E.coli (р<0,00047), B.fragilis group (p=5,6×10^-5), F.prausnitzii (р<0,0062).

Выводы

Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий B.fragilis group коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ.

Ключевые слова

Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, Bacteroides fragilis, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.

" } ["ORGANIZATION_RU"]=> array(37) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26495" ["VALUE"]=> array(2) { ["TEXT"]=> string(1097) "<p>¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> ² Научная лаборатория Эксплана, Санкт-Петербург, Россия <br> ³ Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия <br> ⁴ Городская больница №40, Санкт-Петербург, Россия<br> ⁵ ООО «Сербалаб», Санкт-Петербург, Россия<br> ⁶ Институт экспериментальной медицины, Санкт-Петербург, Россия</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(983) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Научная лаборатория Эксплана, Санкт-Петербург, Россия
³ Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия
⁴ Городская больница №40, Санкт-Петербург, Россия
⁵ ООО «Сербалаб», Санкт-Петербург, Россия
⁶ Институт экспериментальной медицины, Санкт-Петербург, Россия

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(983) "

¹ НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
² Научная лаборатория Эксплана, Санкт-Петербург, Россия
³ Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия
⁴ Городская больница №40, Санкт-Петербург, Россия
⁵ ООО «Сербалаб», Санкт-Петербург, Россия
⁶ Институт экспериментальной медицины, Санкт-Петербург, Россия

" } } } [4]=> array(49) { ["IBLOCK_SECTION_ID"]=> string(3) "149" ["~IBLOCK_SECTION_ID"]=> string(3) "149" ["ID"]=> string(4) "1858" ["~ID"]=> string(4) "1858" ["IBLOCK_ID"]=> string(1) "2" ["~IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["~NAME"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["ACTIVE_FROM"]=> NULL ["~ACTIVE_FROM"]=> NULL ["TIMESTAMP_X"]=> string(19) "04.08.2020 15:14:57" ["~TIMESTAMP_X"]=> string(19) "04.08.2020 15:14:57" ["DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti/" ["~DETAIL_PAGE_URL"]=> string(154) "/ru/archive/tom-9-nomer-2/klinicheskie-issledovaniya/morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti/" ["LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["~LIST_PAGE_URL"]=> string(12) "/ru/archive/" ["DETAIL_TEXT"]=> string(17447) "

Introduction

Studies in molecular pathogenesis of autoimmune activation, vascular pathology and excessive fibrosis in systemic scleroderma (SSD) have provided basis for effective target therapy aimed for immune modulation, antiproliferative and antifibrotic treatment of this disorder [1]. Over last decades, an important role in successful treatment of autoimmune diseases, e.g., SSD, is given to a complex multifaceted effects of hematopoietic stem cell transplantation (HSCT) which sufficiently increases efficiency of preceding high-dose immunosuppressive therapy [2]. Recent clinical reports evaluating HSCT for treatment of severe autoimmune diseases show quite promising results [3]. As a rule, histological control of skin fibrosis changes in the course of treatment includes enumeration of myofibroblasts that are associated with excessive deposition of extracellular matrix components [4]. In cases of positive clinical changes in the SSD patients after HSCT, we were focused on the light microscopy, histochemical, and ultrastructural changes of skin which may be connected with therapeutic effects of the cellular therapy.

The aim of our study was to evaluate morphological and functional state of skin from the SSD patients before and after autologous transplantation of pre-cultured hematopoietic stem cells from bone marrow.

Patients and methods

We have observed twenty-eight patients at the National Scientific Medical Center (Nur-Sultan), aged 26 to 60 years (2 males and 26 females) with identified diagnosis of SSD, according to ACR/EULAR criteria [5]. The duration of the disease was more than 3 years. In the frame of clinical examination, we performed general laboratory assessment, immunological tests, CT of thoracic area, echo-CG with measuring blood pressure in A. pulmonalis. All the patients exhibited skin thickening on both hands, ulceration (3%), digital ischemia (43%). Rainaud syndrome was expressed in 98% of the patients, teleangiectasias in 84%, esophagopathy, in 51%. CT of thoracic area showed interstitial lung affection in 35% cases, pulmonary hypertension in 15% of cases. Rodnan skin scores were determined before and after therapy. The patients were divided into 2 groups without any significant differences for age, duration of disease, and skin scores.

The patients received the following basic therapy: plaquenil (hydroxychloroquine) at 200 mg/day, prednisolone (a mean of 6.9+2.1 mg/day), methotrexate (10-15 mg/week), azathioprine (50-100 mg/day). The control group consisted of 12 patients. The main group (16 persons) was additionally treated with hematopoietic stem cell (HSC) transfusion. Resistance to immunosuppressive therapy was a reason for HSAC transplantation.

After clinical and laboratory examination of the SSD patients, 200 to 300 mL of bone marrow was aspirated via tibial crest with local or peridural anaesthesia under sterile conditions in the surgical block. Isolation of autologous mononuclear bone marrow cells was performed by centrifugation in Percoll density gradient (Sigma Aldrich, P1644). The isolated cell were cultivation in DMEM medium (Dulbecco Modified Eagles Medium, Sigma Aldrich, D1145) with 10% FBS at 37°С for 72 hours. Cell viability was determined by trypan blue staining. Quantification of dual-positive CD45+/ CD34+mononuclear cells` count was done on the BD FACSCalibur flow cytometer (Becton, Dickinson and Company, BD Biosciences, San Jose, CA, USA).

Transfusion of autologous cultured HSCs was carried out in physiological saline (a mean of 140×10⁶ cells per 200 mL) intravenously dropwise, at a rate of 50 mL/h. Clinical efficiency (Rodnan skin scores) was evaluated by the criteria of European Scleroderma Trials and Research Group [6].

Tibial skin bioptates were taken using punch biopsy in 15 patients before cellular therapy and in 9 cases at 3 months after auto-HSCT, upon clinical improvement of skin condition. The paraffin-embedded samples were stained with H&E, as well as by trichrome Masson staining (Bio-Optica,Italy). For electron microscopy, the skin biopsies were treated with 2.5% glutaraldehyde with postfixation in 1% OsO4, gradually dehydrated in ethanol and acetone and embedded in Epon 812 (Sigma, USA) according by routine technique [7, 8]. Semi-thin slices were stained with methylene blue, azur-2 and basic fuchsin by Humphrey and Pittman [9]. Ultrathin slices were contrasted with uranyl acetate and lead citrate by Reynolds. The examinations were performed at the Libra 120 electron microscope (Carl Zeiss, Germany).

Results

Microscopic findings in the patients before HSCT

In the course of routine morphological examination, the skin of SSD patients before treatment was indurated, being characterized by dystrophy, atrophy, destruction of epidermis, along with sclerotizing and hyalinosis of dermal connective tissue, pathology of vascular microcirculatory flow. Upon polychromic staining of semi-thin slices, we observed bright fuchsinophylia and metachromasia of densely packed thin fibers composing papillary and rough bundles of oedematous reticular dermal layer (Fig. 1, A). Upon trichrome Masson staining, the dermal connective tissue looked dense and intensively blue-coloured.

Upon electron microscopic studies, the collagen fibers were presented by disordered fibril bundles of irregular thickness and optical density, with degradation signs (oedema, decondensation, granular and amorphous destruction). Pathological collagen forms, as cross-linked microfibrillar aggregates were also noted. The ribbon-shaped hyalinized fibers were homogenous and dense. Desquamation of corneal scales and thinning of the layers lead to ruptures and epidermal desquamation, especially in the areas of pronounced subepithelial sclerosis and hyalinosis of connective tissue. Single sebaceous follicles, oil and sweat glands showed the signs of dystrophy.

Microcirculatory network of dermal blood capillaries was changed and showed polymorphic structure, dependent on the degree of connective tissue fibrosis. Upon light microscopy, we observed either capillaries with hypertrophic endothelial cells and proliferating pericytes, or obliterated vessels with homogenized dark or light necrotized lining. EM has showed endothelial necrosis in small capillaries "immured" into the dense fibrotic tissue. The capillaries in deeper dermal layers were lined by pathologically changed dark cells with reduplicated, loosened and fragmented basal membranes. Epithelium in less affected capillaries was surrounded by hyperthrophic pericytes. Apoptotic signs and full destruction of endothelial cells were noted.

Myofibroblasts (MFB) comprised the major dermal cell population, along with non-differentiated cells and fibrocytes. When studied by electron microscopy, the myofibroblasts differed from fibroblasts by pronounced reduction of the cell body with fibrils occupying more than a half of cytoplasmic volume. Electron microscopy of the MFB showed swollen mitochondria, and orthodoxal-type mitochondria with translucent matrix, reduced cristae, destruction of external mitochondrial membrane, as well as vacuolized and destroyed canaliculi of the granular endoplasmatic reticulum (GER), thus suggesting higher activity of these cells (Fig. 1, B). The MFB surrounded by closely adjusted bundles of collagen fibrils were destroyed. The infiltrates composed of lymphocytes, fibroblast-like and mast cells were located in perivascular area. Just there, EM revealed scleroderma-specific fibroblasts, i.e., large elongated or triangle-shaped cells without processes with high synthetic activity, dictyosomes of Golgi complex and well developed GER and flake-like intraluminal substance (Fig. 1, C). The lymphocytes with large hyperchromic nucleus had smooth or villous surface. Dense and fissure-like intrercellular contacts between lymphocytes and fibroblasts were noted, with numerous vesicles in hyaloplasm of some lymphocytes (Fig. 1, D). Scattered fibroclasts with typical plasmalemma protrusions resorbed the collagen fibrils. Detritus and organelles of dead cells were seen between the collagen bundles.

Figure 1. Skin morphology of SSD patients before HSCT: A, fuchsinophilia of sclerotized dermal tissue. Semi-thin slice. Methylene Blue- Azur II, Basic fuchsin staining dye at the 1000x magnification. EM photos: B, myofibroblast with orthodoxal-type mitochondria and vacuolized GER; C, activated fibroblast with numerous GER channels and Golgi dictyosomes ; D, lymphocyte with vesicles, dense and slit-like intercellular contact

Clinical and morphological changes after HSCT

Three months after HSCT, the main group of patients exhibited a pronounced clinical effect with sufficient mitigation of skin induration and dysphagia, reduction of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly reduced, with decrease of Rodnan scores by 4.2 points (12.9 to 8.7) compared to 1-point reduction in control group. The SSD disease activity by EScSG criteria was equally diminished from 3.9 to 2.5 points, both in main and control group.

Acanthosis of basal cell layer with inclusions of large vacuoles argued for epidermal regeneration and transdermal fluid transport. Sweat glands and hair follicles appeared. After staining with trichrome Masson decreased density and staining intensity of connective tissue was found, due to reduced collagen deposition (Fig. 2, A). Myofibroblasts, located in papillary layer, acquired elongated form and hyperchromasia. When studied with EM technique, they proved to be altered cells with vacuolized organelles and multiple secondary lysosomes. An increased number of small capillaries with thin walls that were located in papillary layer and even more numerous at the border of reticular layer (Fig. 2, A).

Perivascular space of the de novo formed vessels was characterized by rarefaction of fibrous tissue and occurrence of numerous macrophages with large bright vacuoles (Fig. 2, B). Electron microscopy of capillary endothelium has shown pronounced micropinocytosis. Thin and long protrusions of presumable telocytes were seen in large quantities. These cells had a wide perinuclear and peripheral part which represented thin processes with vacuoles, GER and mitochondria. The intercellular contacts were thin and loosened, with an area of numerous micropinocytic vesicles, or dense and multiple contacts with different cell types. Rare activated fibroblasts had smooth GER contours and pathologically changed mitochondria. We have also seen lymphocyte-like low-differentiated cells with large nuclei and electron-dense hyaloplasm. The macrophages had long protrusions (egrepodes), capturing the degraded material of collagen fibrils. Large electron-bright vacuoles contained the rests of lysed fibrils and small patietally located osmiophylic lysosomes и (Fig. 2, C). Most macrophages contained multiple secondary lysosomes. Fibroclasts also participated in engulfment of collagen fibrils. The macrophages with single large vacuoles without egrepodes and small secretory microvesicles had intercellular contacts with lymphocytes, myofibroblasts and non-differentiated cells (Fig. 2, D).

Figure 2. Skin morphology in SSD patients 3 months after autologous HSCT. A, reduction of density and staining intensity of connective tissue. Increased amounts and proliferation of dermal capillaries, trichrome Masson staining; B, vessels and macrophages with large vacuoles in the focus of rarefied connective tissue are seen in the semi-thin section stained with Methylene Blue Azur II and basic fuchsine dye at the 1000x magnification. EM photos: C, macrophage with protrusions, large phagocytic vacuoles and small lisosomes; D, dense contacts between macrophage and lymphocyte

Discussion

Myofibroblasts from sclerotized connective tissue of skin in SSD patients before treatment exhibited signs of activation. The more intact partner cells in fibrillogenesis were located in perivascular area, i.e., activated lymphocytes and special scleroderma-associated fibroblast population which produces higher amounts of collagen and intermediate matrix [10]. Mononuclear cell infiltration in the areas of extracellular matrix hyperproduction, like as signs of immunocyte activation in scleroderma presume an important role of immune disturbamces in SSD pathogenesis [11].

Transplantation of cultured HSC promoted biodegradation of fibrotic skin tissue in SSD patients post-transplant. The myofibroblasts were subject to destruction, the numbers and length of capillaries were increased. Cellular composition of perivascular infiltrate was also changed, compared to its previous condition associated with active fibrillogenesis. The numerous emerging phagocytic and secretory macrophages appeared, participating in the isolation of angiogenesis inducers, tissue remodeling, regulation of the number and activity of fibroclasts.

Extensive intercellular interactions of telocytes suggested their participation at neoangiogenesis and transduction of complex signals that regulate regeneration events [12].

Conclusion

Transplantation of cultured autologous hematopoietic stem cells from the bone marrow to the patients with systemic scleroderma disease promoted biodegradation of sclerotized dermal tissue, stimulation of angiogenesis, restoration of epithelial layer and dermal appendages within 3 months after transplantation, thus correlating with distinct signs of clinical improvement, as shown by decreased Rodnan skin scores.

Acknowledgement

The study was performed in the frames of National Research Program "Innovative cellular technologies in regenerative medicine" (2013-2015).

Conflict of interests

None declared.

References

1. Tindall A, Matucci-Cerenic M, Muller-Lander U. Future targets in the managements of systemic sclerosis. Rhеumatology. 2009; 48:49-53.
2. van Laar JM, Tyndall A. Adult stem cell in the treatment of autoimmune diseases. Rheumatology. 2006; 45:1187-1193.
3. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematol Am Soc Hematol Educ Program. 2011; 2011: 280-284.
4. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthr Rheum. 2006; 54:3655-3660.
5. Joven BE, Escribano P, Andreu JL, Loza E, Jimenez C, Garcia de Yebenes MJ, Ruiz-Cano MJ, Carmona L, Carreira PE. 2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2018;47(6):870-876.
6. Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka J, Pope J, Müller-Ladner U, Riemekasten G. The European Scleroderma Trials and Research Group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR Activity Index. Ann Rheum Dis. 2017; 76(1): 270-276.
7. Glauert A. Fixation, dehydration and embedding of biological specimens. In: Practical methods in electron microscopy (Ed.: Glauert AM). North-Holland (American Elsevier), 1975.
8. Luft J. Improvements in epoxy resin embedding methods. J Biophys Biochem Cytol. 1961;9:409.
9. Humphrey C, Pittman F. A simple methylene blue-fuze, fuse-stain for epoxy-embedded tissue sections. StainTechnol. 1974;49: 9-14.
10. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 2001; 44(7):1667-1676.
11. Nevskaya TA, Guseva IG, Radenska-Lopovok SG, Speransky AI. T cell immune disturbances in earlyv systemic sclerodermia. Nauchno-Prakticheskaya Revmatologiya. 2006; 4: 35-43 (In Russian).
12. Manole CG, Cismasiu V, Gherghiceanu M, Popescu LM. Experimental acute myocardial infarction:telocytes involvement in neo-angiogenesis J Cell Mol Med. 2011; 15(11):2284-2296. DOI: 10.1111/j.1582-4934.2011.01449.x.

" ["~DETAIL_TEXT"]=> string(17447) "

Introduction

Studies in molecular pathogenesis of autoimmune activation, vascular pathology and excessive fibrosis in systemic scleroderma (SSD) have provided basis for effective target therapy aimed for immune modulation, antiproliferative and antifibrotic treatment of this disorder [1]. Over last decades, an important role in successful treatment of autoimmune diseases, e.g., SSD, is given to a complex multifaceted effects of hematopoietic stem cell transplantation (HSCT) which sufficiently increases efficiency of preceding high-dose immunosuppressive therapy [2]. Recent clinical reports evaluating HSCT for treatment of severe autoimmune diseases show quite promising results [3]. As a rule, histological control of skin fibrosis changes in the course of treatment includes enumeration of myofibroblasts that are associated with excessive deposition of extracellular matrix components [4]. In cases of positive clinical changes in the SSD patients after HSCT, we were focused on the light microscopy, histochemical, and ultrastructural changes of skin which may be connected with therapeutic effects of the cellular therapy.

The aim of our study was to evaluate morphological and functional state of skin from the SSD patients before and after autologous transplantation of pre-cultured hematopoietic stem cells from bone marrow.

Patients and methods

We have observed twenty-eight patients at the National Scientific Medical Center (Nur-Sultan), aged 26 to 60 years (2 males and 26 females) with identified diagnosis of SSD, according to ACR/EULAR criteria [5]. The duration of the disease was more than 3 years. In the frame of clinical examination, we performed general laboratory assessment, immunological tests, CT of thoracic area, echo-CG with measuring blood pressure in A. pulmonalis. All the patients exhibited skin thickening on both hands, ulceration (3%), digital ischemia (43%). Rainaud syndrome was expressed in 98% of the patients, teleangiectasias in 84%, esophagopathy, in 51%. CT of thoracic area showed interstitial lung affection in 35% cases, pulmonary hypertension in 15% of cases. Rodnan skin scores were determined before and after therapy. The patients were divided into 2 groups without any significant differences for age, duration of disease, and skin scores.

The patients received the following basic therapy: plaquenil (hydroxychloroquine) at 200 mg/day, prednisolone (a mean of 6.9+2.1 mg/day), methotrexate (10-15 mg/week), azathioprine (50-100 mg/day). The control group consisted of 12 patients. The main group (16 persons) was additionally treated with hematopoietic stem cell (HSC) transfusion. Resistance to immunosuppressive therapy was a reason for HSAC transplantation.

After clinical and laboratory examination of the SSD patients, 200 to 300 mL of bone marrow was aspirated via tibial crest with local or peridural anaesthesia under sterile conditions in the surgical block. Isolation of autologous mononuclear bone marrow cells was performed by centrifugation in Percoll density gradient (Sigma Aldrich, P1644). The isolated cell were cultivation in DMEM medium (Dulbecco Modified Eagles Medium, Sigma Aldrich, D1145) with 10% FBS at 37°С for 72 hours. Cell viability was determined by trypan blue staining. Quantification of dual-positive CD45+/ CD34+mononuclear cells` count was done on the BD FACSCalibur flow cytometer (Becton, Dickinson and Company, BD Biosciences, San Jose, CA, USA).

Transfusion of autologous cultured HSCs was carried out in physiological saline (a mean of 140×10⁶ cells per 200 mL) intravenously dropwise, at a rate of 50 mL/h. Clinical efficiency (Rodnan skin scores) was evaluated by the criteria of European Scleroderma Trials and Research Group [6].

Tibial skin bioptates were taken using punch biopsy in 15 patients before cellular therapy and in 9 cases at 3 months after auto-HSCT, upon clinical improvement of skin condition. The paraffin-embedded samples were stained with H&E, as well as by trichrome Masson staining (Bio-Optica,Italy). For electron microscopy, the skin biopsies were treated with 2.5% glutaraldehyde with postfixation in 1% OsO4, gradually dehydrated in ethanol and acetone and embedded in Epon 812 (Sigma, USA) according by routine technique [7, 8]. Semi-thin slices were stained with methylene blue, azur-2 and basic fuchsin by Humphrey and Pittman [9]. Ultrathin slices were contrasted with uranyl acetate and lead citrate by Reynolds. The examinations were performed at the Libra 120 electron microscope (Carl Zeiss, Germany).

Results

Microscopic findings in the patients before HSCT

In the course of routine morphological examination, the skin of SSD patients before treatment was indurated, being characterized by dystrophy, atrophy, destruction of epidermis, along with sclerotizing and hyalinosis of dermal connective tissue, pathology of vascular microcirculatory flow. Upon polychromic staining of semi-thin slices, we observed bright fuchsinophylia and metachromasia of densely packed thin fibers composing papillary and rough bundles of oedematous reticular dermal layer (Fig. 1, A). Upon trichrome Masson staining, the dermal connective tissue looked dense and intensively blue-coloured.

Upon electron microscopic studies, the collagen fibers were presented by disordered fibril bundles of irregular thickness and optical density, with degradation signs (oedema, decondensation, granular and amorphous destruction). Pathological collagen forms, as cross-linked microfibrillar aggregates were also noted. The ribbon-shaped hyalinized fibers were homogenous and dense. Desquamation of corneal scales and thinning of the layers lead to ruptures and epidermal desquamation, especially in the areas of pronounced subepithelial sclerosis and hyalinosis of connective tissue. Single sebaceous follicles, oil and sweat glands showed the signs of dystrophy.

Microcirculatory network of dermal blood capillaries was changed and showed polymorphic structure, dependent on the degree of connective tissue fibrosis. Upon light microscopy, we observed either capillaries with hypertrophic endothelial cells and proliferating pericytes, or obliterated vessels with homogenized dark or light necrotized lining. EM has showed endothelial necrosis in small capillaries "immured" into the dense fibrotic tissue. The capillaries in deeper dermal layers were lined by pathologically changed dark cells with reduplicated, loosened and fragmented basal membranes. Epithelium in less affected capillaries was surrounded by hyperthrophic pericytes. Apoptotic signs and full destruction of endothelial cells were noted.

Myofibroblasts (MFB) comprised the major dermal cell population, along with non-differentiated cells and fibrocytes. When studied by electron microscopy, the myofibroblasts differed from fibroblasts by pronounced reduction of the cell body with fibrils occupying more than a half of cytoplasmic volume. Electron microscopy of the MFB showed swollen mitochondria, and orthodoxal-type mitochondria with translucent matrix, reduced cristae, destruction of external mitochondrial membrane, as well as vacuolized and destroyed canaliculi of the granular endoplasmatic reticulum (GER), thus suggesting higher activity of these cells (Fig. 1, B). The MFB surrounded by closely adjusted bundles of collagen fibrils were destroyed. The infiltrates composed of lymphocytes, fibroblast-like and mast cells were located in perivascular area. Just there, EM revealed scleroderma-specific fibroblasts, i.e., large elongated or triangle-shaped cells without processes with high synthetic activity, dictyosomes of Golgi complex and well developed GER and flake-like intraluminal substance (Fig. 1, C). The lymphocytes with large hyperchromic nucleus had smooth or villous surface. Dense and fissure-like intrercellular contacts between lymphocytes and fibroblasts were noted, with numerous vesicles in hyaloplasm of some lymphocytes (Fig. 1, D). Scattered fibroclasts with typical plasmalemma protrusions resorbed the collagen fibrils. Detritus and organelles of dead cells were seen between the collagen bundles.

Figure 1. Skin morphology of SSD patients before HSCT: A, fuchsinophilia of sclerotized dermal tissue. Semi-thin slice. Methylene Blue- Azur II, Basic fuchsin staining dye at the 1000x magnification. EM photos: B, myofibroblast with orthodoxal-type mitochondria and vacuolized GER; C, activated fibroblast with numerous GER channels and Golgi dictyosomes ; D, lymphocyte with vesicles, dense and slit-like intercellular contact

Clinical and morphological changes after HSCT

Three months after HSCT, the main group of patients exhibited a pronounced clinical effect with sufficient mitigation of skin induration and dysphagia, reduction of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly reduced, with decrease of Rodnan scores by 4.2 points (12.9 to 8.7) compared to 1-point reduction in control group. The SSD disease activity by EScSG criteria was equally diminished from 3.9 to 2.5 points, both in main and control group.

Acanthosis of basal cell layer with inclusions of large vacuoles argued for epidermal regeneration and transdermal fluid transport. Sweat glands and hair follicles appeared. After staining with trichrome Masson decreased density and staining intensity of connective tissue was found, due to reduced collagen deposition (Fig. 2, A). Myofibroblasts, located in papillary layer, acquired elongated form and hyperchromasia. When studied with EM technique, they proved to be altered cells with vacuolized organelles and multiple secondary lysosomes. An increased number of small capillaries with thin walls that were located in papillary layer and even more numerous at the border of reticular layer (Fig. 2, A).

Perivascular space of the de novo formed vessels was characterized by rarefaction of fibrous tissue and occurrence of numerous macrophages with large bright vacuoles (Fig. 2, B). Electron microscopy of capillary endothelium has shown pronounced micropinocytosis. Thin and long protrusions of presumable telocytes were seen in large quantities. These cells had a wide perinuclear and peripheral part which represented thin processes with vacuoles, GER and mitochondria. The intercellular contacts were thin and loosened, with an area of numerous micropinocytic vesicles, or dense and multiple contacts with different cell types. Rare activated fibroblasts had smooth GER contours and pathologically changed mitochondria. We have also seen lymphocyte-like low-differentiated cells with large nuclei and electron-dense hyaloplasm. The macrophages had long protrusions (egrepodes), capturing the degraded material of collagen fibrils. Large electron-bright vacuoles contained the rests of lysed fibrils and small patietally located osmiophylic lysosomes и (Fig. 2, C). Most macrophages contained multiple secondary lysosomes. Fibroclasts also participated in engulfment of collagen fibrils. The macrophages with single large vacuoles without egrepodes and small secretory microvesicles had intercellular contacts with lymphocytes, myofibroblasts and non-differentiated cells (Fig. 2, D).

Figure 2. Skin morphology in SSD patients 3 months after autologous HSCT. A, reduction of density and staining intensity of connective tissue. Increased amounts and proliferation of dermal capillaries, trichrome Masson staining; B, vessels and macrophages with large vacuoles in the focus of rarefied connective tissue are seen in the semi-thin section stained with Methylene Blue Azur II and basic fuchsine dye at the 1000x magnification. EM photos: C, macrophage with protrusions, large phagocytic vacuoles and small lisosomes; D, dense contacts between macrophage and lymphocyte

Discussion

Myofibroblasts from sclerotized connective tissue of skin in SSD patients before treatment exhibited signs of activation. The more intact partner cells in fibrillogenesis were located in perivascular area, i.e., activated lymphocytes and special scleroderma-associated fibroblast population which produces higher amounts of collagen and intermediate matrix [10]. Mononuclear cell infiltration in the areas of extracellular matrix hyperproduction, like as signs of immunocyte activation in scleroderma presume an important role of immune disturbamces in SSD pathogenesis [11].

Transplantation of cultured HSC promoted biodegradation of fibrotic skin tissue in SSD patients post-transplant. The myofibroblasts were subject to destruction, the numbers and length of capillaries were increased. Cellular composition of perivascular infiltrate was also changed, compared to its previous condition associated with active fibrillogenesis. The numerous emerging phagocytic and secretory macrophages appeared, participating in the isolation of angiogenesis inducers, tissue remodeling, regulation of the number and activity of fibroclasts.

Extensive intercellular interactions of telocytes suggested their participation at neoangiogenesis and transduction of complex signals that regulate regeneration events [12].

Conclusion

Transplantation of cultured autologous hematopoietic stem cells from the bone marrow to the patients with systemic scleroderma disease promoted biodegradation of sclerotized dermal tissue, stimulation of angiogenesis, restoration of epithelial layer and dermal appendages within 3 months after transplantation, thus correlating with distinct signs of clinical improvement, as shown by decreased Rodnan skin scores.

Acknowledgement

The study was performed in the frames of National Research Program "Innovative cellular technologies in regenerative medicine" (2013-2015).

Conflict of interests

None declared.

References

1. Tindall A, Matucci-Cerenic M, Muller-Lander U. Future targets in the managements of systemic sclerosis. Rhеumatology. 2009; 48:49-53.
2. van Laar JM, Tyndall A. Adult stem cell in the treatment of autoimmune diseases. Rheumatology. 2006; 45:1187-1193.
3. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematol Am Soc Hematol Educ Program. 2011; 2011: 280-284.
4. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthr Rheum. 2006; 54:3655-3660.
5. Joven BE, Escribano P, Andreu JL, Loza E, Jimenez C, Garcia de Yebenes MJ, Ruiz-Cano MJ, Carmona L, Carreira PE. 2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2018;47(6):870-876.
6. Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka J, Pope J, Müller-Ladner U, Riemekasten G. The European Scleroderma Trials and Research Group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR Activity Index. Ann Rheum Dis. 2017; 76(1): 270-276.
7. Glauert A. Fixation, dehydration and embedding of biological specimens. In: Practical methods in electron microscopy (Ed.: Glauert AM). North-Holland (American Elsevier), 1975.
8. Luft J. Improvements in epoxy resin embedding methods. J Biophys Biochem Cytol. 1961;9:409.
9. Humphrey C, Pittman F. A simple methylene blue-fuze, fuse-stain for epoxy-embedded tissue sections. StainTechnol. 1974;49: 9-14.
10. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 2001; 44(7):1667-1676.
11. Nevskaya TA, Guseva IG, Radenska-Lopovok SG, Speransky AI. T cell immune disturbances in earlyv systemic sclerodermia. Nauchno-Prakticheskaya Revmatologiya. 2006; 4: 35-43 (In Russian).
12. Manole CG, Cismasiu V, Gherghiceanu M, Popescu LM. Experimental acute myocardial infarction:telocytes involvement in neo-angiogenesis J Cell Mol Med. 2011; 15(11):2284-2296. DOI: 10.1111/j.1582-4934.2011.01449.x.

" ["DETAIL_TEXT_TYPE"]=> string(4) "html" ["~DETAIL_TEXT_TYPE"]=> string(4) "html" ["PREVIEW_TEXT"]=> string(0) "" ["~PREVIEW_TEXT"]=> string(0) "" ["PREVIEW_TEXT_TYPE"]=> string(4) "text" ["~PREVIEW_TEXT_TYPE"]=> string(4) "text" ["PREVIEW_PICTURE"]=> NULL ["~PREVIEW_PICTURE"]=> NULL ["LANG_DIR"]=> string(4) "/ru/" ["~LANG_DIR"]=> string(4) "/ru/" ["SORT"]=> string(3) "500" ["~SORT"]=> string(3) "500" ["CODE"]=> string(100) "morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti" ["~CODE"]=> string(100) "morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti" ["EXTERNAL_ID"]=> string(4) "1858" ["~EXTERNAL_ID"]=> string(4) "1858" ["IBLOCK_TYPE_ID"]=> string(7) "journal" ["~IBLOCK_TYPE_ID"]=> string(7) "journal" ["IBLOCK_CODE"]=> string(7) "volumes" ["~IBLOCK_CODE"]=> string(7) "volumes" ["IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["~IBLOCK_EXTERNAL_ID"]=> string(1) "2" ["LID"]=> string(2) "s2" ["~LID"]=> string(2) "s2" ["EDIT_LINK"]=> NULL ["DELETE_LINK"]=> NULL ["DISPLAY_ACTIVE_FROM"]=> string(0) "" ["IPROPERTY_VALUES"]=> array(18) { ["ELEMENT_META_TITLE"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["ELEMENT_META_KEYWORDS"]=> string(0) "" ["ELEMENT_META_DESCRIPTION"]=> string(380) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозгаMorphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation" ["ELEMENT_PREVIEW_PICTURE_FILE_ALT"]=> string(9914) "<p style="text-align: justify;">Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга. </p> <h3>Пациенты и методы</h3> <p style="text-align: justify;">Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии. </p> <p style="text-align: justify;">После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017). </p> <p style="text-align: justify;">Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.</p> <h3>Результаты</h3> <p style="text-align: justify;">Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.</p> <p style="text-align: justify;">Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.</p> <h3>Выводы</h3> <p style="text-align: justify;">Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи. </p>" ["ELEMENT_PREVIEW_PICTURE_FILE_TITLE"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["ELEMENT_DETAIL_PICTURE_FILE_ALT"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["ELEMENT_DETAIL_PICTURE_FILE_TITLE"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_META_TITLE"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_META_KEYWORDS"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_META_DESCRIPTION"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_PICTURE_FILE_ALT"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_PICTURE_FILE_TITLE"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_PICTURE_FILE_NAME"]=> string(100) "morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti" ["SECTION_DETAIL_PICTURE_FILE_ALT"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_DETAIL_PICTURE_FILE_TITLE"]=> string(252) "Морфологическая оценка кожи больных системной склеродермией до и после трансплантации гемопоэтических стволовых клеток костного мозга" ["SECTION_DETAIL_PICTURE_FILE_NAME"]=> string(100) "morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti" ["ELEMENT_PREVIEW_PICTURE_FILE_NAME"]=> string(100) "morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti" ["ELEMENT_DETAIL_PICTURE_FILE_NAME"]=> string(100) "morfologicheskaya-otsenka-kozhi-bolnykh-sistemnoy-sklerodermiey-do-i-posle-transplantatsii-gemopoeti" } ["FIELDS"]=> array(1) { ["IBLOCK_SECTION_ID"]=> string(3) "149" } ["PROPERTIES"]=> array(18) { ["KEYWORDS"]=> array(36) { ["ID"]=> string(2) "19" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:46:01" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(27) "Ключевые слова" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "KEYWORDS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "19" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "4" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "Y" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "Y" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(27) "Ключевые слова" ["~DEFAULT_VALUE"]=> string(0) "" } ["SUBMITTED"]=> array(36) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26504" ["VALUE"]=> string(10) "09.04.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "09.04.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL } ["ACCEPTED"]=> array(36) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26505" ["VALUE"]=> string(10) "05.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "05.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL } ["PUBLISHED"]=> array(36) { ["ID"]=> string(2) "22" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Дата публикации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "PUBLISHED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "22" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Дата публикации" ["~DEFAULT_VALUE"]=> NULL } ["CONTACT"]=> array(36) { ["ID"]=> string(2) "23" ["TIMESTAMP_X"]=> string(19) "2015-09-03 14:43:05" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(14) "Контакт" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "CONTACT" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "23" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(14) "Контакт" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHORS"]=> array(36) { ["ID"]=> string(2) "24" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:45:07" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "AUTHORS" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "E" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "Y" ["XML_ID"]=> string(2) "24" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "3" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(13) "EAutocomplete" ["USER_TYPE_SETTINGS"]=> array(9) { ["VIEW"]=> string(1) "E" ["SHOW_ADD"]=> string(1) "Y" ["MAX_WIDTH"]=> int(0) ["MIN_HEIGHT"]=> int(24) ["MAX_HEIGHT"]=> int(1000) ["BAN_SYM"]=> string(2) ",;" ["REP_SYM"]=> string(1) " " ["OTHER_REP_SYM"]=> string(0) "" ["IBLOCK_MESS"]=> string(1) "N" } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> bool(false) ["VALUE"]=> bool(false) ["DESCRIPTION"]=> bool(false) ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> bool(false) ["~DESCRIPTION"]=> bool(false) ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_RU"]=> array(36) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26506" ["VALUE"]=> array(2) { ["TEXT"]=> string(278) "<p>Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(266) "

Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_RU"]=> array(36) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26507" ["VALUE"]=> array(2) { ["TEXT"]=> string(161) "<p>АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(149) "

АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_RU"]=> array(36) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26508" ["VALUE"]=> array(2) { ["TEXT"]=> string(9914) "<p style="text-align: justify;">Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга. </p> <h3>Пациенты и методы</h3> <p style="text-align: justify;">Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии. </p> <p style="text-align: justify;">После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017). </p> <p style="text-align: justify;">Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.</p> <h3>Результаты</h3> <p style="text-align: justify;">Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.</p> <p style="text-align: justify;">Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.</p> <h3>Выводы</h3> <p style="text-align: justify;">Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(9690) "

Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга.

Пациенты и методы

Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии.

После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017).

Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.

Результаты

Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.

Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.

Выводы

Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.

Ключевые слова

Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["DOI"]=> array(36) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26509" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-60-66" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-60-66" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" } ["AUTHOR_EN"]=> array(36) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26512" ["VALUE"]=> array(2) { ["TEXT"]=> string(170) "<p>Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(158) "

Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["ORGANIZATION_EN"]=> array(36) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26513" ["VALUE"]=> array(2) { ["TEXT"]=> string(379) "<p>National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan </p> <br> <p><b>Correspondence</b><br> Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan<br> Phone: +7 (707) 222 3256<br> E-mail: gvf_fedotovskikh@mail.ru</p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(319) "

National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan

Correspondence
Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan
Phone: +7 (707) 222 3256
E-mail: gvf_fedotovskikh@mail.ru

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["SUMMARY_EN"]=> array(36) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26514" ["VALUE"]=> array(2) { ["TEXT"]=> string(4379) "<p style="text-align: justify;">Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.</p> <h3>Patients and methods</h3> <p style="text-align: justify;">Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT. </p> <p style="text-align: justify;">Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×10⁶ cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.</p> <h3>Results</h3> <p style="text-align: justify;">Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.</p> <h3>Conclusion</h3> <p style="text-align: justify;">Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.</p> <h2>Keywords</h2> <p style="text-align: justify;">Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(4187) "

Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.

Patients and methods

Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT.

Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×10⁶ cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.

Results

Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.

Conclusion

Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.

Keywords

Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["NAME_EN"]=> array(36) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26510" ["VALUE"]=> string(128) "Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(128) "Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" } ["FULL_TEXT_RU"]=> array(36) { ["ID"]=> string(2) "42" ["TIMESTAMP_X"]=> string(19) "2015-09-07 20:29:18" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(23) "Полный текст" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(12) "FULL_TEXT_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "42" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(23) "Полный текст" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } } ["PDF_RU"]=> array(36) { ["ID"]=> string(2) "43" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF RUS" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_RU" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "43" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26511" ["VALUE"]=> string(4) "2057" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2057" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF RUS" ["~DEFAULT_VALUE"]=> string(0) "" } ["PDF_EN"]=> array(36) { ["ID"]=> string(2) "44" ["TIMESTAMP_X"]=> string(19) "2015-09-09 16:05:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(7) "PDF ENG" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(6) "PDF_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "F" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "44" ["FILE_TYPE"]=> string(18) "doc, txt, rtf, pdf" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26515" ["VALUE"]=> string(4) "2058" ["DESCRIPTION"]=> NULL ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(4) "2058" ["~DESCRIPTION"]=> NULL ["~NAME"]=> string(7) "PDF ENG" ["~DEFAULT_VALUE"]=> string(0) "" } ["NAME_LONG"]=> array(36) { ["ID"]=> string(2) "45" ["TIMESTAMP_X"]=> string(19) "2023-04-13 00:55:00" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(72) "Название (для очень длинных заголовков)" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "NAME_LONG" ["DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "45" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(80) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> NULL ["VALUE"]=> string(0) "" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(0) "" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(72) "Название (для очень длинных заголовков)" ["~DEFAULT_VALUE"]=> array(2) { ["TYPE"]=> string(4) "HTML" ["TEXT"]=> string(0) "" } } } ["DISPLAY_PROPERTIES"]=> array(10) { ["AUTHOR_EN"]=> array(37) { ["ID"]=> string(2) "37" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(6) "Author" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "37" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26512" ["VALUE"]=> array(2) { ["TEXT"]=> string(170) "<p>Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(158) "

Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(6) "Author" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(158) "

Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat

" } ["SUMMARY_EN"]=> array(37) { ["ID"]=> string(2) "39" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Description / Summary" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "39" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26514" ["VALUE"]=> array(2) { ["TEXT"]=> string(4379) "<p style="text-align: justify;">Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.</p> <h3>Patients and methods</h3> <p style="text-align: justify;">Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT. </p> <p style="text-align: justify;">Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×10⁶ cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.</p> <h3>Results</h3> <p style="text-align: justify;">Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.</p> <h3>Conclusion</h3> <p style="text-align: justify;">Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.</p> <h2>Keywords</h2> <p style="text-align: justify;">Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(4187) "

Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.

Patients and methods

Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT.

Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×10⁶ cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.

Results

Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.

Conclusion

Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.

Keywords

Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Description / Summary" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(4187) "

Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.

Patients and methods

Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT.

Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×10⁶ cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.

Results

Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.

Conclusion

Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.

Keywords

Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.

" } ["DOI"]=> array(37) { ["ID"]=> string(2) "28" ["TIMESTAMP_X"]=> string(19) "2016-04-06 14:11:12" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(3) "DOI" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(3) "DOI" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "28" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26509" ["VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-60-66" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-60-66" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(3) "DOI" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(37) "10.18620/ctt-1866-8836-2020-9-2-60-66" } ["NAME_EN"]=> array(37) { ["ID"]=> string(2) "40" ["TIMESTAMP_X"]=> string(19) "2015-09-03 10:49:47" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(4) "Name" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(7) "NAME_EN" ["DEFAULT_VALUE"]=> string(0) "" ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "80" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "40" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "Y" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> NULL ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26510" ["VALUE"]=> string(128) "Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(128) "Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(4) "Name" ["~DEFAULT_VALUE"]=> string(0) "" ["DISPLAY_VALUE"]=> string(128) "Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation" } ["ORGANIZATION_EN"]=> array(37) { ["ID"]=> string(2) "38" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:02:59" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Organization" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_EN" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "38" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26513" ["VALUE"]=> array(2) { ["TEXT"]=> string(379) "<p>National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan </p> <br> <p><b>Correspondence</b><br> Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan<br> Phone: +7 (707) 222 3256<br> E-mail: gvf_fedotovskikh@mail.ru</p> " ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(319) "

National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan

Correspondence
Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan
Phone: +7 (707) 222 3256
E-mail: gvf_fedotovskikh@mail.ru

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Organization" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(319) "

National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan

Correspondence
Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan
Phone: +7 (707) 222 3256
E-mail: gvf_fedotovskikh@mail.ru

" } ["AUTHOR_RU"]=> array(37) { ["ID"]=> string(2) "25" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(12) "Авторы" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "AUTHOR_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "25" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26506" ["VALUE"]=> array(2) { ["TEXT"]=> string(278) "<p>Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат</p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(266) "

Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(12) "Авторы" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(266) "

Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат

" } ["SUBMITTED"]=> array(37) { ["ID"]=> string(2) "20" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(21) "Дата подачи" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(9) "SUBMITTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "20" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26504" ["VALUE"]=> string(10) "09.04.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "09.04.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(21) "Дата подачи" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "09.04.2020" } ["ACCEPTED"]=> array(37) { ["ID"]=> string(2) "21" ["TIMESTAMP_X"]=> string(19) "2015-09-02 17:21:42" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(25) "Дата принятия" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(8) "ACCEPTED" ["DEFAULT_VALUE"]=> NULL ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "21" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(8) "DateTime" ["USER_TYPE_SETTINGS"]=> NULL ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26505" ["VALUE"]=> string(10) "05.06.2020" ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> string(10) "05.06.2020" ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(25) "Дата принятия" ["~DEFAULT_VALUE"]=> NULL ["DISPLAY_VALUE"]=> string(10) "05.06.2020" } ["SUMMARY_RU"]=> array(37) { ["ID"]=> string(2) "27" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(29) "Описание/Резюме" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(10) "SUMMARY_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "27" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26508" ["VALUE"]=> array(2) { ["TEXT"]=> string(9914) "<p style="text-align: justify;">Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга. </p> <h3>Пациенты и методы</h3> <p style="text-align: justify;">Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии. </p> <p style="text-align: justify;">После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017). </p> <p style="text-align: justify;">Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.</p> <h3>Результаты</h3> <p style="text-align: justify;">Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.</p> <p style="text-align: justify;">Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.</p> <h3>Выводы</h3> <p style="text-align: justify;">Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.</p> <h2>Ключевые слова</h2> <p style="text-align: justify;">Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи. </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(9690) "

Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга.

Пациенты и методы

Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии.

После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017).

Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.

Результаты

Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.

Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.

Выводы

Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.

Ключевые слова

Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи.

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(29) "Описание/Резюме" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(9690) "

Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга.

Пациенты и методы

Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии.

После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017).

Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.

Результаты

Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.

Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.

Выводы

Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.

Ключевые слова

Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи.

" } ["ORGANIZATION_RU"]=> array(37) { ["ID"]=> string(2) "26" ["TIMESTAMP_X"]=> string(19) "2015-09-02 18:01:20" ["IBLOCK_ID"]=> string(1) "2" ["NAME"]=> string(22) "Организации" ["ACTIVE"]=> string(1) "Y" ["SORT"]=> string(3) "500" ["CODE"]=> string(15) "ORGANIZATION_RU" ["DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["PROPERTY_TYPE"]=> string(1) "S" ["ROW_COUNT"]=> string(1) "1" ["COL_COUNT"]=> string(2) "30" ["LIST_TYPE"]=> string(1) "L" ["MULTIPLE"]=> string(1) "N" ["XML_ID"]=> string(2) "26" ["FILE_TYPE"]=> string(0) "" ["MULTIPLE_CNT"]=> string(1) "5" ["TMP_ID"]=> NULL ["LINK_IBLOCK_ID"]=> string(1) "0" ["WITH_DESCRIPTION"]=> string(1) "N" ["SEARCHABLE"]=> string(1) "N" ["FILTRABLE"]=> string(1) "N" ["IS_REQUIRED"]=> string(1) "N" ["VERSION"]=> string(1) "1" ["USER_TYPE"]=> string(4) "HTML" ["USER_TYPE_SETTINGS"]=> array(1) { ["height"]=> int(200) } ["HINT"]=> string(0) "" ["PROPERTY_VALUE_ID"]=> string(5) "26507" ["VALUE"]=> array(2) { ["TEXT"]=> string(161) "<p>АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан </p>" ["TYPE"]=> string(4) "HTML" } ["DESCRIPTION"]=> string(0) "" ["VALUE_ENUM"]=> NULL ["VALUE_XML_ID"]=> NULL ["VALUE_SORT"]=> NULL ["~VALUE"]=> array(2) { ["TEXT"]=> string(149) "

АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан

" ["TYPE"]=> string(4) "HTML" } ["~DESCRIPTION"]=> string(0) "" ["~NAME"]=> string(22) "Организации" ["~DEFAULT_VALUE"]=> array(2) { ["TEXT"]=> string(0) "" ["TYPE"]=> string(4) "HTML" } ["DISPLAY_VALUE"]=> string(149) "

АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан

" } } } }

						Array
(
    [KEYWORDS] => Array
        (
            [ID] => 19
            [TIMESTAMP_X] => 2015-09-03 10:46:01
            [IBLOCK_ID] => 2
            [NAME] => Ключевые слова
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => KEYWORDS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 19
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 4
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => Y
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => Y
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Ключевые слова
            [~DEFAULT_VALUE] => 
        )

    [SUBMITTED] => Array
        (
            [ID] => 20
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата подачи
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUBMITTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 20
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26456
            [VALUE] => 07.05.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 07.05.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата подачи
            [~DEFAULT_VALUE] => 
        )

    [ACCEPTED] => Array
        (
            [ID] => 21
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата принятия
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ACCEPTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 21
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26457
            [VALUE] => 05.06.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 05.06.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата принятия
            [~DEFAULT_VALUE] => 
        )

    [PUBLISHED] => Array
        (
            [ID] => 22
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата публикации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PUBLISHED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 22
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Дата публикации
            [~DEFAULT_VALUE] => 
        )

    [CONTACT] => Array
        (
            [ID] => 23
            [TIMESTAMP_X] => 2015-09-03 14:43:05
            [IBLOCK_ID] => 2
            [NAME] => Контакт
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => CONTACT
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 23
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Контакт
            [~DEFAULT_VALUE] => 
        )

    [AUTHORS] => Array
        (
            [ID] => 24
            [TIMESTAMP_X] => 2015-09-03 10:45:07
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHORS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 24
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_RU] => Array
        (
            [ID] => 25
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 25
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26458
            [VALUE] => Array
                (
                    [TEXT] => <p>Екатерина В. Гончарова<sup>1,2</sup>, Инга Е. Заводова<sup>1</sup>, Никита П. Волков<sup>1</sup>, Ольга А. Иванова<sup>1</sup>, Максим А. Кучер<sup>1</sup>, <br>Алексей Ю. Соколов<sup>2,3</sup>, Максим П. Богомольный<sup>1</sup>, Глеб Э. Ульрих<sup>4</sup>, Людмила С. Зубаровская<sup>1</sup>, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Борис В. Афанасьев<sup>1</sup></span></p>  
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Екатерина В. Гончарова1,2, Инга Е. Заводова1, Никита П. Волков1, Ольга А. Иванова1, Максим А. Кучер1, 
Алексей Ю. Соколов2,3, Максим П. Богомольный1, Глеб Э. Ульрих4, Людмила С. Зубаровская1, Борис В. Афанасьев1
  
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_RU] => Array
        (
            [ID] => 26
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Организации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 26
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26462
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br> 
<sup>2</sup> Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия<br>
<sup>3</sup> Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия<br>
<sup>4</sup> Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия
 
2 Отдел нейрофармакологии Института фармакологии им. А. В. Вальдмана ПСПбГМУ им. акад. И. П. Павлова, Санкт-Петербург, Россия

3 Институт физиологии им. И. П. Павлова Российской академии наук, Санкт-Петербург, Россия

4 Кафедра анестезиологии, реаниматологии и неотложной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета, Санкт-Петербург, Россия
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Организации
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_RU] => Array
        (
            [ID] => 27
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Описание/Резюме
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 27
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26463
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель –  оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.</p>
<h3>Материалы и методы</h3>
<p style="text-align: justify;">В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.</p>
<h3>Результаты</h3>
<p style="text-align: justify;">Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24). </p>
<p style="text-align: justify;">Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.</p>
<h3>Выводы</h3>
<p style="text-align: justify;">Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.</p>
<h2>Ключевые слова</h2>
<p style="text-align: justify;">Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность. </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Во время и после проведения полихимиотерапии (ПХТ) с последующей трансплантацией гемопоэтических стволовых клеток (ТГСК) или без нее значительная часть пациентов сталкивается с развитием болевого синдрома различных интенсивности и этиологии. В этот период у пациента может отмечаться тромбоцитопения и лейкопения, вплоть до агранулоцитоза, что ограничивает назначение нестероидных противовоспалительных препаратов (НПВП). В соответствии с рекомендациями ВОЗ при развитии боли умеренной интенсивности и неэффективности НПВП в педиатрической практике возможно назначение опиоидов. При этом не исключается использование трамадола, который в настоящее время, благодаря облегченному правовому регулированию, широко применяется клинической практике. Цель –  оценить безопасность и эффективность трамадола и морфина в низких дозах при купировании умеренной ноцицептивной боли различной этиологии у детей после ТГСК и ПХТ.
Материалы и методы
В исследование включено 159 пациентов с жалобами на боль различной локализации интенсивностью от 3 до 6 баллов по шкале оценки, соответствующей возрасту и возможностям ребенка. Возраст детей составлял от 1 до 17 лет (медиана 8 лет). Все пациенты не получали опиоиды за 30 суток до включения в исследование (opioid naïve). Препараты вводили внутривенно посредством круглосуточной микроструйной инфузии в условиях стационара. В первой группе (n=118), в качестве терапии 1 линии назначался трамадол в стандартных дозах (от 0,2 до 0,3 мг/кг/час). Участники второй группы (n=41), получали морфин в низких дозах (от 0,01 до 0,019 мг/кг/час). Эффективность терапии оценивалась по совокупности факторов: снижение интенсивности боли до удовлетворительной для пациента, отсутствие ночных пробуждений, связанных с болью, отсутствие препятствий к приему пищи и/или жидкости в виде болевых ощущений и др. Безопасность оценивалась по наличию или отсутствию побочных эффектов, связанных с назначенными препаратами. Статистическая обработка проводилась в программе SPSS, для определения значимости различий использовался критерий согласия X2.
Результаты
Трамадол был эффективен в 40,7% случаев (n=48), низкие дозы морфина – в 58,5% (n=24). 
Назначение 2-й линии терапии, связанное с неэффективностью или плохой переносимостью препаратов первой линии, потребовалось в 1 группе у 53,4% пациентов (n=63), и у 39% (n=16) – во 2 группе. Побочные эффекты, связанные с назначением трамадола, возникли в 5.1% случаев (n=6). В группе морфина у 1 пациентки (2,4%) развился парез кишечника, разрешившийся после смены терапии. При статистическом анализе значимых межгрупповых различий с точки зрения эффективности и безопасности лечения выявлено не было.
Выводы
Оба препарата в сравниваемых дозах показали схожие эффективность и безопасность при купировании умеренной боли у детей после проведения ПХТ и ТГСК.
Ключевые слова
Химиотерапия, противоопухолевая, болевой синдром, мукозиты, трамадол, морфин, эффективность, безопасность. 
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Описание/Резюме
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [DOI] => Array
        (
            [ID] => 28
            [TIMESTAMP_X] => 2016-04-06 14:11:12
            [IBLOCK_ID] => 2
            [NAME] => DOI
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => DOI
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 28
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26459
            [VALUE] => 10.18620/ctt-1866-8836-2020-9-2-20-27
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 10.18620/ctt-1866-8836-2020-9-2-20-27
            [~DESCRIPTION] => 
            [~NAME] => DOI
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_EN] => Array
        (
            [ID] => 37
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Author
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 37
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26464
            [VALUE] => Array
                (
                    [TEXT] => <p>Ekaterina V. Goncharova<sup>1,2</sup>, Inga E. Zavodova<sup>1</sup>, Nikita P. Volkov<sup>1</sup>, Olga A. Ivanova<sup>1</sup>, Maxim A. Kucher<sup>1</sup>, Alexey Y. Sokolov<sup>2,3</sup>, Maxim P. Bogomolny<sup>1</sup>, Gleb E. Ulrikh<sup>4</sup>, Ludmila S. Zubarovskaya<sup>1</sup>, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Boris V. Afanasyev<sup>1</sup> </span></p>

                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Ekaterina V. Goncharova1,2, Inga E. Zavodova1, Nikita P. Volkov1, Olga A. Ivanova1, Maxim A. Kucher1, Alexey Y. Sokolov2,3, Maxim P. Bogomolny1, Gleb E. Ulrikh4, Ludmila S. Zubarovskaya1, Boris V. Afanasyev1 

                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Author
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_EN] => Array
        (
            [ID] => 38
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Organization
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 38
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26465
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br>
<sup>2</sup> Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia<br>
<sup>3</sup> Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia<br>
<sup>4</sup> Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia</p>
<br>
<p><b>Correspondence</b><br>
Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia<br>
Phone: +7 (911) 087 8976<br>
E-mail: ek.v.goncharova@gmail.com</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia

2 Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia

3 Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia

4 Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia


Correspondence

Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia

Phone: +7 (911) 087 8976

E-mail: ek.v.goncharova@gmail.com
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Organization
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_EN] => Array
        (
            [ID] => 39
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Description / Summary
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 39
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26466
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.</p>
<h3>Patients and methods</h3>
<p style="text-align: justify;">The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1<sup>st</sup>-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2<sup>nd</sup> group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.</p>
<h3>Results</h3>
<p style="text-align: justify;">When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups. </p>
<h3>Conclusion</h3>
<p style="text-align: justify;">Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients. </p>
<h2>Keywords</h2>
<p style="text-align: justify;">Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.
Patients and methods
The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.
Results
When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups. 
Conclusion
Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients. 
Keywords
Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Description / Summary
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [NAME_EN] => Array
        (
            [ID] => 40
            [TIMESTAMP_X] => 2015-09-03 10:49:47
            [IBLOCK_ID] => 2
            [NAME] => Name
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 40
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26460
            [VALUE] => Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation
            [~DESCRIPTION] => 
            [~NAME] => Name
            [~DEFAULT_VALUE] => 
        )

    [FULL_TEXT_RU] => Array
        (
            [ID] => 42
            [TIMESTAMP_X] => 2015-09-07 20:29:18
            [IBLOCK_ID] => 2
            [NAME] => Полный текст
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => FULL_TEXT_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 42
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Полный текст
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [PDF_RU] => Array
        (
            [ID] => 43
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF RUS
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_RU
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 43
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26461
            [VALUE] => 2012
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2012
            [~DESCRIPTION] => 
            [~NAME] => PDF RUS
            [~DEFAULT_VALUE] => 
        )

    [PDF_EN] => Array
        (
            [ID] => 44
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF ENG
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 44
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26467
            [VALUE] => 2013
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2013
            [~DESCRIPTION] => 
            [~NAME] => PDF ENG
            [~DEFAULT_VALUE] => 
        )

    [NAME_LONG] => Array
        (
            [ID] => 45
            [TIMESTAMP_X] => 2023-04-13 00:55:00
            [IBLOCK_ID] => 2
            [NAME] => Название (для очень длинных заголовков)
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_LONG
            [DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 45
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 80
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Название (для очень длинных заголовков)
            [~DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

        )

)
					

						Array
(
    [KEYWORDS] => Array
        (
            [ID] => 19
            [TIMESTAMP_X] => 2015-09-03 10:46:01
            [IBLOCK_ID] => 2
            [NAME] => Ключевые слова
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => KEYWORDS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 19
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 4
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => Y
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => Y
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Ключевые слова
            [~DEFAULT_VALUE] => 
        )

    [SUBMITTED] => Array
        (
            [ID] => 20
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата подачи
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUBMITTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 20
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26468
            [VALUE] => 07.05.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 07.05.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата подачи
            [~DEFAULT_VALUE] => 
        )

    [ACCEPTED] => Array
        (
            [ID] => 21
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата принятия
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ACCEPTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 21
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26469
            [VALUE] => 05.06.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 05.06.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата принятия
            [~DEFAULT_VALUE] => 
        )

    [PUBLISHED] => Array
        (
            [ID] => 22
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата публикации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PUBLISHED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 22
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Дата публикации
            [~DEFAULT_VALUE] => 
        )

    [CONTACT] => Array
        (
            [ID] => 23
            [TIMESTAMP_X] => 2015-09-03 14:43:05
            [IBLOCK_ID] => 2
            [NAME] => Контакт
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => CONTACT
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 23
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Контакт
            [~DEFAULT_VALUE] => 
        )

    [AUTHORS] => Array
        (
            [ID] => 24
            [TIMESTAMP_X] => 2015-09-03 10:45:07
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHORS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 24
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_RU] => Array
        (
            [ID] => 25
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 25
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26470
            [VALUE] => Array
                (
                    [TEXT] => <p>Елена В. Морозова<sup>1</sup>, Мария В. Барабанщикова<sup>1</sup>, Татьяна И. Ионова<sup>2</sup>, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Борис В. Афанасьев<sup>1</sup></span></p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Елена В. Морозова1, Мария В. Барабанщикова1, Татьяна И. Ионова2, Борис В. Афанасьев1
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_RU] => Array
        (
            [ID] => 26
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Организации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 26
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26471
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br>
<sup>2</sup> Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия

2 Санкт-Петербургский государственный университетский госпиталь, Санкт-Петербург, Россия
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Организации
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_RU] => Array
        (
            [ID] => 27
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Описание/Резюме
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 27
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26472
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).</p> <p style="text-align: justify;">Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.</p>
<h2>Ключевые слова</h2>
<p style="text-align: justify;">Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы.   </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Целью данной статьи была оценка и обобщение данных, полученных при опросах российских больных и их лечащих врачей, проведенных в рамках международного исследования Landmark для стран с развивающимся рынком, направленного на выяснение проблем и вопросов ведения пациентов с хроническими Ph-негативными миелопролиферативными новообразованиями (МПН).
 
Разосланные онлайн-формы заполняли 40 взрослых пациентов с Ph(-) МПН (истинная полицитемия – 42,5%; миелофиброз – 37,5%; эссенциальная тромбоцитемия – 20%), а также 30 врачей с достаточным опытом лечения Ph(-) МПН. В рамках этого исследования, лечащие врачи и пациенты отвечали на вопросы, касающиеся восприятия симптомов заболевания и их воздействия на качество жизни, повседневную активность и продуктивность работы пациентов, а также их отношения к основным целям терапии и различным аспектам общения больного и врача. Результаты: выявлен ряд различий между восприятием заболевания и лечения больными и врачами, что дополняет данные исследования Landmark, полученные в других странах. Было показано, что больные с различными вариантами Ph(-) МПН сталкиваются со значительными проблемами в повседневной жизни, нарушениями качества жизни и снижением работоспособности, обусловленными заболеванием. Отсутствие совпадения в оценке тяжести и лечения болезни врачом и больным указывает на необходимость новых подходов к улучшению качества клинического обслуживания для этой категории больных. Дальнейшие исследования в этой области были бы важным шагом к внедрению в Российской Федерации программ лечения Ph(-) МПН, ориентированных на больных.
Ключевые слова
Миелопролиферативные неоплазии, хронические, Ph-негативные, опрос пациентов и врачей, симптомы, качество жизни, пациент-ориентированные программы.   
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Описание/Резюме
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [DOI] => Array
        (
            [ID] => 28
            [TIMESTAMP_X] => 2016-04-06 14:11:12
            [IBLOCK_ID] => 2
            [NAME] => DOI
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => DOI
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 28
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26473
            [VALUE] => 10.18620/ctt-1866-8836-2020-9-2-28-39
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 10.18620/ctt-1866-8836-2020-9-2-28-39
            [~DESCRIPTION] => 
            [~NAME] => DOI
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_EN] => Array
        (
            [ID] => 37
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Author
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 37
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26476
            [VALUE] => Array
                (
                    [TEXT] => <p>Elena V. Morozova<sup>1</sup>, Maria V. Barabanshchikova<sup>1</sup>, Tatyana I. Ionova<sup>2</sup>, <span style="border: 1px solid black; margin: 0; padding: 2px 2px;">Boris V. Afanasyev<sup>1</sup></span></p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Elena V. Morozova1, Maria V. Barabanshchikova1, Tatyana I. Ionova2, Boris V. Afanasyev1
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Author
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_EN] => Array
        (
            [ID] => 38
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Organization
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 38
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26477
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br>
<sup>2</sup> Saint Petersburg State University Hospital, St. Petersburg, Russia</p><br>
<p><b>Correspondence</b><br>
Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia<br>
Phone: +7 (962) 710 1711<br>
E-mail: tation16@gmail.com</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia

2 Saint Petersburg State University Hospital, St. Petersburg, Russia


Correspondence

Prof. Dr Sci Tatyana I. Ionova, Saint Petersburg State University Hospital, Fontanka Emb 154, 198103, St. Petersburg, Russia

Phone: +7 (962) 710 1711

E-mail: tation16@gmail.com
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Organization
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_EN] => Array
        (
            [ID] => 39
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Description / Summary
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 39
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26479
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation. </p>
<h2>Keywords</h2>
<p style="text-align: justify;">Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs. </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
The aim of this paper was to present evaluation and synthesis of data derived from a survey of Russian patients and physicians, performed as a part of the international Landmark study for the emerging market countries designed to specify problems and areas of concern in management of patients with chronic Ph-negative myeloproliferative neoplasms (MPN). The online survey forms were filled by 40 adult patients with Ph(-) MPNs (PV, 42.5%; MF, 37.5%; ET, 20%) and 30 physicians with sufficient experience in the Ph(-) MPNs treatment. As a part of this survey, patients and physicians answered questions related to perception of the disease symptoms and their impact on quality of life, daily activities and work productivity of patients, as well as their attitude to main treatment goals and various aspects of the patient-physician communication. The results revealed a number of differences between patient and physician perception of the disease and treatment, thus complementing the data of the Landmark Survey in other countries. It was shown that the patients with different variants of Ph(-) MPNs encounter sufficient disease-related difficulties in everyday life, impaired quality of life and reduced work productivity. Lack of coincidence revealed between the physician and patient assessment of the disease burden and treatment indicates the need for new ways of improving quality of clinical care provided to this category of patients. Further research in this area would be an important step towards implementation of patient-centered Ph(-) MPN treatment programs in Russian Federation. 
Keywords
Myeloproliferative neoplasms, chronic, Ph-negative, physician and patient survey, symptoms, quality of life, patient-centered treatment programs. 
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Description / Summary
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [NAME_EN] => Array
        (
            [ID] => 40
            [TIMESTAMP_X] => 2015-09-03 10:49:47
            [IBLOCK_ID] => 2
            [NAME] => Name
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 40
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26474
            [VALUE] => Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study
            [~DESCRIPTION] => 
            [~NAME] => Name
            [~DEFAULT_VALUE] => 
        )

    [FULL_TEXT_RU] => Array
        (
            [ID] => 42
            [TIMESTAMP_X] => 2015-09-07 20:29:18
            [IBLOCK_ID] => 2
            [NAME] => Полный текст
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => FULL_TEXT_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 42
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Полный текст
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [PDF_RU] => Array
        (
            [ID] => 43
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF RUS
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_RU
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 43
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26475
            [VALUE] => 2019
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2019
            [~DESCRIPTION] => 
            [~NAME] => PDF RUS
            [~DEFAULT_VALUE] => 
        )

    [PDF_EN] => Array
        (
            [ID] => 44
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF ENG
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 44
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26478
            [VALUE] => 2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2020
            [~DESCRIPTION] => 
            [~NAME] => PDF ENG
            [~DEFAULT_VALUE] => 
        )

    [NAME_LONG] => Array
        (
            [ID] => 45
            [TIMESTAMP_X] => 2023-04-13 00:55:00
            [IBLOCK_ID] => 2
            [NAME] => Название (для очень длинных заголовков)
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_LONG
            [DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 45
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 80
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Название (для очень длинных заголовков)
            [~DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

        )

)
					

						Array
(
    [KEYWORDS] => Array
        (
            [ID] => 19
            [TIMESTAMP_X] => 2015-09-03 10:46:01
            [IBLOCK_ID] => 2
            [NAME] => Ключевые слова
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => KEYWORDS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 19
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 4
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => Y
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => Y
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Ключевые слова
            [~DEFAULT_VALUE] => 
        )

    [SUBMITTED] => Array
        (
            [ID] => 20
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата подачи
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUBMITTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 20
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26480
            [VALUE] => 20.04.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 20.04.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата подачи
            [~DEFAULT_VALUE] => 
        )

    [ACCEPTED] => Array
        (
            [ID] => 21
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата принятия
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ACCEPTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 21
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26481
            [VALUE] => 26.06.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 26.06.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата принятия
            [~DEFAULT_VALUE] => 
        )

    [PUBLISHED] => Array
        (
            [ID] => 22
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата публикации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PUBLISHED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 22
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Дата публикации
            [~DEFAULT_VALUE] => 
        )

    [CONTACT] => Array
        (
            [ID] => 23
            [TIMESTAMP_X] => 2015-09-03 14:43:05
            [IBLOCK_ID] => 2
            [NAME] => Контакт
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => CONTACT
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 23
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Контакт
            [~DEFAULT_VALUE] => 
        )

    [AUTHORS] => Array
        (
            [ID] => 24
            [TIMESTAMP_X] => 2015-09-03 10:45:07
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHORS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 24
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_RU] => Array
        (
            [ID] => 25
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 25
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26482
            [VALUE] => Array
                (
                    [TEXT] => <p>Сачин Пунатар<sup>1,2</sup>, Лингарадж Наяк<sup>1,2</sup>, Авинаш Бонда<sup>1,2</sup>, Анант Гокарн<sup>1,2</sup>, Аникет Мохите<sup>1</sup>, Картик Шанмугам<sup>1</sup>, Дипан Раджаманикам<sup>1</sup>, Алок Гупта<sup>1</sup>, Либин Мэтью<sup>1</sup>, Садхана Каннан<sup>3</sup>, Навин Хаттри<sup>1,2</sup></p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Сачин Пунатар1,2, Лингарадж Наяк1,2, Авинаш Бонда1,2, Анант Гокарн1,2, Аникет Мохите1, Картик Шанмугам1, Дипан Раджаманикам1, Алок Гупта1, Либин Мэтью1, Садхана Каннан3, Навин Хаттри1,2
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_RU] => Array
        (
            [ID] => 26
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Организации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 26
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26483
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия<br>
<sup>2</sup> Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия<br>
<sup>3</sup> Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 Отделение ТКМ, Департамент медицинский онкологии, ACTREC, Харгар, Нави Мумбай, Индия

2 Национальный институт Хоми Бхабха, Анушакти Нагар, Мумбаи, Индия

3 Департамент биостатистики, Мемориальный центр Тата, Пэймастер Шодика, ACTREC, Харгарб Нави Мумбай, Индия
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Организации
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_RU] => Array
        (
            [ID] => 27
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Описание/Резюме
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 27
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26484
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов.  </p>
<h2>Ключевые слова</h2>
<p style="text-align: justify;">Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная.  </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
«Лихорадка приживления» (ЛП) является частым осложнением аутологичной трансплантации гемопоэтических стволовых клеток (ТГСК). Ее сложно отличить от инфекционной лихорадки (ИЛ). Мы исследовали значимость показателя соотношения общего числа лейкоцитов крови к концентрации С-реактивного белка при дифференциальном диагнозе между ЛП и ИЛ. Группа из 109 пациентов после ауто-ТГСК была обследована ретроспективно в период между мартом 2011 г. и августом 2013 г. Лихорадочное состояние (ЛС) определялось как лихорадка, развивающаяся de novo после афебрильного периода более 48 часов. Эпизоды ЛС классифицировали как ЛП или ИЛ. Инфекционную лихорадку диагностировали в случае позитивной гемокультуры, радиологических симптомов инфекции или лихорадки, продолжающейся в течение 48 часов после смены антибиотика. «Лихорадку приживления» определяли в случаях, связанных с повышением лейкоцитоза без очевидного инфекционного очага. ЛП хорошо отвечала на лечение стероидными гормонами. Ежедневные показатели лейкоцитоза и С-реактивного белка фиксировали по историям болезни. Оптимальный показатель отсечения (cut-off value) данного соотношения на день появления лихорадочного состояния определяли методом построения кривых ROC. Чувствительность и специфичность метода вычисляли по этому показателю. По результатам анализа 109 случаев, лихорадочные состояния проявились у 70 пациентов. Медианным сроком развития лихорадочного состояния был день +9 после ТГСК. 62 пациента имели ЛП. Медиана соотношения лейкоцитоза к С-реактивному белку в день развития лихорадочного состояния была значительна повышена у пациентов с ЛП по сравнению с ИЛ (соответственно, 0,139 и 0,038, p=0,013). При ROC-анализе, площадь под кривой (AUC) была 0,78 (95%CI – 0,66-0,89, p<0,0001). Из графика ROC вычислено оптимальное соотношение лейкоцитоза к С-реактивному белку, равное >0.056 для «лихорадки приживления» при чувствительности и специфичности, соответственно, 63% (95%CI 50-75%) и 100% (95%CI 63-100%). Соотношение числа лейкоцитов к С-реактивному белку (>0,056) высоко специфично для лихорадки приживления. Необходимы проспективные исследования для подтверждения этих результатов.  
Ключевые слова
Лейкоцитоз общий, С-реактивный белок, лихорадка приживления, инфекционная лихорадка, трансплантация стволовых кроветворных клеток, аутологичная.  
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Описание/Резюме
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [DOI] => Array
        (
            [ID] => 28
            [TIMESTAMP_X] => 2016-04-06 14:11:12
            [IBLOCK_ID] => 2
            [NAME] => DOI
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => DOI
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 28
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26485
            [VALUE] => 10.18620/ctt-1866-8836-2020-9-2-40-46
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 10.18620/ctt-1866-8836-2020-9-2-40-46
            [~DESCRIPTION] => 
            [~NAME] => DOI
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_EN] => Array
        (
            [ID] => 37
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Author
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 37
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26488
            [VALUE] => Array
                (
                    [TEXT] => <p>Sachin Punatar<sup>1,2</sup>, Lingaraj Nayak<sup>1,2</sup>, Avinash Bonda<sup>1,2</sup>, Anant Gokarn<sup>1,2</sup>, Aniket Mohite<sup>1</sup>, Karthik Shanmugam<sup>1</sup>, Deepan Rajamanickam<sup>1</sup>, Alok Gupta<sup>1</sup>, Libin Mathew<sup>1</sup>, Sadhana Kannan<sup>3</sup>, Navin Khattry<sup>1,2</sup></p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Sachin Punatar1,2, Lingaraj Nayak1,2, Avinash Bonda1,2, Anant Gokarn1,2, Aniket Mohite1, Karthik Shanmugam1, Deepan Rajamanickam1, Alok Gupta1, Libin Mathew1, Sadhana Kannan3, Navin Khattry1,2
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Author
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_EN] => Array
        (
            [ID] => 38
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Organization
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 38
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26489
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India<br>
<sup>2</sup> Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India<br>
<sup>3</sup> Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India</p>
<br>
<p><b>Correspondence</b><br>
Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India<br>
Phone +91 989 2501 884<br>
E mail: nkhattry@gmail.com</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 HSCT unit, Department of Medical Oncology Tata Memorial Centre, HSCT unit, ACTREC, Kharghar, Navi Mumbai, India

2 Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India

3 Department of Biostatistics, Tata Memorial Centre, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai, India


Correspondence

Dr. Navin Khattry, Professor and BMT Programme Co-ordinator, HSCT unit, Department of Medical Oncology, Room 211, Paymaster Shodhika, ACTREC, Kharghar, Navi Mumbai 410210, Maharashtra, India

Phone +91 989 2501 884

E mail: nkhattry@gmail.com
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Organization
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_EN] => Array
        (
            [ID] => 39
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Description / Summary
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 39
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26490
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value. </p>
<p style="text-align: justify;">Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 <i>vs</i> 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings. </p>
<h2>Keywords</h2>
<p style="text-align: justify;">Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous.   </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Engraftment fever (EF) is a common complication of autologous HSCT (AHSCT). It is difficult to discern it from infectious fever (IF). We studied the significance of total blood leucocyte count (TLC) to C-reactive protein (CRP) ratio in differentiating EF from IF. 109 consecutive AHSCT patients were retrospectively analysed between March 2011 and August 2013. Breakthrough fever (BF) was defined as new-onset fever preceded by an afebrile period of at least 48 hours. The BF episodes were classified as IF or EF. Infectious fever was diagnosed in case of blood culture positivity, radiological signs of infection, or fever subsiding within 48 hours of changing the antibiotics. Engraftment fever was defined in cases associated with rising leucocyte counts without identifiable infective focus. EF responded well to steroid therapy. Daily TLC and CRP values were obtained from patients’ records. Optimal cut-off value of ratio on day of BF was obtained by plotting ROC curve. Sensitivity and specificity were calculated at this value. 
Among 109 cases, the breakthrough fever manifested in seventy patients. The median term for BF was day +9. Sixty-two patients had the EF. Median value of TLC/CRP ratio on the day of BF was significantly higher in patients with EF than with IF (0.139 vs 0.038, p=0.013). With ROC analysis, the AUC value was 0.78 (95%CI – 0.66-0.89, p<0.0001). The ROC curve provided the optimal TLC/CRP value of 0.056. Using a ratio >0.056 for EF, the sensitivity and specificity were 63% (95%CI 50-75%) and 100% (95%CI 63-100%) respectively. TLC/CRP ratio >0.056 is highly specific for EF. Prospective studies are warranted to confirm these findings. 
Keywords
Total leukocyte count, C-reactive protein, engraftment fever, infectious fever, stem cell transplant, autologous.   
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Description / Summary
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [NAME_EN] => Array
        (
            [ID] => 40
            [TIMESTAMP_X] => 2015-09-03 10:49:47
            [IBLOCK_ID] => 2
            [NAME] => Name
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 40
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26486
            [VALUE] => Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Ratio of total leukocyte count to C-reactive protein: does it help to differentiate infectious fever from engraftment fever in patients undergoing autologous hematopoietic stem cell transplant?
            [~DESCRIPTION] => 
            [~NAME] => Name
            [~DEFAULT_VALUE] => 
        )

    [FULL_TEXT_RU] => Array
        (
            [ID] => 42
            [TIMESTAMP_X] => 2015-09-07 20:29:18
            [IBLOCK_ID] => 2
            [NAME] => Полный текст
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => FULL_TEXT_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 42
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Полный текст
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [PDF_RU] => Array
        (
            [ID] => 43
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF RUS
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_RU
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 43
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26487
            [VALUE] => 2031
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2031
            [~DESCRIPTION] => 
            [~NAME] => PDF RUS
            [~DEFAULT_VALUE] => 
        )

    [PDF_EN] => Array
        (
            [ID] => 44
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF ENG
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 44
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26491
            [VALUE] => 2032
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2032
            [~DESCRIPTION] => 
            [~NAME] => PDF ENG
            [~DEFAULT_VALUE] => 
        )

    [NAME_LONG] => Array
        (
            [ID] => 45
            [TIMESTAMP_X] => 2023-04-13 00:55:00
            [IBLOCK_ID] => 2
            [NAME] => Название (для очень длинных заголовков)
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_LONG
            [DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 45
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 80
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Название (для очень длинных заголовков)
            [~DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

        )

)
					

						Array
(
    [KEYWORDS] => Array
        (
            [ID] => 19
            [TIMESTAMP_X] => 2015-09-03 10:46:01
            [IBLOCK_ID] => 2
            [NAME] => Ключевые слова
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => KEYWORDS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 19
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 4
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => Y
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => Y
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Ключевые слова
            [~DEFAULT_VALUE] => 
        )

    [SUBMITTED] => Array
        (
            [ID] => 20
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата подачи
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUBMITTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 20
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26492
            [VALUE] => 10.06.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 10.06.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата подачи
            [~DEFAULT_VALUE] => 
        )

    [ACCEPTED] => Array
        (
            [ID] => 21
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата принятия
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ACCEPTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 21
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26493
            [VALUE] => 26.06.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 26.06.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата принятия
            [~DEFAULT_VALUE] => 
        )

    [PUBLISHED] => Array
        (
            [ID] => 22
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата публикации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PUBLISHED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 22
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Дата публикации
            [~DEFAULT_VALUE] => 
        )

    [CONTACT] => Array
        (
            [ID] => 23
            [TIMESTAMP_X] => 2015-09-03 14:43:05
            [IBLOCK_ID] => 2
            [NAME] => Контакт
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => CONTACT
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 23
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Контакт
            [~DEFAULT_VALUE] => 
        )

    [AUTHORS] => Array
        (
            [ID] => 24
            [TIMESTAMP_X] => 2015-09-03 10:45:07
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHORS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 24
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_RU] => Array
        (
            [ID] => 25
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 25
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26494
            [VALUE] => Array
                (
                    [TEXT] => <p>Олег В. Голощапов<sup>1</sup>, Евгений А. Бакин<sup>1</sup>, Максим А. Кучер<sup>1</sup>, Оксана В. Станевич<sup>1</sup>, Мария А. Суворова<sup>2</sup>, Владимир В. Гостев<sup>3</sup>, Олег С. Глотов<sup>4</sup>, Юрий А. Эйсмонт<sup>4</sup>, Дмитрий Е. Полев<sup>5</sup>, Анастасия Ю. Лобенская<sup>5</sup>, Руслана В. Клементьева<sup>1</sup>, Мария О. Голощапова<sup>1</sup>, Людмила С. Зубаровская<sup>1</sup>, Сергей В. Сидоренко<sup>3</sup>, Александр Н. Суворов<sup>4</sup>, Иван С. Моисеев<sup>1</sup>, Алексей Б. Чухловин<sup>1</sup></p> 
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Олег В. Голощапов1, Евгений А. Бакин1, Максим А. Кучер1, Оксана В. Станевич1, Мария А. Суворова2, Владимир В. Гостев3, Олег С. Глотов4, Юрий А. Эйсмонт4, Дмитрий Е. Полев5, Анастасия Ю. Лобенская5, Руслана В. Клементьева1, Мария О. Голощапова1, Людмила С. Зубаровская1, Сергей В. Сидоренко3, Александр Н. Суворов4, Иван С. Моисеев1, Алексей Б. Чухловин1
 
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_RU] => Array
        (
            [ID] => 26
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Организации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 26
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26495
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия<br>
<sup>2</sup> Научная лаборатория Эксплана, Санкт-Петербург, Россия <br>
<sup>3</sup> Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия <br>
<sup>4</sup> Городская больница №40, Санкт-Петербург, Россия<br>
<sup>5</sup> ООО «Сербалаб», Санкт-Петербург, Россия<br>
<sup>6</sup> Институт экспериментальной медицины, Санкт-Петербург, Россия</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой, Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова, Санкт-Петербург, Россия

2 Научная лаборатория Эксплана, Санкт-Петербург, Россия 

3 Детский научно-клинический центр инфекционных болезней, Санкт-Петербург, Россия 

4 Городская больница №40, Санкт-Петербург, Россия

5 ООО «Сербалаб», Санкт-Петербург, Россия

6 Институт экспериментальной медицины, Санкт-Петербург, Россия
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Организации
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_RU] => Array
        (
            [ID] => 27
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Описание/Резюме
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 27
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26496
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.</p>
<h3>Пациенты и методы</h3>
<p style="text-align: justify;">В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.</p>
<h3>Результаты</h3>
<p style="text-align: justify;">При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); <i>Escherichia coli</i> (p=0,001); <i>Bacteroides fragilis group</i> (p=0,05); <i>Faecalibacterium prausnitzii</i> (p=0,005). В то же время количества <i>Lactobacillus spp.</i> и <i>Bacteroides thetaiotaomicron</i>, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: <i>Bifidobacterium spp.</i> (р<0,047), <i>E.coli</i> (р<0,00047), <i>B.fragilis group</i> (p=5,6×10<sup>-5</sup>), <i>F.prausnitzii</i> (р<0,0062).</p>
<h3>Выводы</h3>
<p style="text-align: justify;">Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. <i>Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii</i> может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий <i>B.fragilis group</i> коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ.  </p>
<h2>Ключевые слова</h2>
<p style="text-align: justify;">Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, <i>Bacteroides fragilis</i>, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Показания, технология, методы контроля динамики и приживления микробиоты при трансплантации фекальной микробиоты (ТФМ), нуждаются в стандартизации. Целью работы было сравнение возможностей и результатов полимеразной цепной реакции в режиме реального времени (ПЦР) и методики 16S-секвенирования для контроля динамики состава фекальной микробиоты у пациентов после ТФМ.
Пациенты и методы
В проспективное, одноцентровое исследование включено 27 пациентов с острой и хронической (overlap-синдром) реакцией «трансплантат против хозяина» (РТПХ) желудочно-кишечного тракта после аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). У 19 пациентов проводили ТФМ, преимущественно, с ингестией капсул. В контрольную группу вошли 8 пациентов, получавшие плацебо. Количественные изменения бактериального состава микроорганизмов фекальной микробиоты оценивали методом ПЦР и 16S-секвенирования в сроки от 3 до 120 сут. после ТФМ. Клинический ответ определяли по 4 шкалам оценки кишечного синдрома и РТПХ.
Результаты
При оценке консистенции стула по Бристольской шкале, как показателя эффективности терапии РТПХ, полный клинический ответ к Д+120 после ФМТ отмечен в 9 случаях (47% с оценкой Бристоля ≤4 баллов), у 9 пациентов (47%) – улучшение консистенции стула (>4 балла). В группе плацебо полный или частичный ответ был выявлен, соответственно, у 1 (13%) и 4 (50%) пациентов. Мультиплексная ПЦР фекальной микробиоты в режиме реального времени показала различную динамику у пациентов после ТФМ или плацебо, по сравнению с исходными уровнями до ТФМ. Общая бактериальная масса и число генокопий отдельных микробных видов значительно повышались после ТФМ. Такие изменения были особенно показательными через 30 сут. для общей микробной массы (p=0,002); Escherichia coli (p=0,001); Bacteroides fragilis group (p=0,05); Faecalibacterium prausnitzii (p=0,005). В то же время количества Lactobacillus spp. и Bacteroides thetaiotaomicron, в целом, не изменялись на протяжении этого периода. Кроме того, в контрольной группе не выявлено существенных изменений фекальной микробиоты против исходных уровней в течение всего периода наблюдений. Также обнаружены некоторые различия в динамике микробиоты для подгрупп с полным ответом, частичным/отсутствием ответа: Bifidobacterium spp. (р<0,047), E.coli (р<0,00047), B.fragilis group (p=5,6×10-5), F.prausnitzii (р<0,0062).
Выводы
Полуколичественная ПЦР основных бактериальных групп кишечной микробиоты, в т.ч. Bifidobacterium spp., Escherichia coli, B.fragilis group, F.prausnitzii может использоваться как микробиологический показатель оценки микробного ландшафта после ФМТ в качестве рутинной молекулярно-биологической методики. Число генокопий B.fragilis group коррелирует с клиническим ответом у пациентов с кишечной формой РТПХ после алло-ТГСК после процедуры ТФМ.  
Ключевые слова
Реакция «трансплантат против хозяина», фекальная микробиота, трансплантация, Bacteroides fragilis, полимеразная цепная реакция, мультиплексная, секвенирование следующего поколения, ген 16S рРНК.
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Описание/Резюме
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [DOI] => Array
        (
            [ID] => 28
            [TIMESTAMP_X] => 2016-04-06 14:11:12
            [IBLOCK_ID] => 2
            [NAME] => DOI
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => DOI
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 28
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26497
            [VALUE] => 10.18620/ctt-1866-8836-2020-9-2-47-59
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 10.18620/ctt-1866-8836-2020-9-2-47-59
            [~DESCRIPTION] => 
            [~NAME] => DOI
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_EN] => Array
        (
            [ID] => 37
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Author
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 37
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26500
            [VALUE] => Array
                (
                    [TEXT] => <p>Oleg V. Goloshchapov<sup>1</sup>, Evgenyi A. Bakin<sup>1</sup>, Maxim A. Kucher<sup>1</sup>, Oksana V. Stanevich<sup>1</sup>, Maria A. Suvorova<sup>2</sup>, Vladimir V. Gostev<sup>3</sup>, Oleg S. Glotov<sup>4</sup>, Yury A. Eismont<sup>4</sup>, Dmitry E. Polev<sup>5</sup>, Anastasia Yu. Lobenskaya<sup>5</sup>, Ruslana V. Klementeva<sup>1</sup>, Maria O. Goloshchapova<sup>1</sup>, Ludmila S. Zubarovskaya<sup>1</sup>, Sergey V. Sidorenko<sup>3</sup>, Alexander N. Suvorov<sup>6</sup>, Ivan S. Moiseev<sup>1</sup>, Alexei B. Chukhlovin<sup>1</sup> </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Oleg V. Goloshchapov1, Evgenyi A. Bakin1, Maxim A. Kucher1, Oksana V. Stanevich1, Maria A. Suvorova2, Vladimir V. Gostev3, Oleg S. Glotov4, Yury A. Eismont4, Dmitry E. Polev5, Anastasia Yu. Lobenskaya5, Ruslana V. Klementeva1, Maria O. Goloshchapova1, Ludmila S. Zubarovskaya1, Sergey V. Sidorenko3, Alexander N. Suvorov6, Ivan S. Moiseev1, Alexei B. Chukhlovin1 
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Author
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_EN] => Array
        (
            [ID] => 38
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Organization
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 38
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26501
            [VALUE] => Array
                (
                    [TEXT] => <p><sup>1</sup> RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia<br>
<sup>2</sup> Explana Research Laboratory, St. Petersburg, Russia<br>
<sup>3</sup> Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia<br>
<sup>4</sup> City Hospital No. 40, St. Petersburg, Russia<br>
<sup>5</sup> Cerbalab Ltd, St. Petersburg, Russia<br>
<sup>6</sup> Institute of Experimental Medicine, St. Petersburg, Russia</p>
<br>
<p><b>Correspondence</b><br>
Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia<br>
Phone: + 7 (921) 979 2913<br>
E-mail: golocht@yandex.ru</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
1 RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia

2 Explana Research Laboratory, St. Petersburg, Russia

3 Pediatric Research and Clinical Center of Infectious Diseases, St. Petersburg, Russia

4 City Hospital No. 40, St. Petersburg, Russia

5 Cerbalab Ltd, St. Petersburg, Russia

6 Institute of Experimental Medicine, St. Petersburg, Russia


Correspondence

Dr. Oleg V. Goloshchapov, Head, Anesthesiology Department No.3, Pavlov University, L. Tolstoy St. 6-8, 197022, St. Petersburg, Russia

Phone: + 7 (921) 979 2913

E-mail: golocht@yandex.ru
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Organization
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_EN] => Array
        (
            [ID] => 39
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Description / Summary
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 39
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26502
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.</p>
<h3>Patients and methods</h3>
<p style="text-align: justify;">The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.</p>
<h3>Results</h3>
<p style="text-align: justify;">When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); <i>Escherichia coli</i> (p=0.001); <i>Bacteroides fragilis group</i> (p=0.05); <i>Faecalibacterium prausnitzii</i> (p=0.005). Meanwhile, the numbers <i>Lactobacillus spp.</i>, and <i>Bacteroides thetaiotaomicron</i>, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: <i>Bifidobacterium spp.</i> (р<0.047), <i>E.coli</i> (р<0.00047),
<i>B. fragilis group</i> (p=5.6×10<sup>-5</sup>), <i>F.prausnitzii</i> (р<0.0062). 
<h3>Conclusions</h3>
<p style="text-align: justify;">1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., <i>Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii</i> could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.</p>
<h2>Keywords</h2>
<p style="text-align: justify;">Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, <i>Bacteroides fragilis</i>, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Fecal microbiota transplantation (FMT), as any other medical procedure, requires standardization of results, approaches, monitoring of its dynamics and microbiota engraftment evaluation. The aim of the present study was to compare efficiency and results of PCR and 16S RNA-based sequencing in order to trace the dynamics of microbiota composition after FMT.
Patients and methods
The prospective, single-center study included 27 patients with acute intestinal and chronic (overlap syndrome) graft-versus-host disease (GvHD) developed after allogeneic hematopoietic stem cell transplantation (HSCT). FMT in 19 cases was performed, mostly, with ingestible capsules, eight placebo-treated patients were included into control group. Quantitative changes of different bacterial groups in fecal microbiota were assessed by means of real-time multiplex PCR, being compared with16S rRNA sequencing technique at the terms of D+3, D+16, D+30, D+60 and D+120 following FMT. Clinical response was determined by 4 scales evaluating intestinal syndrome and GvHD grade.
Results
When evaluating stool consistence according to Bristol scale as an index of GvHD therapy efficiency, we have observed complete clinical response by the D+120 after FMT in nine cases (47% with Bristol score of ≤4 points), and nine patients (47%) showed improved stool properties (>4 points). In the placebo group, complete or partial response was revealed, respectively, in one (13%), and four cases (50%) on the D+120. Multiplex PCR of fecal microbiota has shown a different time course in FMT- and placebo-treated patients, when compared to their initial (pre-FMT) levels. Total bacterial mass and copy numbers of distinct microbial species exhibited sufficient increase after FMT. Such shifts were demonstrable on D+30 for total microbial mass (p=0.002); Escherichia coli (p=0.001); Bacteroides fragilis group (p=0.05); Faecalibacterium prausnitzii (p=0.005). Meanwhile, the numbers Lactobacillus spp., and Bacteroides thetaiotaomicron, generally, were not changed over this time period. Moreover, in the control group (placebo) we have not found significant fecal microbiota changes against initial levels during 120 days monitoring period. Over 120 days of observation, we have also found some differences of the microbiota dynamics for the subgroups with complete response and partial/no response: Bifidobacterium spp. (р<0.047), E.coli (р<0.00047),
B. fragilis group (p=5.6×10-5), F.prausnitzii (р<0.0062). 
Conclusions
1. Quantitative PCR of the major bacterial groups of gut microbiota, e.g., Bifidobacterium spp., E. coli, B. fragilis group, F. prausnitzii could be used as microbiological markers for evaluation of changing microbial landscape after FMT as a routine molecular biology technique. 2. The genocopy counts of B. fragilis group correlate with clinical response in the patients with intestinal GvHD after HSCT, either with, or without FMT procedure.
Keywords
Graft-versus-host disease, fecal microbiota, transplantation, gut microbiome, Bacteroides fragilis, polymerase chain reaction, multiplex, next generation sequencing, 16S rDNA gene.
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Description / Summary
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [NAME_EN] => Array
        (
            [ID] => 40
            [TIMESTAMP_X] => 2015-09-03 10:49:47
            [IBLOCK_ID] => 2
            [NAME] => Name
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 40
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26498
            [VALUE] => Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Bacteroides fragilis is a potential marker of effective microbiota transplantation in acute graft-versus-host disease treatment
            [~DESCRIPTION] => 
            [~NAME] => Name
            [~DEFAULT_VALUE] => 
        )

    [FULL_TEXT_RU] => Array
        (
            [ID] => 42
            [TIMESTAMP_X] => 2015-09-07 20:29:18
            [IBLOCK_ID] => 2
            [NAME] => Полный текст
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => FULL_TEXT_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 42
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Полный текст
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [PDF_RU] => Array
        (
            [ID] => 43
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF RUS
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_RU
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 43
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26499
            [VALUE] => 2039
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2039
            [~DESCRIPTION] => 
            [~NAME] => PDF RUS
            [~DEFAULT_VALUE] => 
        )

    [PDF_EN] => Array
        (
            [ID] => 44
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF ENG
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 44
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26503
            [VALUE] => 2040
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2040
            [~DESCRIPTION] => 
            [~NAME] => PDF ENG
            [~DEFAULT_VALUE] => 
        )

    [NAME_LONG] => Array
        (
            [ID] => 45
            [TIMESTAMP_X] => 2023-04-13 00:55:00
            [IBLOCK_ID] => 2
            [NAME] => Название (для очень длинных заголовков)
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_LONG
            [DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 45
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 80
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Название (для очень длинных заголовков)
            [~DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

        )

)
					

						Array
(
    [KEYWORDS] => Array
        (
            [ID] => 19
            [TIMESTAMP_X] => 2015-09-03 10:46:01
            [IBLOCK_ID] => 2
            [NAME] => Ключевые слова
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => KEYWORDS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 19
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 4
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => Y
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => Y
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Ключевые слова
            [~DEFAULT_VALUE] => 
        )

    [SUBMITTED] => Array
        (
            [ID] => 20
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата подачи
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUBMITTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 20
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26504
            [VALUE] => 09.04.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 09.04.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата подачи
            [~DEFAULT_VALUE] => 
        )

    [ACCEPTED] => Array
        (
            [ID] => 21
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата принятия
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ACCEPTED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 21
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26505
            [VALUE] => 05.06.2020
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 05.06.2020
            [~DESCRIPTION] => 
            [~NAME] => Дата принятия
            [~DEFAULT_VALUE] => 
        )

    [PUBLISHED] => Array
        (
            [ID] => 22
            [TIMESTAMP_X] => 2015-09-02 17:21:42
            [IBLOCK_ID] => 2
            [NAME] => Дата публикации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PUBLISHED
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 22
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => DateTime
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Дата публикации
            [~DEFAULT_VALUE] => 
        )

    [CONTACT] => Array
        (
            [ID] => 23
            [TIMESTAMP_X] => 2015-09-03 14:43:05
            [IBLOCK_ID] => 2
            [NAME] => Контакт
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => CONTACT
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 23
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Контакт
            [~DEFAULT_VALUE] => 
        )

    [AUTHORS] => Array
        (
            [ID] => 24
            [TIMESTAMP_X] => 2015-09-03 10:45:07
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHORS
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => E
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => Y
            [XML_ID] => 24
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 3
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => EAutocomplete
            [USER_TYPE_SETTINGS] => Array
                (
                    [VIEW] => E
                    [SHOW_ADD] => Y
                    [MAX_WIDTH] => 0
                    [MIN_HEIGHT] => 24
                    [MAX_HEIGHT] => 1000
                    [BAN_SYM] => ,;
                    [REP_SYM] =>  
                    [OTHER_REP_SYM] => 
                    [IBLOCK_MESS] => N
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_RU] => Array
        (
            [ID] => 25
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Авторы
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 25
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26506
            [VALUE] => Array
                (
                    [TEXT] => <p>Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Галина В. Федотовских, Галия М. Шаймарданова, Манарбек Б. Аскаров, Айнаш А. Жусупова, Наталья А. Криворучко, Татьяна Г. Ежеленко, Сапаргуль Марат
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Авторы
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_RU] => Array
        (
            [ID] => 26
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Организации
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 26
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26507
            [VALUE] => Array
                (
                    [TEXT] => <p>АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
АО «Национальный научный медицинский центр», г. Нур-Cултан (Астана), Казахстан 
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Организации
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_RU] => Array
        (
            [ID] => 27
            [TIMESTAMP_X] => 2015-09-02 18:01:20
            [IBLOCK_ID] => 2
            [NAME] => Описание/Резюме
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 27
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26508
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга. </p>
<h3>Пациенты и методы</h3>
<p style="text-align: justify;">Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии. </p>
<p style="text-align: justify;">После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017).  </p>
<p style="text-align: justify;">Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.</p>
<h3>Результаты</h3>
<p style="text-align: justify;">Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.</p>
<p style="text-align: justify;">Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.</p>
<h3>Выводы</h3>
<p style="text-align: justify;">Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.</p>
<h2>Ключевые слова</h2>
<p style="text-align: justify;">Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи. </p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Результаты клинических отчетов по оценке трансплантации гемопоэтических стволовых клеток (ГСК) при лечении тяжелых форм различных аутоиммунных заболеваний являются обнадеживающими. В гистологический контроль динамики фиброза кожи в процессе лечения больных системной склеродермией (ССД), как правило, включается счет миофибробластов, отвечающих за избыточное отложение компонентов внеклеточного матрикса. Цель исследования состояла в оценке морфофункционального состояния кожи больных системной склеродермией до и после трансплантации аутологичных гемопоэтических стволовых клеток костного мозга. 
Пациенты и методы
Под клиническим наблюдением в Национальном научном медицинском центре г. Нур-Султана находилось 28 больных, средний возраст 45+11 лет (мужчин 2, женщин 26) с достоверным диагнозом ССД согласно ACR/EULAR, 2013. Продолжительность заболевания составляла 12+5,4 года. Контрольную группу, получавшую базисную терапию составляли 12 человек. В протокол лечения основной группы (16 человек) дополнительно включали трансфузию ГСК. Основанием для проведения трансплантации стволовых клеток послужила резистентность к иммуносупрессивной терапии. 
После клинико-лабораторного обследования больных ССД проводилась аспирация костного мозга из гребня подвздошной кости в количестве 200-300 мл под местной или эпидуральной анестезией в стерильных условиях хирургического отделения. Выделение мононуклеарных клеток полученных из аутологичных клеток костного мозга, проводили центрифугированием после наслоения на градиентную среду плотности с использованием Percoll (Sigma Aldrich, P1644). Выделенные клетки культивировали в среде DMEM (среда Игла, модифицированная Dulbecco, Sigma Aldrich, D1145) с 10% FBS при 37°С в течение 72 часов. Жизнеспособность клеток определяли окрашиванием трипановым синим. Количественное определение двойных положительных CD45 + / CD34 + мононуклеарных клеток проводили на проточном цитометре BD FACSCalibur (США). Переливание аутологичных культивированных HSC проводили в физиологическом растворе (в среднем 140×106 клеток на 200 мл) внутривенно капельно со скоростью 50 мл/ч. Клиническую эффективность (оценки по шкале Роднана) оценивали по критериям Европейской группы исследований и исследований по склеродермии (2017).  
Материалом для морфологического исследования послужил биопсийный материал кожи голени, взятый методом панч-биопсии у 15 пациентов до клеточной терапии и у 9 пациентов через 3 месяца после трансплантации при клиническом улучшении состояния кожных покровов. Гистологические парафиновые срезы окрашивались гематоксилином и эозином, а также по Массон – трихром. Для электронной микроскопии биопсийные кусочки кожи проводили по общепринятой методике и заключали в Эпон. Полутонкие срезы окрашивали метиленовым синим, азуром – 2 и основным фуксином по C. Humphrey и F. Pittman [5]. Ультратонкие срезы для ЭМ контрастировали уранилацетатом и цитратом свинца.
Результаты
Кожа больных ССД до лечения находилась в состоянии индурации и характеризовалась дистрофией, атрофией и деструкцией эпидермиса, склерозированием и гиалинозом соединительной ткани дермы, патологией сосудов микроциркуляторного русла. Ультраструктура миофибробластов, расположенных в склерозированной дерме характеризовалась признаками функциональной перегрузки. Активные участники процесса фибрилогенеза располагались в периваскулярной зоне и были представлены лимфоцитами и фибробластами особой склеродермаспецифической популяции, продуцирующими повышенное количество коллагена и межуточного матрикса.
Через три месяца после трансплантации ГСК в основной группе пациентов отмечался выраженный клинический эффект со значительным уменьшением индурации кожи, дисфагии, купировались мышечные контрактуры, уменьшались приступы вазоспазма (синдром Рейно). Достоверно уменьшались плотность кожи со снижением кожного счета по Роднану на 4,2 балла с 12,9 до 8,7 (в контрольной группе – лишь на 1 балл). Трансплантация ГСК способствовала биодеградации фиброзной ткани кожи больных ССД основной группы. Подвергались деструкции миофибробласты, увеличивалось количество и протяженность капилляров, менялся клеточный состав периваскулярного инфильтрата, направленный ранее на активный процесс фибрилогенеза. Появлялись многочисленные фагоцитарные и секреторные макрофаги, участвующие в выделении индукторов ангиогенеза, ремоделировании ткани, регуляции количества и активности фиброкластов, супрессии Т- и В-лимфоцитарных механизмов иммунитета, играющих важную роль в патогенезе ССД. Обширные межклеточные связи, предположительно, телоцитов свидетельствовали об их участии в неоангиогенезе и передаче сложных регулирующих сигналов в процессе регенерации.
Выводы
Трансплантация культивированных аутологичных гемопоэтических стволовых клеток костного мозга больным ССД способствовала биодеградации склерозированной ткани дермы, стимуляции ангиогенеза, восстановлению эпителия и придатков кожи через 3 месяца после трансплантации, что соответствовало признакам улучшения клинической симптоматики.
Ключевые слова
Системная склеродермия, трансплантация гемопоэтических стволовых клеток, костный мозг, морфология кожи. 
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Описание/Резюме
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [DOI] => Array
        (
            [ID] => 28
            [TIMESTAMP_X] => 2016-04-06 14:11:12
            [IBLOCK_ID] => 2
            [NAME] => DOI
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => DOI
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 28
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26509
            [VALUE] => 10.18620/ctt-1866-8836-2020-9-2-60-66
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 10.18620/ctt-1866-8836-2020-9-2-60-66
            [~DESCRIPTION] => 
            [~NAME] => DOI
            [~DEFAULT_VALUE] => 
        )

    [AUTHOR_EN] => Array
        (
            [ID] => 37
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Author
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => AUTHOR_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 37
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26512
            [VALUE] => Array
                (
                    [TEXT] => <p>Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Galina V. Fedotovskikh, Galija M. Shaymardanova, Manarbek B. Askarov, Ainash A. Zhusupova, Natalya A. Krivoruchko, Tatyana G. Ezhelenko, Sapargul Marat
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Author
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [ORGANIZATION_EN] => Array
        (
            [ID] => 38
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Organization
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => ORGANIZATION_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 38
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26513
            [VALUE] => Array
                (
                    [TEXT] => <p>National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan </p>
<br>
<p><b>Correspondence</b><br>
Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan<br>
Phone: +7 (707) 222 3256<br>
E-mail: gvf_fedotovskikh@mail.ru</p> 

                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
National Scientific Medical Center, Nur-Sultan (Astana), Kazakhstan 


Correspondence

Prof. Galina V. Fedotovskikh, MD, National Scientific Medical Center, Abylaikhan Avenue 42, 010000, Nur-Sultan (Astana), Kazakhstan

Phone: +7 (707) 222 3256

E-mail: gvf_fedotovskikh@mail.ru
 

                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Organization
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [SUMMARY_EN] => Array
        (
            [ID] => 39
            [TIMESTAMP_X] => 2015-09-02 18:02:59
            [IBLOCK_ID] => 2
            [NAME] => Description / Summary
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => SUMMARY_EN
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 39
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 26514
            [VALUE] => Array
                (
                    [TEXT] => <p style="text-align: justify;">Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.</p>
<h3>Patients and methods</h3>
<p style="text-align: justify;">Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT. </p>
<p style="text-align: justify;">Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×10<sup>6</sup> cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.</p>
<h3>Results</h3>
<p style="text-align: justify;">Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.</p>
<h3>Conclusion</h3>
<p style="text-align: justify;">Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.</p>
<h2>Keywords</h2>
<p style="text-align: justify;">Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.</p>
                    [TYPE] => HTML
                )

            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Array
                (
                    [TEXT] => 
Some promising clinical results of hematopoietic stem cell transplantation (HSCT) are reported in severe autoimmune diseases. When treating the patients with systemic scleroderma (SSD), histological evaluation of skin fibrosis includes scoring of myofibroblasts that are associated with excessive deposition of extracellular matrix components. The aim of our study was to evaluate morphological condition of skin in SSD patients before and after transplantation of autologous hematopoietic bone marrow stem cells.
Patients and methods
Twenty-eight patients were observed at the National Research Medical Center (Nur-Sultan), at the age of 45+11 years old (2 males, 26 females) with verified diagnosis of SSD according to ACR/EULAR (2013). Duration of the disease was 12+5.4 years old. Control group (12 persons) received conventional basic therapy Treatment protocol for the main group included autologous HSCT. Resistance to immunosuppressive therapy was a pre-requisite for HSCT. 
Bone marrow aspiration was performed from the iliac crest, the autologous mononuclear cells were isolated in Percoll density gradient and incubated for 72 hours at 37°С. Autologous HSCT was performed at a mean dose of 88×106 cells in 200 mL of physiological saline i/v over 3 hours. Clinical effect was evaluated by the recognized criteria (European Scleroderma Trials and Research Group, skin score by Rodnan). For morphological studies, the punch biopsies of tibial skin were taken in 15 patients before therapy, and in 9 three months after the treatment. The cellular therapy was accompanied by improved skin condition. The paraffin sections were stained with hematoxilin and eosin, as well as by Masson-trichrome technique. For electron microscopy, the skin biopsies were processed by conventional method, then being Epon-embedded. Semi-thin slices were stained with Methylene Blue, Azur II and basic fuchsine. For EM, the ultrathin sections were contrasted with uranyl acetate and lead citrate.
Results
Skin of SSD patients before treatment was characterized by induration and dystrophy and epithelial destruction, sclerosis and hyalinosis of dermal connective tissue, pathology of microcirculatory vessels. Ultrastructure of myofibroblasts in the sclerotized derma was characterized by functional overload. The active participants of fibrillogenesis were located in perivascular area, being represented by lymphocytes and fibroblasts of a specific SSD-specific population producing higher amounts of collagen and interstitial matrix. However, three months after HSCT, the main group of the patients exhibited a pronounced clinical effect with sufficient decrease of skin induration, reduced dysphagia, mitigation of muscle contractures, couping vasospasm attacks (Raynaud syndrome). Skin density was significantly decreased, with Rodnan scores changed from 12.9 to 8.7 (only 1-point decrease in the controls). HSCT promoted biodegradation of skin fibrotic tissue in SSD patients. The myofibroblasts were subjected to destruction, multiple and prolonged capillaries were observed, the cell composition of perivascular infiltrate shifted to normal state. Numerous phagocytic and secretory macrophages appeared, thus suggesting angiogenesis induction, tissue remodeling, regulation of fibroclast population, suppression of T- and B-lymphocytes playing an important role on SSD pathogenesis. Extensive telocyte connections presumed their participation in neoangiogenesis and transmission of regeneration signaling.
Conclusion
Transplantation of cultured autologous hematopoietic marrow stem cells in SSD patients promoted biodegradation of sclerotized dermal layer, as well as angiogenesis stimulation, restoration of epithelium and skin appendages 3 months after HSCT, thus corresponding to improvement of clinical symptoms.
Keywords
Systemic scleroderma, hematopoietic stem cell transplantation, bone marrow, skin morphology.
                    [TYPE] => HTML
                )

            [~DESCRIPTION] => 
            [~NAME] => Description / Summary
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [NAME_EN] => Array
        (
            [ID] => 40
            [TIMESTAMP_X] => 2015-09-03 10:49:47
            [IBLOCK_ID] => 2
            [NAME] => Name
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 80
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 40
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => Y
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26510
            [VALUE] => Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => Morphological skin evaluation in the patients with systemic scleroderma before and after hematopoietic stem cell transplantation
            [~DESCRIPTION] => 
            [~NAME] => Name
            [~DEFAULT_VALUE] => 
        )

    [FULL_TEXT_RU] => Array
        (
            [ID] => 42
            [TIMESTAMP_X] => 2015-09-07 20:29:18
            [IBLOCK_ID] => 2
            [NAME] => Полный текст
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => FULL_TEXT_RU
            [DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 42
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 200
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Полный текст
            [~DEFAULT_VALUE] => Array
                (
                    [TEXT] => 
                    [TYPE] => HTML
                )

        )

    [PDF_RU] => Array
        (
            [ID] => 43
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF RUS
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_RU
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 43
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26511
            [VALUE] => 2057
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2057
            [~DESCRIPTION] => 
            [~NAME] => PDF RUS
            [~DEFAULT_VALUE] => 
        )

    [PDF_EN] => Array
        (
            [ID] => 44
            [TIMESTAMP_X] => 2015-09-09 16:05:20
            [IBLOCK_ID] => 2
            [NAME] => PDF ENG
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => PDF_EN
            [DEFAULT_VALUE] => 
            [PROPERTY_TYPE] => F
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 44
            [FILE_TYPE] => doc, txt, rtf, pdf
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => 
            [USER_TYPE_SETTINGS] => 
            [HINT] => 
            [PROPERTY_VALUE_ID] => 26515
            [VALUE] => 2058
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 2058
            [~DESCRIPTION] => 
            [~NAME] => PDF ENG
            [~DEFAULT_VALUE] => 
        )

    [NAME_LONG] => Array
        (
            [ID] => 45
            [TIMESTAMP_X] => 2023-04-13 00:55:00
            [IBLOCK_ID] => 2
            [NAME] => Название (для очень длинных заголовков)
            [ACTIVE] => Y
            [SORT] => 500
            [CODE] => NAME_LONG
            [DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

            [PROPERTY_TYPE] => S
            [ROW_COUNT] => 1
            [COL_COUNT] => 30
            [LIST_TYPE] => L
            [MULTIPLE] => N
            [XML_ID] => 45
            [FILE_TYPE] => 
            [MULTIPLE_CNT] => 5
            [TMP_ID] => 
            [LINK_IBLOCK_ID] => 0
            [WITH_DESCRIPTION] => N
            [SEARCHABLE] => N
            [FILTRABLE] => N
            [IS_REQUIRED] => N
            [VERSION] => 1
            [USER_TYPE] => HTML
            [USER_TYPE_SETTINGS] => Array
                (
                    [height] => 80
                )

            [HINT] => 
            [PROPERTY_VALUE_ID] => 
            [VALUE] => 
            [DESCRIPTION] => 
            [VALUE_ENUM] => 
            [VALUE_XML_ID] => 
            [VALUE_SORT] => 
            [~VALUE] => 
            [~DESCRIPTION] => 
            [~NAME] => Название (для очень длинных заголовков)
            [~DEFAULT_VALUE] => Array
                (
                    [TYPE] => HTML
                    [TEXT] => 
                )

        )

)